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ABSTRACT 
Structure and Function of the Deleted in Azoospermia Gene.  (December 2006) 
David Chase Cameron Sprague, B.S., Saint Edward’s University 
Co-Chairs of Advisory Committee:  Dr. Thomas J. Kuehl  
Dr. Allison C. Rice-Ficht 
 
 
 
 A number of genes have been associated with variation in human 
spermatogenesis related to fertility.  One of these, the Deleted in Azoospermia (DAZ) 
gene, exists as copies on two chromosomes, 3 and Y.  The autosomal copy, DAZ-like 
(DAZL), has one RNA recognition motif (RRM) and is homologous to the DAZL gene 
found throughout the vertebrate lineage.  There are four copies of DAZ on the Y 
chromosome with a pair at each of two sites.  One pair contains a single RRM and the 
other has three RRMs.  Human DAZ is homologous to genes in old world primates and 
ape Y chromosomes.  Both DAZ and DAZL bind messenger RNAs at U-rich sequences 
near the poly-A tail in a manner that facilitates translation.  Both are expressed in 
spermatogonia during the transition from mitotic cellular expansion through meiotic 
chromosomal reduction and during spermiogenesis. This study examined genomic 
variation in DAZ and DAZL, including deletion of DAZ from individuals with various 
levels of sperm cell production and mutations of DAZL in male partners of infertile 
couples.  Deletions in DAZ are not as common in azoospermic men from central Texas 
as compared to other reports.  Single nucleotide polymorphisms (SNPs) were identified 
in anonymous infertility patients, but were not located in the exons of the RRM.  
Proteins produced from transcripts encoded by genes from human DAZL, DAZL with 
iv 
SNPs within and outside the RRM, and a DAZ with single RRM were identified.  
Binding activity of DAZL to mRNA was confirmed using a microarray method, and 
mRNA from human testes was screened to identify at least 1,313 mRNA potential 
targets for DAZL.  These targets were involved in ribosome construction, pyruvate 
metabolism, cell cycle control, and proteasome function.  Variations in binding of 
protein to a high and a low bound target mRNA were demonstrated between protein 
constructs of DAZL, DAZL with mutations, and DAZ.   Binding of DAZL to mRNA 
was also confirmed using electrophoretic mobility shift assays.  With materials and 
procedures developed during this study, comparisons of genetic variants of DAZ and 
DAZL can be performed to identify mechanisms responsible for structural and 
functional differences in control of spermatogenesis. 
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CHAPTER I  
 INTRODUCTION: INFERTILITY AND THE DAZ FAMILY OF 
GENES 
 
Infertility 
 Human infertility is associated with male factors in about 50% of cases[1].  Male 
infertility has been estimated at 15% in Western populations and can be explained by 
problems with hormones, immunology, sperm delivery, and the physical structure of the 
reproductive organs [2].  However, in a number of cases, the cause of infertility is 
unknown due to the lack of knowledge of genetic and molecular mechanisms which play 
a role in the control of sperm cell production and maturation.  One assessment for 
fertility in males is based on sperm concentration in the semen[3].  Azoospermia 
indicates no sperm cells in the semen while severe oligozoospermia is the presence of up 
to five million spermatozoa per milliliter in the ejaculate.  Oligozoospermia is the 
presence of between five and twenty million sperm cells per milliliter in the semen and 
normozoospermia is the presence of twenty or more million sperm cells per milliliter.  
To briefly review, spermatogenesis begins with the primordial germ cells (PGCs) 
increasing in number through multiple rounds of mitosis[1].  The PGCs then migrate to 
the developing gonadal tissue where they proceed to divide further through mitosis to 
maintain their numbers or go on to a pathway that leads to meiosis and spermatogenesis. 
_________ 
This thesis follows the style of Biology of Reproduction. 
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The pathway to spermatogenesis begins with the division to produce spermatogonial 
cells that enter into meiosis.  Meiosis results in haploid germ cells where the final 
product is fully functional mature spermatozoa.  Producing these cells properly has been 
attributed to more than 3,000 genes operating in conjunction with one another through 
experimentation involving knockouts in the mouse and fly[4].  Defects in any of these 
genes has the potential to affect germ cell development.  Genetic abnormalities are 
involved in about 30% of all male infertility, many of which manifest themselves in the 
form of genetic mutations affecting spermatogenesis[4].  The other 70% of male 
infertility can be explained by defects in anatomy, errors within the complex myriad of 
endocrinological pathways, problems with the immune system, and the environmental 
insults.  Genomic errors can generally be classified into three different groups[4].  The 
first group contains aneuploidies which can be found in 14% of azoospermic patients 
and 3% of oliogozoospermic patients.  The largest group of patients with aneuploidy is 
the group containing Kleinfelter patients (47,XXY).  The majority of these patients are 
azoospermic, but the exact cause of the infertility is not currently known.  The second 
group contains the presence of submicroscopic deletions or “microdeletions” which are 
deletions of groups of genes on the Y chromosome involved in spermatogenesis as well 
as rearrangement of those genes (examples include duplications, inversions, and 
amplifications).  The term microdeletion was coined to describe deletions on the Y 
chromosome that were not detectable to whole chromosomal staining[4].  Thirdly, there 
also is the altered expression of a single gene that leads to infertility of which an 
example is a point mutation leading to infertility which is found within the Androgen 
3 
Insensitivity Syndromes (AIS)[4].  AIS include testicular feminization, Reifenstien, and 
Infertile Male syndrome where a point mutation in the androgen receptor (AR) gene 
leads to infertility.  Androgen receptor binds either testosterone or dihydrotestosterone, 
is activated, dimerizes, is transported to the nucleus, and binds DNA.  However, point 
mutations in either the transactivation domain or the androgen binding domain reduce 
the ability of the downstream genes to organize sexual differentiation. 
 
 Structure of Genomic DNA on the Y Chromosome 
         Deletions of the Y chromosome were first associated with infertility by Teipolo and 
Zuffardi[5].  The area specifically deleted was the q11 band of the Y chromosome and 
has since been termed the azoospermia factor (AZF) region[4].  In 1992, to search for a 
q11
D1 D2 D3 D4 D5 D6 D7 D8 D9 D10 D11 D12 D13 D14 D15 D16 D17 D18 D19 D20 D21 D22 D23 D25D24
AZFa AZFb AZFc
Y Chromosome
Figure 1.  Y Chromosome, Deletion Intervals, and AZF Regions.  Adapted from Vogt et al. 2004.  The 
sizes of each of the deletion intervals are arbitrary sizes and no conclusions can be made with regard to 
comparison between each of the intervals.  However, the size of genomic DNA which includes AZFb and 
AZFc is about 8 Mb in size. 
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gene or set of genes deleted on the Y chromosome of infertile patients, Vollrath et al. 
created a deletion map of the Y chromosome from 96 males with partial deletions which 
is highlighted in Figure 1[6].  Yeast artificial chromosomes containing DNA fragments 
of the patients were sequenced, aligned, and ordered to give a complete, contiguous 
sequence.  Deletion intervals were identified as areas where patients were deleted on the 
Y chromosome as compared with normal patients.  Where common deletions were 
discovered, an interval was created in association with a particular genotype.  Deletion 
intervals were defined using PCR primers and the sequences were used to further define 
the regions of AZFa, AZFb, and AZFc.  Since the sequence of the primers was known as 
well as what comprised the AZF regions, it could be deduced which deletion intervals 
contained each of the AZF regions.  In 1993, Ma et al. suggested that a gene family 
residing in the AZF region of the Y chromosome contained RNA-binding motifs[7].  
The AZF region has been further subdivided into three separate regions termed AZFa, 
AZFb, and AZFc; each involved in different presentations of male infertility as 
illustrated in Figure 1.  The phenotype in patients with deletions in AZFa is described as 
“Sertoli Cell Only” which means that there are no spermatids or spermatogonia present 
in the seminiferous tubules[8].  Sertoli cells function to support the developing sperm 
during the early stages of spermatogenesis.  AZFb deletions are associated with sperm 
cell maturation stalling at the spermatocyte stage where the cells appear to have normal 
cytology, but no postmeiotic cells are present.  The main outcome of a complete deletion 
in the AZFc region is severe infertility[9].  AZF deletions, specifically in the distal Yq11 
region, result in variability in the development of spermatozoa.  Some tubules only have 
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Sertoli cells while others contain sperm cells at various stages of meiosis and 
development.  Partial deletions in the AZF region are responsible for removing some of 
the DAZ genes on the Y chromosome which reside within the AZFc region.  To date, 
there is not complete agreement as to whether partial deletions of the DAZ genes afford 
reduced fertility to the same extent as complete deletion of the AZFc region [9-11]. 
Within the AZFc region, a sequence-tagged site (STS), sY254, is the most 
commonly deleted fragment of DNA in patients with reduced fertility[12].  Sequence-
tagged sites are unique pieces of DNA that can be detected by the polymerase chain 
reaction (PCR) and serve as “landmarks” for genome mapping procedures[6].  The 
sY254 resides within the RNA-binding domain of a gene termed Deleted in 
Azoospermia, or DAZ[12] that was identified through nucleotide analysis of the gene 
from a cDNA library derived from human testis.  However, at the time it was thought 
that there was only a single copy of the gene represented by sY254.  Subsequent 
research on AZFc indicated the presence of four copies of the DAZ gene and a highly 
variable number of DAZ copies [13, 14]. 
 
DAZ Family of Proteins 
          Figure 2 illustrates DAZ gene configurations found on the Y chromosome and the 
autosomal homologue of DAZ, termed DAZL for DAZ-like.  All family members 
consist of at least one RRM (from one to three) at the N terminus and a 24 amino acid 
motif repeated 9 to15 times at the C-terminus (DAZ-repeat domain).  Researchers in 
Taiwan described a cohort of patients with reduced fertility whose RRMs in DAZL 
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contained a point mutation within the RRM and another point mutation outside of the 
RRM[15].  These mutations are indicated as vertical yellow and red bars in Figure 2.  In 
addition, the structure of the DAZ genes is further complicated by the fact that different 
patients exhibit polymorphisms in the number of repeats in the repeat region of the DAZ 
gene as well as the composition of the repeats themselves within the region[16].  For 
example, patient A may have fifteen repeats in DAZ2 as indicated in Figure 2.  
However, patient B may have fourteen repeats in DAZ2 and also have a different 
complement of repeats B, C, D, E, F, G,H, and I (Table 1).  Furthermore, the repeat 
region is currently thought to be the facilitator of protein-protein interactions between 
DAZ and other proteins [17].  When the RRMs of human and mouse are compared it 
becomes evident that there are no differences in the amino acid sequence (Figure 3).  On 
the other hand, the DAZL RRM and the DAZ RRM differ in a few places.  At position 
seven of the RRM, DAZL contains a methionine whereas DAZ contains a valine.  At 
position 18, DAZL contains a valine while DAZ contains an alanine residue.  At position 
29, DAZL contains phenylalanine where DAZ contains a cytosine and so forth.  Of note 
is that none of the differences between DAZ and DAZL lie within the two 
ribonucleoprotein (RNP) domains.  RNP1 and RNP2 are conserved sequences which 
describe RRM domains[18].  RNP1 is well conserved as an octapeptide containing the 
sequence Lys/Arg – Gly – Phe/Tyr – Gly/Ala – Phe – Val – X – Phe/Tyr[19].  The 
RNP2 hexapeptide is less well conserved but is rich in aliphatic residues such as valine, 
glycine, and isoleucine as well as aromatic residues such as phenylalanine.
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Figure 2.  DAZ Family Gene Structure.  Blue boxes indicate the RRMs .  Small yellow triangles indicate the repeat region and the letters within the 
triangles indicate different repeats based on sequence.  Within the DAZL RRM, DAZLmut2 shows the mutation from the Taiwanese public 
resulting in a correlation with reduced fertility.  Just outside of the RRM is another line (DAZLmut1) which indicates a mutation in the Taiwanese 
public that is not associated with reduced fertility.  In addition, the RNP domains are indicated.  Sequences were obtained from Genbank and the 
graphics produced with Accelrys. 
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Table 1.  DAZ Repeat Sequences. 
 Repeat Sequence 
A AYPTYPNSPVQVITGYQLPVYNYQ  
B AYSAYPHSPGQVITGCQLLVYNYQ 
 C EYPTYPDSAFQVTTGYQLPVYNYQ 
D PFPAYPRSPFQVTAGYQLPVYNYQ 
 E AFPAYPNSPFQVATGYQFPVYNYQ 
F PFPAYPSSPFQVTAGYQLPVYNYQ  G AFPAYPNSPVQVTTGYQLPVYNYQ 
H AFPAYPSSPFQVTTGYQLPVYNYQ  
I AFPAYPNSAVQVTTGYQFHVYNYQ 
The left column indicates the lettered repeat found in 
Figure 2.  The right-hand column indicates the sequence 
for each of the repeats. 
 
 
Figure 3 illustrates that both the DAZ and DAZL RRMs fit both of these criteria.  
At least for the U1 spliceosomal protein, the RRM domain folds into an alternating 
series of alpha helices and beta sheets with the RNP domains next to each other on 
opposite beta sheets in an antiparallel fashion[20].  Noticing this feature, Ruggiu et al., 
2000 proceeded to knock out the functionality of the mouse Dazl protein by modifying 
its RRM[21].  Their experiments demonstrated that the RNP domains were required for 
RNA binding. 
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1- LPEGKIMPNTVFVGGIDVRMDETEIRSFFARYGSVKEVKIITDRTGVSKGYGFVSFFNDVDVQKIVESQINFHGKKLKLGPAIR 
2- LPEGKIMPNTVFVGGIDVRMDETEIRSFFARYGSVKEVKIITDRTGVSKGYGFVSFYNDVDVQKIVESQINFHGKKLKLGPAIR 
3- LPEGKIVPNTVFVGGIDARMDETEIGSCFGRYGSVKEVKIITNRTGVSKGYGFVSFVNDVDVQKIVGSQIHFHGKKLKLGPAIR 
4- LPEGKIMPNTVFVGGIDVRMDEAEIRSFFARYGSVKEVKIITDRTGVSKGYGFVSFFNDVDVQKIVESQINFHGKKLKLGPAIR 
5- LPEGKIVPNTVFVGGIDARMDETEIGSCFGRYGSVKEV 
6- LPEGKIMPNTVDVGGIDVRMDETEIRSFFARYGSVKEVKIITDRTGVSKGDGDVSDYNDVDVQKIVESQINFHGKKLKLGPAIR 
       RNP-2     RNP-1 
Figure 3.  Comparison of RRMs of Mouse and Variants Found in Humans.  Line 1 is the human DAZL 
RRM, Line 2 is the mouse Dazl RRM, Line 3 is the human DAZ RRM, Line 4 is the RRM containing 
DAZLmut2 which has been associated with infertility in the Tiawanese public. Line 5 is sY254’s 
complement of the RRM, and Line 6 is the mouse knockout RRM.  Line 5 shows where sY254 would 
amplify in genomic DNA and Line 6 contains the RRM from a mouse that was blocked of Dazl function 
with mutations within the RNP domains which are indicated by underlining.  The two underlined RNP 
(ribonucleoprotein) domains are required features of RNA-binding proteins.  
An autosomal copy of DAZ, DAZL, found on chromosome 3 has been described 
as a, “…master control gene for premeiotic germ cell development,” functioning as an 
RNA-binding protein expressed in the germline of both males and females[4].  DAZL is 
conserved in vertebrates (mouse, zebrafish, and xenopus) and in invertebrates (c. elegans 
and drosophila)[22].  DAZL protein is expressed in the tails of spermatozoa and its RNA 
transcript is also found in the residual cytoplasm of mature spermatozoa[23].  The 
function of Dazl, the autosomal homologue of DAZ in mice, indicates a role in both 
spermatogenesis and oogenesis since disruption of the gene leads to sterility in both 
males and females [24].  Much of the information on DAZ function was derived from 
the Drosophila system in which the DAZ homologue, boule, is required for 
spermatogenesis; when knocked out, spermatogenesis is arrested at the G2/M phase of 
meiosis [25].  The mechanism behind this suggests that boule plays a role in translational 
control of specific mRNAs required for cell cycle progression from G2 to M during 
mitosis [26]. Delayed translation of specific subsets of mRNA is a well documented 
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regulatory mechanism of key importance in spermatogenesis [27]; [28, 29].  As an 
example, in the mouse model, Prbp (Prm-1 RNA binding protein) binds to the 3’UTR of 
Prm-1 mRNA to repress translation for several days during the round spermatid stage of 
spermatogenesis.  Prm1 (mouse protamine 1) is a protein involved in replacing histones 
as packaging constituents of DNA and stabilizes DNA in late spermatogenesis.  
Importantly, regulation of signals in the developing gametes is primarily by post-
transcriptional means and is necessary as one major goal during development in the 
packaging of genetic material into a dense, transcriptionally-silent structure[1].  The 
mRNAs are produced early in spermatogenesis, genomic DNA becomes silent through 
condensation with protamines, and protein production is supported through the effects of 
proteins such as those of the DAZ family. 
The DAZ proteins have a variety of interactions including homodimerization and 
interaction with other proteins expressed during spermatogenesis[17, 21].  Using the 
yeast two-hybrid assay, DAZ was found to interact with two other proteins, DAZAP1 
and DAZAP2 (DAZ Associated Protein) [17].  DAZAP1 is a gene whose product is an 
RNA-binding protein, but DAZAP2 has not been associated with any function.  Both of 
the proteins bind to DAZ and DAZL through the repeat region, whereas DAZL only has 
one “repeat.”  Neither of these proteins was linked to disease states such as reduced 
fertility based on mapping techniques.  In addition, in the mouse, Dazl was found to 
homodimerize in vivo and in vitro in a manner independent of RNA[21].  Considering 
these interactions, the expression of specific subsets of family members may well 
produce widely different outcomes with respect to sperm viability and function.  
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Early investigations involving potential spermatogenesis proteins in the AZF 
region included RBMY, BPY2, and CDY1[30].  The RBMY (RNA-binding motif Y) 
protein contains an RNA-binding domain and is found in the nucleus of germ cells.  The 
BPY2 (basic charge, y-linked 2) protein is not well characterized, but may play a role in 
spermatogenesis[31].  The CDY1 (chromodomain protein, Y-linked 1) protein possesses 
a chromodomain and a histone acetyltransferase domain[32].  The chromodomain is 
implicated in gene repression while the histone acetyltransferase domain is involved in 
histone hyperacetylation.  Histone hyperacetylation facilitates the transition from 
histone-coated DNA to protamine-coated DNA during DNA packaging for 
spermatogenesis.  In addition, CDY1 is found in the nucleus of late spermatids. 
Expression patterns of the DAZ family proteins led researchers to determine that 
the human DAZ and DAZL genes are initially expressed in primordial germ cells and 
continue to be expressed throughout meiosis to haploid post-meiotic germ cells[1].  
Figure 4 illustrates the expression patterns in different species over the course 
spermatogenesis.  Antibody staining showed that the DAZ, DAZL, and boule genes are 
expressed exclusively in germ cells.  Of interest is the comparison between the 
expression patterns between the mouse and human.  Mouse Dazl is expressed from the 
beginning of mitosis to the beginning of differentiation of the sperm cells.  However, in  
12 
Organism Gene Mitosis Meiosis Differentiation
Drosophila boule
C. elegans daz-1
Zebrafish zDAZL
Xenopus Xdazl
Boule
Dazl
Marmoset DAZL
Macaque DAZ/DAZL
BOULE
DAZL
DAZ
Mouse
Human
 
 
Figure 4.  Expression Profiles of the DAZ Family of Genes in Different Organisms.  This graphic 
represents many different experiments by different researchers where the main product detected 
is protein localization through antibody staining  Adapted from Reynolds et al. [1]. 
 
humans, the expression of human DAZL is from mitosis until the end of differentiation.  
Interestingly, DAZ contains the same expression pattern in humans as in mice.  This 
suggests similar, but different roles of DAZ and DAZL in human versus mouse 
reproduction.  Therefore, it may not be possible to fully elucidate the role of the human 
DAZ and DAZL genes in the mouse model. 
 
Deletions, Inversions, and Reordering of Genomic DNA in the AZF Region 
 The presence of repeated regions in DAZ genes as well as the presence of 
multiple gene copies may promote recombination and alterations in gene sequence [33].  
Since the DAZ genes on the Y chromosome exist as multiple copies and indeed the DAZ 
gene itself contains internal repeated motifs, many deletions and rearrangements in the 
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DAZ region affecting expression are likely to occur.  It is also clear that the DAZ region 
is polymorphic, with individual males exhibiting different copy numbers and 
arrangements of DAZ genes as well as different numbers of DAZ repeats within DAZ 
genes [16].  Deletions in the AZF regions occur through recombination events of 
homologous sequences common in the AZF regions of the Y chromosome [34, 35]. 
 
 
P5 P4 P3 P2 P1
D
A
Z2
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Z1
D
A
Z3
D
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Z4
P1.1P1.2
P5/P1.2
P5/P1.1
1 Mb
AZFc
 
Figure 5.  Palindromes in the AZF Region.  Palindrome P5 can roughly be used as a size marker of 1 Mb.  
There are five major palindromes of interest in the AZF region.  Within palindrome 1, there are two 
minipalindromes: P1.2 and P1.1.  The AZFc region is defined by the distal portion of palindrome 3 to the 
distal portion of palindrome 1.  Within palindrome 1 are two minipalindromes: palindrome 1.2 and 
palindrome 1.1.  Depending on where homolgous recombination occurs, either all of the DAZ genes are 
removed or only two of them.  Adapted from Repping et al., 2002. 
 
Within the AZFb and AZFc regions, the genomic sequence is arranged in sets of 
five palindromes (Figure 5)[33].  Because of the complex nature of the palindromic 
sequences, different outcomes to the deletions can be seen.  Figure 5 highlights two of 
the more common examples of deletions due to the presence of palindromic sequences.  
For example, if an ectopic recombination event takes place between palindromes 5 and 
1.1, the entire AZFc region is deleted along with all copies of the DAZ genes which 
reside in palindromes 2 and 1.  However, if a recombination event occurs between 
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palindromes 5 and 1.2, then DAZ3 and DAZ4 remain.  The research involved in 
determining what events took place in certain patients involved the use of PCR primers 
designed specifically to amplify only regions that were not repeated within the AZF 
region[36].  The PCR products afforded the researchers patterns of plus/minus hits from 
which the genomic sequence could be deduced and, therefore, the events leading to the 
deletions determined.  
The AZF region is complicated by deletions or duplications arising from sister 
chromatid exchange between repeated regions within AZF[14].  Through the mechanism 
highlighted in Figure 6, it is possible to delete all copies of DAZ, or delete two copies, 
retain four normal copies, gain two copies, or gain four copies.  In addition, inversions 
can occur due to intrachromsomal exchange between inverted repeats found common 
within the AZF region[37].  When all of the possible mutational events due to the 
repetitive and polymorphic nature of the AZF region are taken into account, the 
complexity of the AZF region can be appreciated. 
 
Putative Role for DAZL 
         The function of DAZ is currently under intense scrutiny by a number of groups.  
Recently a possible role for DAZL as a recruitment protein for poly-A binding protein 
(PABP) in Xenopus was introduced[38].  It was found that DAZL bound the 3’ 
untranslated region (3’UTR) on a reporter mRNA construct and recruited PABP to link 
to the mRNA construct.  In translation the first step begins with the recruitment of the 
cap complex to the 5’ methyl-G cap.  Next, the small ribosomal subunit binds to the 
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initiator codon (AUG) at which point the large ribosomal subunit binds.  Initiation is 
then stimulated with protein construction.  Multiple ribosomal units can initiate and 
follow the mRNA producing a structure called a polysome.  When each ribosome 
reaches a stop codon, the subunits separate.  Circularization of the mRNA by the poly-A 
binding proteins binding the poly-A tail and escorting it close to the 5’ end of the 
transcript would allow for increased translation as the ribosomal units in the 
neighborhood of the initiator codon[38].  The authors suggested that DAZL binds to the 
3’ UTR of mRNAs with shortened poly-A tails to recruit PABP for stimulation of 
translation via this circularization mechanism.  As DAZL and DAZ share similarities in 
their RRM, it is possible that these proteins function in similar fashions to augment 
translation.  However, the presence of some variation could relate to specific differences 
in mRNA specificities or to differences between species so that both DAZL and DAZ 
are needed to allow normal progression of spermatogenesis in those species with both 
genes.  Some overlap in function between DAZL and DAZ is also likely as patients with 
deleted DAZ genes may still produce some sperm cells that are present in their ejaculate 
(Table 2, page 18).  While variation in DAZ copy number and the mechanisms that 
produce this variation have been cited previously in this section, only the absence of all 
copies of DAZ has been consistently related to the phenotype of male infertility [9-11].  
In addition, the role of variation between the separate copies of DAZ, for example those 
with three RRM regions versus one RRM region, is currently unknown.
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Figure 6.  Gene Duplication and Deletion in AZFc by Unequal Crossing Over.  The gr/gr deletion shown above is a deletion mechanism shown to 
increase or decrease the number of DAZ genes shown by the green arrows labeled with r1, r2, r3, and r4.  The “r” number refers to the DAZ gene 
number and is labeled red.  Different sister chromatids can have errors in exchange to produce these results of two versions- one with 2 DAZ genes and 
one with six DAZ genes.  Adapted from Lin et al., 2005.  The terminology above each of the arrows indicate the color that was assigned to them by 
researchers from David Page’s group.  They indicate the color of the arrows and are representative of identical sequences found within the AZF region.  
Grey arrows indicate unique regions within the AZF region.  Additionally, palindromes are indicated above in brackets. 
500K 1M 1.5M 2M 2.5M 3M 3.5M 4M 4.5M
u1 b1 t1 u2 t2 b2 u3 g1 r1 r2 b3 g2 r3 r4 g3 b4
u1 b1 t1 u2 t2 b2 u3 g1 r1 r2 b3 g2 r3 r4 g3 b4
u1 b1 t1 u2 t2 b2 u3 g1 r1 r2 b3 g2 r3 r4
3 g1 r1 r2 b3 g2 r3 r4 g3 b4u1 b1 t1 u2 t2 b2 u3 g1 r1 r2 b3
Full Sequence
tween the gr R peats on matids
Products
+
P3 P2 P1
Non-allelic Recombination Be e  Different Sister Chro
u1 b1 t1 u2 t2 b2 u3 g2 r3 r4 g3 b4
 
17 
CHAPTER II 
GENOMIC ANALYSIS OF DAZ 
 
Introduction 
 Infertility is a medical condition responsible for frustration and significant 
expenditures of healthcare dollars affecting about 15% of couples during their 
reproductive ages (20 to 40 years of age).  Infertility can be attributed to male factors in 
50% of such couples. The mechanisms of male factor-related causes of infertility act 
primarily through reducing numbers of functional spermatozoa that are capable of 
capacitation and fertilization.  In such cases, though the male may be the primary 
affected partner, the most effective treatments involve significant manipulation and risk 
to the female in the process of obtaining ova for fertilization using assisted reproductive 
technologies. The combination of the development of techniques for enhancing 
fertilization using affected sperm cells and advancements in molecular biology of the Y 
chromosome have resulted in identification of genes involved in gametogenesis[13]. In 
particular, at least three regions of the Y chromosome contain genes that are 
occasionally deleted in males with defects in spermatogenesis [39].  Research interests in 
such genes are two-fold. The first is to understand the frequency of such deletions in 
male partners of a general population of infertile couples to elucidate the consequences 
of microdeletions as a form of “inherited infertility.”  The second is to trace the 
molecular function of at least one of the genes to improve understanding of genetic 
regulation of spermatogenesis. Measurements of molecular function may identify 
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portions of the gene product that are critical and where mutations would limit function. 
This insight would lead to improvements in diagnostic screening tests that go beyond 
assessment of the presence or absence of genes to presence of intact, functional gene 
products using reagents and methods currently unavailable.  This study focuses on the 
DAZ gene (deleted in azoospermia). 
 While numerous publications, (Table 2), document the frequency of 
microdeletions of the DAZ region of the Y chromosome in males referred to centers for 
specialized assisted reproduction procedures, few reports provide an assessment of the 
frequency in a general population of male partners of infertile couples.  The reports for 
the centers cited in Table 2 suggest frequencies of DAZ deletions on the order of 11% 
among males with few or no sperm in the ejaculate and on the order of 6% for males 
with sperm concentrations up to 5 million/ml.  As infertility from Y chromosome 
microdeletions affecting spermatogenesis can be overcome by assisted reproduction 
techniques when even a few sperm cells are present, the males born to couples using 
these procedures will inherit their fathers’ affected Y chromosome.  Therefore, 
knowledge of the frequency of microdeletions is needed to justify decisions about 
adding DNA screening procedures to routine semen analysis and for couples considering 
assisted reproduction.  The tagged sequence site (sY254) is located within the RNA-
binding domain of the DAZ genes[40].  The absence of sY254 has been used as a 
diagnostic test for the microdeletion of genes which reside in AZFc (Table 2).  Research 
on DAZ has focused on screening for deletions in the Y chromosome in areas where the 
DAZ genes reside.  A possibility exists that the DAZ proteins produced from these genes 
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might also be defective.  Defective proteins might be produced by minute defects in a 
region critical for protein function. 
 In addition to large deletions, an attractive working hypothesis suggests that 
males may not be deleted in DAZ or DAZL, but might possess mutations in the RRM of 
any or each of the proteins.  Mutations in the RRM could lead to a conformational 
change in DAZ proteins due to amino acid substitutions that affect binding to RNAs.  
One type of mutation frequently found throughout the genome is the single nucleotide 
polymorphism (SNP) associated with a variety of clinical conditions and susceptibilities 
[66], [67].  A group from Taiwan used SNP analysis to identify two SNPs in DAZL[15].  
One SNP, located within the RRM, is associated with abnormal semen quality, while a 
second SNP, located outside of the RRM, was not associated with defects in 
spermatogenesis.  Therefore, men with abnormal semen analyses may have other SNPs 
in their DAZL or DAZ genes.  Men in central Texas have not been characterized for 
SNPs in relation to abnormal semen analysis.  Another goal of this study was to perform 
SNP analysis in men with reported abnormal semen analysis in hopes to find a 
correlation between SNPs and reduced fertility in patients.  Ultimately, haplotype 
analysis on a large cohort of patients will yield the most meaningful results.
 
  
 
 
Azoospermia† Severe Oligozoospermia† Oligozoospermia
† Fertile†  
Ref Date 
Deletion Total Deletion Total Deletion Total Deletion Total Total Patients 
Locus 
[12] 1995 21 89     0 90 179 sY254 directly and Includes sY254 
[41] 1996   2 2     2 sY254 directly 
[42] 1996 0 40 0 9   0 16 65 Includes sY254 
[43] 1996 1 51 2 38 0 11 0 100 200 sY254 Directly & sY149 
[44] 1996 0 19   0 14† 0 10 43 Includes sY254 by sY149 
[8] 1996   13 370   0 200 570 Includes sY254 
[40] 1997 3 74 2 94   0 86 254 sY254 Directly 
[45] 1997 1 26 1 30 0 42 0 302 400 sY254 Directly 
[46] 1997 1 13 0 79 0 79 0 33 204 sY254 Directly 
[47] 1997 4 108 3 32 0 10 0 10 160 sY254 Directly 
[48] 1997 0 19   7 111† 0 34 164 sY254 Directly 
[49] 1997 6 25 2 61   0 35 121 sY254 by sY255 
[50] 1997 5 43 0 28 0 87 0 55 213 sY254 Directly 
[51] 1998 3 43 3 86 0 39 0 135 303 sY254 Directly 
[52] 1998 8 50   2 136† 0 100 286 sY254 Directly 
[53] 1999 1 22 2 68 0 27 0 27 144 sY254 Directly 
[54] 1999 10 83 3 39 0 7 0 52 181 sY254 Directly 
[39] 1999 10 36 26 278 5 200 4 920 1434 sY254 Directly 
[55] 1999 14 55 14 85 0 40 0 100 280 sY254 Directly 
[56] 1999 3 21   3 32† 0 35 88 sY254 Directly 
Table 2.  Estimation of Frequency of Y Chromosome DAZ Microdeletions in Relation to Sperm Cell Concentration of Semen.  Publications cited 
utilized PCR primers found in the RRM of the DNA sequence for DAZ. 
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Azoospermia† Severe Oligozoospermia† Oligozoospermia
† Fertile†  
Ref Date 
Deletion Total Deletion Total Deletion Total Deletion Total Total Patients 
Locus 
Table 2.  Continued.
[57] 1999 7 40     0 14 54 sY254 Directly 
[58] 2000 1 15 0 50 0 62 0 141 268 sY254 Directly 
[59] 2000 8 57 0 71     128 sY254 by sY149 
[60] 2001 1 44 4 83   0 30 157 sY254 Directly 
[61] 2001 5 54       54 sY254 by sY255 
[62] 2001 2 5 5 14     19 sY254 Directly 
[63] 2002   14 77   0 107 184 sY254 Directly 
[64] 2003 8 142 1 38      sY254 Directly 
[65] 2003 2 29 2 31   0 12  sY254 Directly 
Tot.  125 1203 99 1663 17 897 4 2632   
%  10.39% 5.95% 1.90% 
0.15
%   
    
†Azoospermia indicates no sperm found in the semen, severe oligozoospermia indicates a sperm number concentration of up to 5 million sperm cells / ml, 
oligozoospermia indicates between 5 and 20 million sperm cells / ml, and normal is above 20 million sperm cells / ml. 
‡These references were pooled because the authors did not identify patients specifically as severe oligozoospermic.  Therefore the more conservative 
description of oligozoospermic was utilized. 
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Materials and Methods 
 
PCR 
 Polymerase Chain Reaction (PCR) was performed using standard techniques 
where the PCR reactions contained 1X PCR Buffer (50mM KCl, 10mM Tris-HCl, pH 
8.3, 0.001% gelatin), 2.5mM MgCl2, 1.25mM each dNTPs, 0.5 Units/µl AmpliTaq Gold, 
and 5.3 µM of each primer.  The reagents used for each of the PCR reactions were 
obtained from Applied Biosystems (Foster City, CA).  PCR cycle parameters were 
specific to each product and determined empirically.  The template used for the PCR 
reactions is described in the following section entitled “sY254 Screening.” 
 
sY254 Screening 
For surveying the presence or absence of the sY254 locus, an anonymous 
submission procedure was used to obtain and evaluate cellular residues of semen 
samples from a population of male partners of infertile couples referred from a general 
population to a subspecialty practice of Reproductive Endocrinology and Infertility at 
Scott and White Hospital and Clinics (Temple, TX).  This allowed for complete 
sampling of this patient population.  The infertility practice is located in a central Texas 
multi-specialty clinic that provides healthcare services to a 16 county region of diverse 
racial, ethnic, social, and economic classes.  The anonymous sampling procedure was 
established in 1996 and has added about 200 new patients each year.  Males provide 
samples to the Scott & White Andrology Laboratory for semen analysis as a part of 
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evaluation for infertility.  Men who were fertile or who had previously undergone 
vasectomies or surgical and medical interventions that reduced fertility, such as 
treatment for various cancers, were excluded.  When the requested semen analysis was 
completed, the residual sample was cryopreserved for future study   Only one sample per 
individual was saved.  This residue was diluted in sterile saline and centrifuged at 800 x 
g for 20 min to produce a cell pellet. The supernatant was removed and a small quantity 
of sterile water was provided to wet the pellet to allow transfer to a sterile plastic 
cryovial. The vial was labeled with a unique random number from a computer-generated 
list that does not allow for repeats. The semen analysis results and certain demographic 
information such as patient age and smoking status were recorded on a form that 
included a random number as the only identifier.  Samples were frozen and stored at -
80°C.  Results of the semen analysis were posted to a Microsoft Excel database along 
with results from molecular-based assays. At the time of this trial, the inventory of 
samples represented more than 1,300 individuals, 6 years of collections, and projected 
annual increases of 200 to 300 unique males each year.  
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Figure 7.  2% Agarose Gel with SYBR®-Green Labeling of PCR Products in Screening 
Assay for sY254 Marker of Y Chromosome DAZ Locus.  A.  Lane 1: molecular size markers, 
Lane 2: negative control, Lane 3: male DNA (380 bp product of DAZ and 272 bp product 
from chromosome 17) with extra band on top, Lane 4: control female DNA (272 bp product 
of chromosome 17 marker).  B.  Gel showing that an increase in annealing temperature can 
get rid of the extra band found from the D17S804 primers.  Lane 1: molecular weight 
standards, Lane 2: negative control, Lanes 3-6: an increase in annealing temperature gets rid 
of the extra band found in D17S804. 
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 The DNA was extracted using the GenElute Kit (Sigma Chemical Co., St. Louis, 
MO) and assayed by PCR using primers for sY254 that map to the DAZ locus and 
primers for D17S804 that map to chromosome 17 as a control.  DAZ primers for sY254 
produce a 380 bp product with 5’-GGG TGT TAC CAG AAG GCA AA-3’ and 5’-GAA 
CCG TAT CTA CCA AAG CAG C-3’ while the D17S804 primers produce 272 bp 
product with 5’-TGT TCC ACG TGT AGG TGT CA-3’ and 5’-CAC TGT GAT GAG 
ATG TCA TTC C-3’. The PCR products were separated by using an agarose submarine 
gel (Figure 7). 
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Additionally, in this series, 88 DNA extracts were tested using Y Chromosome 
Deletion Detection System (Promega Corp, Madison, WI), a commercially available 
multiplex PCR system for screening multiple markers of the Y-chromosome .  
Manufacturer’s guidelines were followed. When specific PCR product bands were 
absent, individual PCR assays were performed to verify the results. 
 
SNP Analysis 
For SNP analysis of the DAZL RRM, DNA was extracted from 32 residual 
semen samples using the GeneElute kit.  The samples were placed into 96-well plates 
and supplied to Polymorphic DNA Technologies (Alameda, CA) for processing.  This 
company was used to minimize the cost of performing the sequence analysis on multiple 
patients.  While the samples were in transit an e-mail was sent to Polymorphic DNA 
containing a text file with the DAZL genomic DNA sequence to be evaluated.  Resulting 
sequences were examined using Microsoft Excel and DSGene from Accelrys (San 
Diego, CA).  The approach to primer selection for the PCR reactions included the use of 
multiple primers sets to amplify the region of interest.  Because of the similarity between 
DAZL and DAZ, only sequences which only contained DAZL sequence and no Y 
chromosome DAZ sequence were used in the final sequence analysis. 
 
 
 
 
 
26 
Results 
DAZ Deletion Screening 
A total of 1,325 semen residues were collected by the Andrology Laboratory at 
Scott & White, Temple, TX and results of semen analyses are summarized in Table 3. 
About 30% of samples had some type of abnormality based on sperm concentration. 
 
Table 3.  Semen Analysis Results of 1,325 Male Partners of Infertile Couples. 
Characteristic Units Mean ± 
SD Median Range 
Percent outside 
reference range * 
Semen volume mL 3.7 ± 2.4 3.1 0.1 – 18.6 24 
Sperm concentration Millions/mL 51± 76 38 0 –2,200 29 
Progressive motility % 43 ± 20 43 0-96 21 
Normal morphology % 18± 9 17 0-61 43 
Total number of sperm cells 
in semen sample Millions 
158 ± 
161 112 0-1,452 22 
*Samples outside of reference range for volume (<2.0 mL), sperm cell concentration (<20 million/mL), progressive motility (<25%), 
normal morphology using strict criteria (<15%), total sperm cells in ejaculate (<40 million)[3]. 
# Only 450/1325 (34%) samples were within reference range for all characteristics. 
 
 
 
According to WHO standards[3], the most common abnormality is reduced 
concentrations of sperm cells in the ejaculate related to, but not identical to a reduction 
in the total number of sperm cells in the sample. Of the semen residues available for 
analysis, 669 were extracted and subjected to PCR for analysis for DAZ deletion.  Two 
of these samples were shown by PCR to be deficient in the sY254 locus in the RRM of 
DAZ. One sample contained 0.4 million and the other contained 17 million total sperm 
cells.  Tables 4 and 5 summarize results of the DAZ deletion screening analyses based 
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on sperm cell concentration, the most commonly reported result, and total sperm cell 
content, a more stringent classification system for oligozoospermia.  None of the 43 
semen samples lacking sperm cells were deleted for the sY254 locus.  Although 
information from clinical examinations was not available to verify that these men had 
unobstructed azoospermia, none had a history of vasectomy, vasectomy reversal, or 
cancer treatment.  However, the frequency of genetic abnormalities associated with 
congenital absence of the vas deferens was not assessed, so some men might have 
absence of the vas deferens and, therefore, suffer from obstructed azoospermia.  In this 
case, semen volume would be expected to be in the range of 0.5 ml.  However, all men 
tested in the current study had semen volumes of 1.0 ml or greater.  With this limitation, 
these samples may not include men with unobstructed azoospermia.  Nevertheless, the 
frequency of 0/43 might underestimate the actual population frequency. 
The frequency of DAZ deletions in male partners of infertile couples in this 
sample of central Texas patients (Table 4) is significantly less than published results 
(Table 2).  In men with normal concentrations of sperm cells in their semen, the 
frequency of microdeletions in this series was low and similar to that reported in the 
literature. 
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Table 4.  Relationship of Y Chromosome DAZ Microdeletion to Sperm Cell Concentration Results 
for Male Partners of Infertile Couples in Central Texas.  All samples were screened for the presence 
or absence of the sY254 locus. 
Sperm concentration 
(million/mL) N 
Frequency in 
Population (%) 
DAZ deleted / 
Screened (%) 95% CI 
Reported 
estimates 
“0” (azoospermia) 51 3.8 0/43 (0%) 0 to 8.2% 
125/1203 
(10.4%) 
> 0 to < 5 66 5.0 2/63 (3.2%)† 0.6 to 12.0% 
99/1663 
(6.0%) 
5 to < 20 264 19.9 0/201 (0%) 0 to 2.3% 5/604 (0.8%) 
20 and greater 944 71.3 0/362 (0%) 0 to 1.0% 4/2632 (0.2%) 
Total 1325 100 2/669   
 
†Sample 729 with 4 million/mL and sample 237 with 0.089 million/mL 
 
 
As DAZ deletions from the Y chromosome relate most closely to sperm cell 
production, comparing the frequency of deletions in association with sperm cell 
concentration can be misleading.  For example, some men may have low numbers of 
sperm in their ejaculate, but a reduced volume of seminal vesicle secretions results in a 
normal concentration.  Others may have normal numbers of sperm with high volume of 
semen resulting in reduced concentrations.  Therefore, results from this series based on 
sperm cell content in the total ejaculate are summarized in Table 5.  Using this system 
the two males with DAZ deletions can be classified as having either severe 
oligozoospermia or oligozoospermia (Table 5).  Other reports in the literature have not 
been based on this system and have not provided semen volumes to allow similar 
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comparisons.  Table 6 summarizes results from multiple tagged sequence testing of #237 
male deleted for DAZ using a commercially-available kit.  Semen residue #729 did not 
provide enough DNA after repeated analyses to support additional multiple sequence 
testing.  However, sample #237 was used for this analysis.  The tagged sites, sY152 
through sY157, included five DAZ-specific sites found to be deleted.  Other regions of 
the Y chromosome associated with the AZFa and AZFb portions were present in 
genomic DNA from this male.  This supports the observation that the male providing the 
sample #237 has a palindromic deletion (P1.1 to P3) as described by Repping et al. [36].  
Figure 8 shows the regions amplified with PCR using the Promega kit. 
 
 
Table 5.  Relationship of DAZ Deletion to Total Number of Sperm Cells in Semen Samples of Male 
Partners of Infertile Couples in Central Texas. 
Total sperm cells (millions) N (% Population) % DAZ deleted 95% CI 
“0” azoospermia 51 (3.8%) 0/43 (0%) 0 to 8.1% 
> 0 to < 5 31 (2.3%) 1†/31 (3.2%) 0.8 to 21.4 % 
5 to <20 74 (5.6%) 1††/71 (1.4%) 0 to 5.1% 
20 to <40 135 (10.2%) 0/103 (0%) 0 to 3.6 % 
40 and greater 1034 (78.1%) 0/421 (0%) 0 to 0.9 % 
† Sample 237 with 398,000 sperm cells 
†† Sample 729 with  16.8 million sperm cells 
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Table 6.  PCR Detection of Y Chromosome Deletions*. 
Primer set Y chromosome site Presence of PCR product from semen residue #237 
SY81 DYS 271 + 
SY181 KAL-Y + 
SY121 DYS212 + 
SYPR3 SMCY + 
SY124 DYS215 + 
SY127 DYS218 + 
SY128 DYS219 + 
SY130 DYS221 + 
SY133 DYS223 + 
SY145 DYF51S1 + 
SY153 DYS237 + 
SY152 DYS236 - 
SY242 DAZ - 
SY239 DAZ - 
SY208 DAZ - 
SY254 DAZ - 
SY255 DAZ - 
SY157 DYS240 - 
* Y chromosome microdeletion screening with Y Chromosome Deletion Detection System (Promega 
Corp, Madison, WI), a multiplex PCR system for screening multiple markers of the Y-chromosome. 
 
 
Illustrated are the three AZF regions, the five major palindrome locations, and 
the various STS sites used in the multiplex Promega assay.  The STSs highlight the 
repetitive nature of the Y chromosome in this region.  The sequences used to generate 
this map are from Kuroda-Kawaguchi et al. and the sequence can be found in online 
supplemental material[33].  Figure 9 illustrates a magnified portion of the AZF region 
focusing mainly on AZFc and the STSs used primarily in PCR detection to identify the 
structure of deletions on the Y chromosome.
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Figure 8.  The AZF Regions and STS Sites on the Long Arm of the Y Chromosome.  The three AZF regions are shown on the bottom as darker red 
bars where the palindromes are brighter red and shown just above.  Above the black line showing distances are the locations of each of the STS 
sites found in the Promega kit. 
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Figure 9.  AZFc Region and STS Sites.  The palindromes are located on the bottom of the figure with small blue boxes indicating 
minipalindromes which are hotspots for recombination; deleting portions of the DAZ copy number.  Above the black line are the STSs 
found within the various AZF regions demonstrating the locations of multiple copies.  The green arrows represent the DAZ copies 
found on the Y chromosome. 
 
33 
Are There Point Mutations in the DAZL RRM? 
Another type of genomic mutation that could manifest itself in the form of aberrant 
function of DAZ proteins is the point mutation.  The DNA from semen samples from 32 
anonymous patients was subjected to sequence analysis of the RRM genomic DNA 
portion of the DAZL gene.  The DAZL gene was chosen instead of the DAZ gene for 
two reasons.  The first reason that DAZL was chosen instead of DAZ is that it was 
already stated that the DAZL is necessary for spermatogenesis.  There will be no 
Patient 1738, wt, C
Patient 59, A
Patient 101, M (C and A)
Figure 10.  A Sample Comparison of Chromatographs from Different Patients.  This figure 
represents SNP#2 found in Table 7.  Patient 1738 represents “wild type” at this position, which 
contains cytosine.  Patient 59 possesses an adenosine at the position, and Patient 101 contains both 
forms. 
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spermatogenesis if there is no DAZL gene.  In addition, detecting an SNP in one of the 
many copies of the DAZ gene would prove to be a difficult task.  If there were an SNP 
in one of the DAZ genes, the result would be hidden from view by the other copies.  The 
RRM was chosen because it is the defining feature of a group of RNA-binding proteins 
containing two RNP (ribonucleoprotein) sites.  Because of the cost of sequencing and 
the difficulties in designing primers, only the RRM was focused on as a site for SNP 
exploration.  The hypothesis of the experiment was that a point mutation leading to an 
amino acid substitution in the RRM within DAZL would change the function of DAZL 
due to modifications of structure and binding of DAZL to RNA.   
The DNA sequence chromatograms were examined for the presence of SNPs 
within the area of exons in the RRM of DAZL.  The size of the genomic fragment 
analyzed was 1,508 bp in genomic DNA on chromosome 3.  Figure 10 provides an 
example of patient sequences aligned with wild-type through a region of interest within 
the RRM.  It illustrates what results look like when sequences are aligned with each 
other and for each of the possible nucleotides at each position.  The SNP was found at 
position 262 of the genomic DNA complement of the RRM, which localizes to an intron.  
Patient 1738 has a cytosine while patient 59 has an adenosine at this position, and patient 
101 had equal amounts of cytosine and adenosine at a single position.  The double signal 
at position 262 of the RRM for patient 101 indicates equal amounts of template for 
detection in the PCR reaction.  This suggests that the sperm cell population contains 
equal numbers of sperm with each SNP at this position.  Because there were 14 other 
patients exhibiting this genotype it is unlikely that this is an artifact of the PCR reaction.
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5 0 1 0 0 1 5 0 2 0 0 2 5 0 3 0 0 3 5 0
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4 0 0 4 5 0 5 0 0 5 5 0 6 0 0 6 5 0 7 0 0 7 5 0
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8 0 0 8 5 0 9 0 0 9 5 0 1 ,0 0 0 1 ,0 5 0 1 ,1 0 0
R R M
S e q u e n ce  N a m e : U nt it led1  - S equenc e
L e n g th : 1508
1 ,2 0 0 1 ,2 5 0 1 ,3 0 0 1 ,3 5 0 1 ,4 0 0 1 ,4 5 0 1 ,5 0 0
Figure 11.  DAZL RRM Genomic SNPs.  The location of the various SNPs within the genomic DNA comprising the RRM of DAZL are indicated along with 
the exons depicted as red horizontal bars.  The size of the compete genomic complement of the RRM is also shown as 1508 bp.  All SNPs which were 
discovered were found within introns except SNP1 which was a silent or null mutation. 
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The resulting SNPs were arranged graphically (Figure 11) to reveal the absence 
of  SNPs within any exon, except for one SNP in an exon resulting in a silent mutation 
that presents as a polymorphic nucleotide without a resulting change in amino acid 
sequence.  In this case there was an isoleucine to isoleucine conservative change (ATT 
to ATA).  The location of SNPs within introns were unlikely to have a direct effect on 
splicing signals present in the genomic complement of DNA which could potentially 
disrupt the RNA binding domain of DAZL.  Four sequences essential for splicing 
include the 5’ splice site, the 3’ splice site, the branch site, and the polypyrimidine tract 
[68].  The 5’ splice site possesses the sequence Exon+AG|GURAGU where the splicing 
There were a total of six SNPs detected in the genomic region of 32 patients within the RRM of 
DAZL.  Of the six SNPs detected, only SNP#1 was located within an exon while the remainder were 
within introns.  Within SNP#1 the only mutation found was a silent mutation- not leading to an 
amino acid change.  The remainder of the SNPs found was within introns and found not to affect 
splicing of the DAZL protein.  Sperm numbers are also indicated where normal is considered >20 
million sperm cells / ml, oligozoospermic is considered up to 5 million sperm cells / ml, and 
azoospermic is considered no sperm cells in the semen. 
SNP Intron/Exon Nucleotide(s) # Patients Mutation/Transversion # Normal # Oligozoospermic # Azoospermic
T (wt) 17 3 11 3
W (A and T) 1 ATT (Ile) - ATA (Ile) 0 0 1
C (wt) 3 1 2 0
M (C and A) 14 None 0 10 4
A 11 None 1 8 2
A (wt) 23 3 15 5
C 1 None 0 1 0
G (wt) 21 1 15 5
K (T and G) 1 None 0 1 0
A (wt) 21 3 14 4
R (A and G) 10 None 0 8 2
A (wt) 11 1 6 4
M (C and A) 5 None 0 4 1
SNP#5
SNP#6
Intron
Intron
SNP#1
SNP#2
Exon
Intron
Intron
Intron
SNP#3
SNP#4
Table 7.  Summary of Distribution of SNP Types.
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site is delineated by the vertical bar.  The two bold nucleotides which follow the bar are 
highly conserved and rarely, if ever, change.  The key to the nucleotides is: R represents 
purine nucleotides, Y represents pyrimidine nucleotides, and N is any nucleotide.  The 3’ 
splice site contains the sequence YAG|+Exon where the vertical bar precedes the 
following exon.  The branch site, found between 18 and 40 nucleotides upstream of the 
3’ splice site, contains the sequence YNCURAY where the branch formation site is 
underlined.  Finally, the polypyrimidine tract Yn precedes the 3’ splice site in a distance 
that is variable.  By examining sequence data directly, no SNP in the DAZL region 
 contained a mutation in any of these sites.  Furthermore, when the genomic sequence, 
imbued with SNPs garnered from this experiment, was applied to the exon prediction 
program Genscan (http://genes.mit.edu/GENSCAN.html) it was found that no SNP 
altered the predicted peptide sequence.  To organize the data, Table 7 lists the number of 
individuals with each type of SNP.  All individuals had at least one type of SNP.  
Additionally, semen characteristics are indicated for each of the SNP groups. 
 Extensive SNP analysis on patients within the DAZL region created haplotypes 
from which susceptibility to spermatogenic failure can be associated[69].  When their 
data were compared to that from the present study, SNP6 was the same nucleotide found 
to be polymorphic within the population studied by Teng (2006).  The nucleotide in 
question was not found, however, to be associated with any type of spermatogenic 
failure. 
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Discussion 
 
While numerous publications have documented the frequency of microdeletions 
in the DAZ region of the Y chromosome in males referred to centers for specialized 
assisted reproduction procedures, few reports indicate results of assessment of the 
frequency in a general population of male partners of infertile couples.  Kent-First et al. 
1999, evaluated 514 infertile males with 7% of 200 of the men from an unselected 
infertile population described as a consecutive series referred to a urology  
practice for male factor infertility and having microdeletions[39].  Subgroups of highly 
selected patients in this study had between 20.5% and 58.3% of individuals with 
microdeletions.  These results indicate that highly selected subgroups of men have 
higher frequencies of microdeletions than the general population of infertile subjects.  
Male partners of infertile couples in central Texas included 1300 individuals from which 
the present study provides results from screening 669 samples. 
 Earlier reports suggested frequencies of DAZ deletions of 11% among males 
with no sperm in the ejaculate and 6% for males with sperm concentrations up to 5 
million/ml (Table 2).  These results were used to support the recommendation that 
laboratories offering semen analysis for evaluation of male partners of subfertile couples 
include PCR-based screening methods.  However, in the present study, over a period of 
6 years, only 1300 individual males had an initial semen analysis.  Of these, only 2 of 
669 samples were screened for DAZ deletion using optimized PCR with STS marker 
sY254 to detect a deletion. Both semen samples contained sperm cells and one sample 
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had sufficient numbers of motile sperm to suggest a good likelihood of success with 
assisted reproduction procedures.  Because of the anonymous nature of the sampling 
process, a follow-up assessment was not possible.  However, the frequency of affected 
males is rare in this study’s population.  Singh et al. (2005) stated that their patients had 
no AZFa deletion whereas reports from others in India indicated AZFa deletions 
correlated with reduced fertility in males, perhaps due to, “…different backgrounds and 
effect modifiers.  Since male infertility is a multifactorial disorder, the contributions of 
environmental and occupational insults may not be underestimated.” 
The sY254 marker is utilized to assess the presence of genomic copies of DAZ 
because of its location in the expressed portion of the mRNA binding domain.  At least 
eight such domains exist in the four copies of DAZ located on the Y-chromosome, so the 
absence of a PCR signal suggests that all copies of Y-chromosome DAZ have been lost.  
However, the presence of the PCR signal does not prove that the DAZ genes will result 
in expression of functional protein which adds complexity to the interpretation of 
screening data for this single Y-chromosome gene locus. 
  In addition to relatively large changes in the final structure of the DAZ proteins,  
subtle genomic mutations may have a measurable effect on fertility in humans.  One 
such example is a point mutation where a single nucleotide causes a single amino acid 
substitution in an area critical for protein function.  Diseases commonly associated with 
SNPs are cystic fibrosis, Creutzfeldt–Jakob, and Crohn’s disease [67], as well as 
Alzheimer’s Disease [70] in which SNPs in brain-derived neurotrophic factor influence 
development of the disease.  As mentioned in Chapter I, a mutation in the androgen 
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receptor can also have a dire consequence on male fertility.  Furthermore, a SNP in the 
protamine 1 (PRM-1) gene is a candidate for infertility in the male [71].  The SNP 
within the PRM-1 gene disrupts an arginine-rich conserved core of the protamine needed 
for binding DNA.  Additionally this SNP may add another phosphorylation site within 
the protein to affect secondary structure of the protein. 
In the current study, a mutation in exon 1 of the RRM of DAZL was identified 
and proved to be a silent mutation encoding isoleucine in both cases.  The goal of SNP 
screening was to find a point mutation associated with reduced fertility due perhaps to 
conformational changes in the encoded protein.  The other SNPs in genomic DNA of the 
32 patients were confined to introns.  One mechanism by which SNPs in introns can 
affect fertility is alteration of splice sites that affect how the DAZL protein is assembled.  
An example of the effect of a SNP upon splicing is the alternative splicing observed 
from a SNP in humans with reduced nicotinamide adenine dinucleotide 
phosphate:quinone oxidoreductase-1 variant 2.  When this SNP is present, exon 4 is 
removed from the gene leading to expression of a truncated, nonfunctional gene 
product[72].  In the present study, SNPs were located in  regions remote from known 
splice junctions or signals. 
Recently, Teng et al. performed a more comprehensive SNP analysis within the 
DAZL region on the Han population in Tiawan[69].  They found a SNP within an intron 
of DAZL dense with polypyrimidines called the PCE or polypyrimidine controlling 
element.  This was interesting because Zuccato et al. reported that a mutant within the 
PCE determined whether exon 9 was present within the cystic fibrosis transmembrane 
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conductance regulator gene[73].  Because Teng et al. found SNPs outside of the RRM, it 
is important for to examine sequences outside of the RRM and cover the complete 
genomic sequence for mutations that may lead to changes in functional proteins.  
Because of potential splice variants, RT-PCR should be used to identify potential exons 
that could be removed from the total DAZL protein. 
 More patient samples are needed to identify rare SNPs that may affect the DAZL 
gene.  When more data are present, haplotypes can be formed and linked to specific 
semen analyses to establish association with sperm production.  However, there may be 
more levels of regulation when Y chromosome DAZ’s function is included in 
spermatogenesis as DAZ can exist in several forms that have greater or fewer repeat 
regions important for protein-protein interactions.  A number of proteins that interact 
with DAZ directly have been identified [17, 74, 75].  The DAZAP1 codes for an RNA-
binding protein, whereas DAZAP2 has no known function.  Both of these proteins bind 
DAZ proteins through the repeat region and are expressed in the testis.  The DAZAP1 is 
also expressed in ovarian luteal cells and may have functions similar to DAZ proteins in 
that they bind RNAs related to cell cycle control.  The DZIP1 also binds DAZ proteins 
and is expressed in premeiotic spermatogonial cells.  Because of the potential for 
interactions of DAZ with other proteins, even single amino acid changes and small 
changes in secondary structure may affect binding to RNA or other proteins to affect 
downstream functions of DAZ.  To assess function, the proteins encoded by the various 
forms of DAZ must be expressed and experiments performed to determine specific 
functionality. 
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CHAPTER III 
ISOLATION, CLONING, AND VERIFICATION OF DAZL 
PROTEINS AND VARIANTS 
 
 
 
Introduction 
  
Genomic DNA can be used to infer amino acid primary sequence of a protein, 
but not function.  It is necessary to express the DAZL and DAZ genes in the form of 
proteins to assess their function.  It has been suspected for some time that the DAZ 
family of proteins are RNA-binding proteins[7, 76].  DAZ proteins have been expressed 
in E. coli systems and used in yeast for two hybrid assays[38, 77-81] and a variety of 
other assays have been utilized to determine their function.  These include the 
electrophoretic gel shift mobility assay (EMSA) which is commonly used for 
determining equilibrium and kinetic constants of RNA-protein interactions[82].  Other 
assays to assess RNA-protein interactions include RNA footprinting, nitrocellulose filter 
binding, and northwestern screening of libraries[83].  In this study DAZL, mutant forms 
of DAZL, DAZ, and MBP proteins were cloned, expressed, and tested for binding to 
radiolabeled synthetic RNA to assess RNA binding activity. 
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Materials and Methods 
 
PCR from Phage Library to Amplify DAZL 
 
The basic construction of DAZL and all other proteins involved in this study 
made use of the TEV protease linker on the amino terminus of the protein.  A TEV 
protease linker was incorporated into the protein such that upon cleavage of the desired 
protein, there would be only an additional glycine on the amino terminus.  Glycine was 
chosen to minimize potential effects on protein function due to its small size and neutral 
charge.  Shown below in Figure 12 is an example of the 5’ end configuration when 
designing primers were used to amplify a gene with the TEV protease linker.  The 
premise is that the 3’ end of the primer will anneal to the sequence of interest and the 
amplifications during PCR will amplify not only the gene of interest but will include, on 
its 5’ end, the signal to create a TEV protease site. 
 
 
Sequence  GGG GAG AAC CTG TAC TTC CAG GGG ATG TCT GCT GCA AAT CC 
aa Sequence Gly Glu Asn Leu Tyr Phe Gln Gly DAZ------------------> 
Function        |TEV Protease Site---------| 
Cleavage Site                          ^ 
        Figure 12.  Illustration of TEV Protease Linker. 
 
 
PCR conditions used to generate a DNA copy of the DAZL coding sequence 
from the Clontech phage library included a final concentration of 2mM MgCl2, 200µM 
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each dNTPs, 530µM each primer, 1X PCR buffer (see Chapter II Materials and 
Methods), and 1.25 units of AmpliTaq Gold.  All reagents were obtained from Applied 
Biosystems (Foster City, CA).  The primers (designed specifically for this procedure) 
were DAZLF+TEV- 5’-GGG GAG AAC CTG TAC TTC CAG GGG ATG TCT ACT 
GCA AAT CCT GAA-3’ and the reverse primer DAZLR+3Stops-  5’-TCA GCT AAT 
TAT CAA ACA GAT TTA AGC ATT GC-3’.  The PCR was performed in Stratagene’s 
Robocycler (La Jolla, CA) with an initial denaturation of 95°C for 15 min then 35 cycles 
at 94°C for 30 sec, 56°C annealing for 1 min, and a 72°C extension for 1 min and 30 sec.  
A final extension for 5 min at 72°C finished the PCR.  5 µl of 6X loading dye consisting 
of 2.5 g/ml Ficoll and 25 mg/ml bromophenol blue was used in a 25 µl PCR reaction.  
The agarose gel used for product detection was a 1% SeaKem LE (BioWhittaker 
Molecular Applications, Rockland, ME) gel run under standard conditions of 70V for 90 
to 120 min in 1X TBE. 
 
Cloning of PCR Products 
Cloning employed the quick cloning protocol as described by Invitrogen using 
the pCR2.1 cloning vector and the following transformation into TOP10 cells 
(Invitrogen, Carlsbad, CA).  Briefly, 4 µl of the PCR reaction was mixed with 1 µl 10 
ng/µl of the pCR2.1 vector and incubated at room temperature for 5 min.  Four 
microliters of the cloning reaction was mixed with the contents of a tube of TOP10 cells 
and gently mixed by flicking the tube softly.  The transformation was allowed to proceed 
on ice for 30 minutes and 60 µl of the transformed cells were plated onto prewarmed and 
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dried LB/agar plates containing 50 µg/ml of carbenicillin.  The plates were incubated 
overnight at 37°C. 
 
Streak Plates 
 Streak plates were made by picking single colonies from the cloning plate and 
streaking separate lines on LB/agar plates containing antibiotics.  PCR was performed on 
individual isolates to confirm identity and the primers used were specific for each 
application. 
 
Midipreps 
Midipreps were performed according to manufacturer’s instructions (Qiagen, 
Valencia, CA).  The only modifications were to midipreps involving low-copy plasmids 
such as pMAL (New England Biolabs, Ipswich, MA).  In these cases, the amounts of 
cells and denaturants were increased two-fold.   However, all of the lysed samples were 
pooled for application to a single column for increase in DNA amount.  In the majority 
of cases, 25 ml of an overnight culture was centrifuged for 15 min. in a Beckman JA-20 
rotor at 4°C at 7,000 rpm in polycarbonate tubes.  After centrifugation, the supernatants 
were discarded and the pellets were placed at -20°C overnight.  The pellet was 
suspended in 4ml of QIAGEN Buffer P1.  The pellets were homogenized with pipetting 
and vortexing until no visible clumps remained.  Four milliliters of QIAGEN Buffer P2 
was added to lyse the cells and mixed with gentle rocking by hand.  The solution was 
then allowed to incubate at room temperature for no more than 5 minutes.  If lysis was 
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not complete after 1 minute then more of buffer P2 was added until lysis was complete.  
Complete lysis of cells had the appearance of a translucent rather than opaque liquid in 
the tube.  After lysis was complete, an equal volume of QIAGEN Buffer P3 to QIAGEN 
Buffer P2 was added to the tube and rocked gently by hand.  The solution containing 
QIAGEN Buffer P3 was incubated on ice for 15 min.  The samples were then 
centrifuged in a JA-20 rotor for 30 minutes at 4°C at 13,000 rpm.  The supernatant was 
promptly poured off and re-centrifuged under the same conditions but only for 15 min.  
The subsequent supernatant was poured into a new tube. 
During centrifugation, a QIAGEN-tip 100 was equilibrated with 4 ml of 
QIAGEN Buffer QBT, and the supernatant was applied to the column to let the DNA 
bind.  If the midiprep made use of multiple tubes for lysis of the same construct, all of 
the tubes containing DNA were applied to the column.  The column was washed two 
times with 10 ml of QIAGEN Buffer QC.  The DNA was eluted with 5 ml of QIAGEN 
Buffer QF.  For precipitation, 3.5ml of 100% -20°C isopropanol was added to the DNA-
containing solution.  The samples were centrifuged in a JA-20 rotor for 30 min. at 4°C at 
12,000 rpm to pellet the precipitated plasmid DNA.  The supernatants were carefully 
poured off and the pellet was washed with 2ml of room-temperature 70% ethanol and 
immediately centrifuged again for 10 min.  The supernatant was poured off, and the 
pellet was air-dried for 30 min. then solubilized in 300 µl of QIAGEN Buffer EB. 
  
 
 
47 
Digests of pMAL and DAZL 
 Digests were performed on plasmids containing DAZL and the pMAL vector using 
EcoRI (New England Biolabs) so that the EcoRI fragment containing the DAZL cDNA 
could be inserted into the EcoRI site of the pMAL vector.  With the exception of a single 
EcoRI site in the 3’ UTR, the sequence of DAZL is not known to have any EcoRI sites.  
The reaction conditions for the DAZL plasmid were 7 µl of water, 2 µl of 10X NEB 
EcoRI Buffer (final reaction concentration was 50 mM KCl, 100 mM Tris-HCl, ph 7.5, 
10 mM MgCl2, and 0.025% Triton X-100), 2 µl of NEB EcoRI enzyme (Cat# R0101S, 
20 Units/µl), and 9 µl of the 312 ng/µl DAZL template DNA in a solution of 10 mM TE.  
The pMAL reaction contained 12 µl of water, 2 µl of the 10X EcoRI buffer, 1 µl of the 
EcoRI enzyme, and 0.5 µg of the pMAL C2X plasmid which was supplied in a tube with 
10 µg of DNA.  The digests were incubated at 37°C for 3.75 hr.  The pMAL digest was 
treated with CIAP (Calf Intestinal Phosphatase) where 1 µl of 1 U/µl of diluted CIAP (5 
µl of 25 U/µl CIAP + 120 µl dilution buffer) was added to the pMAL digest.  The 
reaction was incubated at 37°C for 5 min. at which point 5 µl of 50 mM EDTA, pH 8.0 
was added.  The reaction containing the EDTA was incubated at 65°C for 15 min.  After 
enzymatic digest, the product was electrophoresed on a 1% SeaKem GTG gel 
(BioWhittaker) and the bands of interest extracted with a scalpel.  After excision from 
the gel, the DNA was recovered using the Genelute Minus Kit (Sigma) according to 
manufacturer’s instructions. 
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Ligation Reactions 
 Ligation of the pMAL digest and the DAZL digest was performed using NEB’s T4 
DNA Ligase (Cat# M0202S, 400 U/µl).  The reaction consisted of 2 µl of 10X T4 
Ligase Buffer (1X Final Concentration of 50mM Tris-HCl, pH 7.5, 10mM MgCl2, 
10mM DTT, 1mM ATP, and 25 µg/ml BSA), 400U of T4 DNA Ligase, 16 µl of the 
digested insert, and 1 µl of the digested vector from above.  The volumes of vector and 
insert were arbitrarily selected.  The reaction proceeded at 16°C overnight. 
 
Test Expression of Clones 
 Clones were tested for expression of protein with separate 5 ml cultures grown from 
picks from streak plates to an OD600 of 0.5 and induced with 0.3mM final isopropyl β-D-
1-thiogalactopyranoside (IPTG), a molecular mimic of allolactose.  Separate samples of 
1 ml each were collected and the cells pelleted.  Each pellet was dissolved with 2X SDS 
Buffer in Tris, pH 6.8 (30% glycerol, 10% SDS, 0.6M DTT, 0.012% bromophenol blue).  
The denatured proteins were electrophoresed on a 10% Tris-HCl BioRad Criterion gel 
(Hercules, CA).  Protein gels were stained with Coomassie using standard molecular 
biological laboratory practices. 
 
Freezer Stocks of Clones 
 Clones were grown to mid-log phase started from overnight cultures in LB with 
appropriate antibiotics at the proper concentrations, diluted to 50% with glycerol, and 
stored at -80°C. 
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Electroporation 
 Electroporation was performed using an Eppendorf Electroporator 2510 (Madison, 
WI) and BioRad Gene Pulser®/E. coli Pulser™ Cuvettes (Hercules, CA) set at 1900V 
for all samples.  The procedure involved mixing DNA and electrocompetent cells 
together in an electroporation cuvette and applying the voltage.  A high time constant for 
each pulsing run indicated a desirable run (~ 5.2 milliseconds). 
 
Assessing Purity of DNA Samples 
 A 1:200 dilution of the sample to be read was made in 1 ml ddH2O and absorbance 
was read at 260nm and 280nm.  From these numbers the concentration and purity of 
DNA was calculated as concentration of DNA = A260 X dilution factor X 50 ng/µl.  
Purity of the sample was easily calculated by A260 / A280 with the expectation of a ratio 
in the range of 1.7 as ratio values of 2.0 or greater indicate ribonucleic acid 
contamination and ratios of 1.6 or less indicate protein contamination. 
 
Sequencing Verification 
 All sequencing was performed by Lone Star Labs (Houston, TX) and compared with 
data from Genbank.  After plasmid preparations were performed and the DNA evaluated 
for amount and purity, a sample was sent via overnight courier.  If needed, primers 
specific for amplification were also sent conforming to Lone Star Labs’ requirements for 
Tm, length, and concentration. 
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Site-Directed Mutagenesis 
The mutagenesis procedure used to fix a mutation in the generated clone in 
DAZL was performed using Stratagene’s QuikChange® Site-Directed Mutagenesis Kit 
(Cat# 200519-5, La Jolla, CA) according to manufacturer’s instructions.  Briefly, this 
method requires creating a non-methylated copy of the plasmid with a point mutation 
included in complementary primers.  The chosen primers were based on size, specificity, 
and thermodynamic characteristics.  Stratagene recommends that the primers be between 
25 and 45 bases in length, the Tm’s should be greater than 78°C, the desired mutation 
should be in the middle of the primer with at least 10 to 15 bases of correct sequence on 
each side, should have a minimum GC content of 40%, should terminate in one or more 
C or G bases, and should be purified by PAGE or HPLC.  For the current study, 125 
ng/5 µl of each PAGE-purified primer was added to the PCR reaction along with 5 ng/5 
µl total input plasmid, 29 µl of water, 5 µl of 10X Buffer (final reaction concentration of 
10 mM KCl, 10 mM (NH4)2SO4, 20 mM Tris-HCl (pH 8.8), 2 mM MgSO4, 0.1% Triton 
X-100, and 0.1 mg/ml BSA), 1 µl dNTP mix supplied in the kit, and 1 µl of 2.5 U/µl Pfu 
Turbo.  The PCR reaction was carried out in Stratagene’s Robocycler with the following 
program:  Step 1: 95°C for 30 seconds and 55°C for 1 minute, Step 2: 12 cycles of 95°C 
for 30 seconds, Step 3: 68°C for 8 minutes.  After the PCR reaction, the methylated non-
mutated DNA was degraded by the addition of 10 units of enzyme DpnI and the 
resultant nicked circle DNA was transformed into supercompetent XL-1 Blue cells.  
Primers specifically developed to repair mutations were:  forward primer DAZL0.1 to 
0.2F (5’ CCT GTT GGG GAG CAA AGG AGC TAT GTT GTA CCT CCG GC 3’) and 
51 
reverse primer, DAZL0.1 to 0.2R (5’-GCC GGA GGT ACA ACA TAG CTC CTT TGC 
TCC CCA ACA GG-3’.   
In addition, published point mutations in DAZL were produced using this 
method.  The primers were specifically developed from sequence data provided by Teng, 
et al.[15] who found two major mutations in the general Taiwanese population.  Both 
SNPs encode an A to G transition encoding for a Thr to Ala amino acid alteration.  The 
second mutation (labeled DAZLmut2) was in the RNA recognition motif, but the first 
mutation (labeled DAZLmut1) was not and preceded the RRM region in the sequence.  
The DAZLmut1 forward sequence was 5’- GCA AAT CCT GAA ACT CCA AAC TCA 
GCC ATC TCC AGA GAG G -3’ And the reverse primer sequence was 5’- CCT CTC 
TGG AGA TGG CTG AGT TTG GAG TTT CAG GAT TTG -3’.  DAZLmut2 forward 
primer sequence was 5’- GGA GGA ATT GAT GTT AGG ATG GAT GAA GCT GAG 
ATT AGA AGC -3’ and the reverse primer was 5’- GCT TCT AAT CTC AGC TTC 
ATC CAT CCT AAC ATC AAT TCC TCC -3’.  The methodology used in the PCR 
reaction and all associated calculations used in the previous example were used in 
creating these primers and PCR reaction. 
 
Expression and Purification of DAZL Proteins 
Stabs from freezer stocks were used to start 10 ml overnight incubations of each 
clone in LB containing 100 µg/µl carbenicillin at 37°C with shaking.  The overnight 
solution of LB was seeded with 10 ml into a 2 L aeration flask containing 1 L of LB with 
100 µg/µl carbenicillin and 2 g/l glucose to inhibit amylase formation which would 
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therefore inhibit the MBP fusion proteins from binding to the amylose resin.  The culture 
was grown at 28°C with shaking to an OD600 of 0.5 which required about 5 hours.  IPTG 
was added to a final concentration of 0.3 mM and expression of protein induced for 3 
hrs.  The cells were pelleted and stored at -20°C overnight.  The pellets were suspended 
in column buffer (20mM Tris-HCl, pH 7.4, 200mM NaCl, and 1mM EDTA) and poured 
into 50 ml conical tubes, dounced 10X to reduced clumping of cells and solutions passed 
through a French Press two times.  The lysate was clarified through centrifugation and 
the desired proteins were enriched using amylose resin with multiple washes with 
buffers according to manufacturer’s instructions (New England Biolabs, Ipswich, MA). 
 
Cloning of DAZ+TEV from Clontech Phage Library 
Specifically developed primers were synthesized by IDT (Coralville, IA).  The 
forward primer sequence, ‘YDAZ+TEV’ to clone Y chromosome DAZ was 5’- GGG 
GAG AAC CTG TAC TTC CAG GGG ATG TCT GCT GCA AAT CC- 3’.  The 
reverse primer, YDAZ2&3R, was 5’- ATT TAA ATA CTG GGA AAC TTC TTC TAA 
AGC -3’.  A TEV protease linker was incorporated in the design such that the desired 
protein with only an additional glycine on the amino terminus could be prepared by 
enzymatic cleavage from MBP.  Glycine was chosen to minimize potential effects on 
protein function due to its small size and neutral charge. 
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Creation of RNA Probe for DAZL Binding 
Venables et al. determined an RNA consensus sequence preferred by DAZL in 
mice[84].  A series of oligonucleotides were designed based on three long 
 
Synthetic RNA Scheme
141 bp probe
Forward primer with T7 promoter
Reverse primer
Round. 1 “Template Oligo”
Round. 2, top
Figure 13.  Schematic of Synthetic RNA Scheme.  The brown arrows indicate 
primers that were ordered.  The green arrows indicate the newly-synthesized 
DNA.  In round one, only the forward primer with the T7 promoter binds with 
the “template” oligo where extension progresses in two directions.  In round 
two, the reverse primer is able to bind the extension primer.  Polymerization 
proceeds in both directions giving the full, final product. 
 
 
oligonucleotides (ordered from IDT) that contained the repeat region 
GU7GU10GU10GU7.  The forward primer, T7Univ, contained the sequence 5’-CGC GGA 
TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT -3’.  The 
reverse primer, RevUniv_2 contained the sequence 5’- CCC GAC ACC CGC GGA TCC 
ATG GGC ACT ATT TAT ATC AAC -3’.  Finally, the “template” oligo, CDC25C_2, 
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contained the sequence 5’- TGG GCA CTA TTT ATA TCA ACA AAA AAA CAA 
AAA AAA AAC AAA AAA AAA ACA AAA AAA CAA TGT CGT TGG TGG CCC -
3’.  The 100 µl PCR reaction consisted of 52 µl ddH2O, 10 µl of 10X PCR Buffer, 10 µl 
of 25 mM MgCl2, 8 µl of 2.5 mM each dNTP mix, 5 µl of the 0.1 µg/µl T7Univ primer, 
9 µl of the 0.1 µg/µl RevUniv_2 primer, 1 µl of 5 U/µl AmpliTaq Gold, and 5 µl of the 
0.01 µg/µl CDC25C_2 “template” oligo.  The PCR program was run on a Stratagene 
Robocycler at 95°C for 20 minutes, 35 cycles of 95°C for 15 seconds, 60°C for 30 
seconds, and 72°C for 5 minutes.  After PCR was performed to concatenate the 
sequences, the PCR product was cloned into pCR2.1 using the quick cloning method 
mentioned previously, and the sequence verified.  Figure 13 depicts the basic scheme for 
creation of the probe from three oligonucleotides (Appendix 3).  The 5’ end of the 
sequence contains a T7 promoter for in vitro transcription in the presence of  32P-UTP.  
The resulting PCR product was 121 bp and the radiolabeled probe was 95 bp. 
 In vitro transcription was performed by incubating the DNA generated through 
PCR with T7 polymerase, nucleotides, and a radiolabeled nucleotide.  In vitro 
transcription was carried out using Ambion’s MaxiScript T7 Kit (Cat# 1314, Austin, 
TX).  The reaction conditions contained 5 µl of the PCR-generated CDC25C template, 2 
µl of 10X transcription buffer (specific contents not disclosed by the company), 1 µl of 
10 mM ATP, 1 µl of 10mM CTP, 1µl of 10mM GTP, 2 µl of 50 µM UTP, 3.5 µl of 
nuclease-free water, 2.5 µl of [α-32P] UTP (Amersham Pharmacia, Cat# PB20383, 20 
mCi/ml, 800 Ci/mmol, 250 µCi total), and 2 µl (15 units/µl) T7 RNA Polymerase.  The 
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reaction was incubated at 15°C for 3 hours whereupon 1 µl of (2 units/µl) DNase I was 
added.  Another incubation period at 37°C for 15 min. followed. 
 A control template found in the Ambion MaxiScript T7 Kit (Austin, TX) was 
used in addition to other probes.  The mouse antisense β-actin (pTRI-Actin-Mouse) 
probe was labeled as per manufacturer’s instructions and treated the same way as the 
other probes used in this study. 
Specific activity was determined by comparing the percentage of TCA-
precipitated material with information in Ambion’s in vitro Maxi-Script kit instructions 
(Austin, TX).  Briefly, TCA precipitates RNA enhanced by the presence of a carrier such 
as sheared salmon sperm DNA.  The solution is poured through a filter under vacuum 
and the ratio of what is counted on the filter is compared to the input RNA.   
After radiolabeling the RNA it was necessary to determine the specific activity of 
the probe.  Radiolabel incorporation was assessed through TCA (trichloroacetic acid) 
precipitation.  One hundred fifty microliters from a solution of 1 mg/ml Sheared Salmon 
Sperm DNA (Ambion, Austin, TX Cat#9680) was pipetted into a 1.5 ml centrifuge tube.  
To this solution, 2µl of the transcription reaction was added and mixed well with 
pipetting.  50µl of the mixed DNA and radiolabeled RNA was pipetted onto a Whatman 
GF/F glass filter.  Another 50µl of the mixture was pipetted into a borosilicate tube to 
which 2ml of 4°C 10% TCA was added.  This mixture was allowed to incubate on ice 
for 10 minutes.  After 10 minutes the solution was vortexed and poured through a 
Whatman GF/F glass filter under minimal vacuum in a filter setup.  The tube was rinsed 
2X with 1 ml of 4°C 10% TCA with vortexing and pouring through the GF/F filter.  
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Finally the tube was rinsed with 5ml of 4°C 95% ethanol and applied to the filter under 
minimal vacuum. 
 Each of the filters was dried for 30 minutes under a sunlamp to evaporate all of 
the ethanol remaining on the filters because ethanol is a known quencher of beta 
particles in scintillation fluid. 
 After the filters had dried, they were placed in glass vials with 5 ml Ecoscint XR 
(National Diagnostics) and vortexed.  They were read in a Beckman 6500 scintillation 
counter for 5 minutes each and the counts were documented. 
 
Specific Activity Calculations 
The following is an ex ific activity from the 
synthes ut 
tal 
 
 
   
ample of how to calculate spec
is of a probe found later in this document.  The calculations stay the same, b
the number and complement of specific nucleotides are adjusted based on the probe 
generated.  The amount of precipitated material was 227,055.00 CPM whereas the to
signal was 1,419,675.20 CPM.  Therefore 227,055.00 / 1,419,675 = 0.16.  So roughly 
16% of the material that was synthesized was incorporated into precipitated RNA.  The
next step was to calculate the number of moles of [α-32P]UTP in the reaction.  To do this
the number of millicuries (mCi) of UTP in the reaction is calculated.  In the reaction, 3 
µl of 10 mCi/ml UTP was added into the mix.  The equation for the calculation follows:
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mCi
ml
mCiml 03.0
1
10*003.0 =
. 
The next step was to calculate the number of millimoles of [α-32P] UTP in the reaction. 
pmoles mmol
mCi
Ci
Ci 
mmolmCi 0.10101
1000
1
3000 
1 03 . 0 8 =×=×× −
 
In addition, the moles of unlabeled UTP in the reaction was calculated as:   
pmol mol
l
ml
ml
moll 000,1001.0
1000
1
1000 
000 , 10 1 ==×× υυ
υυ 
 
It follows that the total amount of UTP in the reaction was 10.0 pmoles labeled 
UTP + 10,000 pmoles unlabeled UTP = 10,010 pmoles total UTP in the reaction.  The 
concentration of total UTP in the reaction was calculated as 10,010 pmol / 20 µl = 500 
pmol/µl = 500 µM.  Next, total UTP incorporated into the RNA was calculated by 
multiplying the total number of pmoles of total UTP in the reaction by the fraction 
incorporated into RNA:  10,010 pmol x 0.159934 = 1,601 pmol 
 The number of moles of UTP incorporated into the RNA was used to calculate 
the mass of RNA synthesized.  The transcript from NM_014814 contains 1275 bases 
which consist of 390 A residues, 250 C residues, 307 G residues, and 328 U residues.  
The fraction of the transcript given by each nucleotide is calculated in Table 8. 
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Table 8.  Nucleotide Base Count for NM_014814. 
 Base Count Fraction of Total Transcript 
A 390 0.306 
C 250 0.196 
G 307 0.241 
U 328 0.257 
Total 1275 1.000 
  
 
 
Since the amount of UTP incorporated was 1,601 pmoles, the other residues can 
be calculated by first dividing the pmoles of UTP by its complementary fraction to give 
the total amount synthesized.  1,601 / 0.257 = 6230 pmoles. 
 From this total amount synthesized, the number of  picomoles of the other 
nucleotides present in the transcript can be calculated.  From this, the amount 
synthesized in grams is derived utilizing dimensional analysis using residue A as an 
example.  This was done for all of the nucleotides and the results were added to 
determine total amount of RNA synthesized in grams. 
07g6.29E
1mole
329.208g
1000pmoles
1nmole
1000nmoles
1mmole
1000mmoles
1mole1910pmoles −=××××  
 
Table 9.  RNA Synthesis Calculations. 
   
Nucleotide Base Count Fraction 
Pmoles Total 
RNA 
Pmoles 
Nucleotide MW 
Amt. Synthesized 
(g) 
A 390 0.306 6,223.18 1910 329.208 6.29E-07 
C 250 0.196 6,223.18 1220 305.183 3.72E-07 
G 307 0.241 6,223.18 1500 345.207 5.18E-07 
U 328 0.257  1,601 306.168 4.90E-07 
Totals 1275 1.000  6230  20.09E-06 
The resultant final amount of RNA synthesized in nanograms was 20.09 ng 
(Table 9).  The number of counts per minute incorporated into the product was 
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determined from the number of µl represented in the reaction as 2 µl / (2 µl + 150 µl) = 
0.7 µl counted on the filter containing the precipitate.  From this the CPM/µl was 
determined to be the same as CPM of the filter divided by the number of µl counted, i.e., 
227,055 CPM / 0.7 = 300,000 CPM / µl.  The volume of the transcription reaction before 
TCA precipitation was 22µl so 22 µl x 300,000 CPM / µl = 6,600,000 CPM.  Finally, 
specific activity can be calculated by dividing the total number of counts per minute by 
the number of nanograms of RNA synthesized, 6,600,000 CPM / 20.09 ng = 328,522 
CPM/ng, or by dividing the total number of counts per minute by the number of pmoles 
synthesized 6,600,000 CPM / 6,230 pmoles = 1,059 CPM / pmole. 
  
RNase Detection 
 RNase contamination in laboratory reagents was detected using a commercially-
available kit from Ambion (RNaseAlert Lab Test Kit, Cat# 1964, Austin, TX).  Forty 
five microliters of the solution to be tested was added to sample substrate and buffer 
which was included in the kit.  The mixture was incubated at 37°C for 25 minutes.  The 
results were read in a fluorometer where the substrate was excited at 490 nm and read at 
520 nm. 
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Gel Shift with CDC25C 
 A gel shift was performed to test whether or not DAZL bound CDC25C RNA 
construct.  The binding reaction consisted of 2 µl of water, 5 µl of binding buffer (final: 
20mM Tris-HCl, pH 7.6, 50 mM KCl, 5 mM MgCl2, 1 mM DTT, 10% glycerol, and 100 
µg/ml BSA), 1 µl of SUPERaseIn (Ambion, Cat# 2694, Austin, TX), 1 µl of RNA 
construct (710 pM final), and 1 µl of the DAZL protein construct (a 2-fold reduction 
serial dilution from 8 µM to 7.8 nM).  The reactions were incubated at 36°C for 15 
minutes and electrophoresed on a pre-run (80 volts for 15 minutes) 7.5% Tris-HCl 
BioRad Criterion Precast Gel (Cat# 345-0005) for 1 hour and 40 minutes at 80 volts in 
tris glycine buffer.  The gel was dried between cellulose and mylar and detected on a 
phosphorimager screen for three hours at room temperature.  MBP was purchased 
through NEB (Ipswich, MA), Cat # 800-44S. 
 
Nitrocellulose Filter Binding 
 1- 4” X 5.25” piece of nitrocellulose paper (Schleicher & Schuell Protran 
Bioscience Pure Nitrocellulose Transfer and Immobilization Membrane, BA83, Pore 
Size 0.2 µm, Cat# 10402488, Keene, NH) was incubated at room temperature in 1X 
Binding Buffer (20 mM Tris, pH 7.4, 50 mM KCl, 0.75 mM MgCl2, and 4.5 % Glycerol) 
for 30 minutes prior to the experiment.  20 µl binding reactions consisting of 1 pmol of 
radiolabeled RNA (50 nM final), 10 µl of 2X binding buffer (same as above for the 
nitrocellulose), and 5 µl of protein diluted appropriately for series.  The binding 
reactions were performed in PCR tubes on ice for 30 minutes and applied to the 
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membrane through the filter and chased with 50 µl 1X binding buffer.  A template was 
used to cut out the proper portions of the filter and the dots were placed in scintillation 
vials and counted 5 minutes in a Beckman LS6500 scintillation counter. 
 
Gradient Centrifugation 
A 5-30% glycerol gradient in binding buffer was created using a 12 ml gradient 
maker based on methods utilized by Dember et al[85].  The gradient consisted of two 
containers, one containing a 5% glycerol solution in binding buffer and the other 
containing a 30% solution of glycerol in binding buffer.  The mixture was fed through a 
small tube into clear polycarbonate centrifuge tubes from Beckman that were balanced 
within 1 mg of each other with the 5% solution.  The binding reactions were applied to 
the top of the gradients and the samples centrifuged in an ultracentrifuge at 35,000 RPM 
in a Beckman SW41-Ti rotor for 40 hours at 4°C.  After centrifugation the bottom of 
each tube was pierced with a needle from a fractionator and drops were collected into 
separate scintillation vials.  Five milliliters Ecoscint XR was added to each tube and each 
tube was counted in a Beckman LS6500.  This technique was based on work done by 
Baumann et al. [86]. 
 
Affinity Chromatography Binding Experiments 
Proteins used in the binding reaction were expressed in 1 liter of LB with 
antibiotics from E. coli strain ER2508, extracted from the crude lysate after utilizing the 
french press, and washed from other non-bound proteins from amylose resin according 
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to New England Biolabs’ instructions.  Binding reactions for each of the three 
experiments were as follows.  Experiment 1 contained 22 nM final of CDC25C RNA 
construct in the binding reaction.  Columns were pre-treated with 10 µl of 0.1 mg/ml 
BSA in 1X Binding Buffer (20 mM Tris, pH 7.4, 50 mM KCl, 0.75 mM MgCl2, and 
4.5% glycerol.  The reaction mixture consisted of 25 µl of resin containing the washed 
protein of interest, 9 µl of water, 40 µl of 2X binding buffer, 1 µl of 5 mg/ml BSA, and 5 
µl of RNA for a total volume of 80 µl.  The reaction was allowed to proceed on ice for 
20 minutes.  In experiment 2, the columns were pre-treated with 10 µl of 0.1 mg/ml BSA 
in 1X binding buffer with centrifugation for 1 minute at maximum rpm on a tabletop 
centrifuge.  The reaction mixture consisted of 100 µl of resin with attached and washed 
proteins, 5 µl of RNA (2.2 nM final), and 50µl of 1X binding buffer.  The binding 
reaction was allowed to proceed on ice for 20 minutes.  In experiment 3, the Qiagen 
Small Spin Columns were pre-treated with 100 µl of 100mg/ml BSA in 1X binding 
buffer.  The reaction mixture was 500 µl of resin, 250 µl of 1X binding buffer, and 25 µl 
of RNA (13.5 nM final).  In each case, the binding reactions were applied to Qiagen 
Small Spin Columns and centrifuged for 1 minute at maximum rpm on a tabletop 
centrifuge.  The flowthrough was applied to 5 ml of Ecoscint XR and counted in a 
scintillation counter (LS6500, Beckman, Fullerton, CA). 
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Results 
 
The first step in producing active recombinant DAZL was the use of PCR to 
amplify the coding region of DAZL from a cDNA library.  PCR primers were designed 
to include a TEV protease cleavage site which allows excision and removal of the MBP 
(maltose-binding protein) portion of the fusion protein.  The template for PCR was a 
Human Testis cDNA library (Clontech, Mountain View, CA) in the λTriplEx2 phage 
vector.  Results in Figure 14 indicate that the PCR product in the “+” lane contains the 
coding sequence of DAZL of 930bp. 
 
MW - +
500 bp
1,000 bp
1,500 bp
2,000 bp
930 bp
 
 
 
Figure 14.  PCR of DAZL from Clontech 
Phage Library.  The gel indicates PCR 
product of DAZL + TEV from phage 
library in the + lane at the proper size, 
the 1 kb MW ladder , and the negative 
control of water (-). 
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Figure 15. PCR Products from Positive Clones from the pCR2.1 Cloning 
Reaction.  The first lane is a 1kb ladder, The second lane is the negative control 
of water, and the remaining lanes are PCR reaction products indicating the 
presence of DAZL of the correct size. 
 
The DAZL PCR product was ligated into the TOPO pCR2.1 vector using the 
manufacturer’s short cloning protocol and transformed into TOP10 cells.  The 
transformed cells were plated onto a selective LB plate and incubated overnight at 37°C 
and colonies tested with PCR.  Figure 15 shows clones 1, 2, 4, 5, 6, 7, and 10 that were 
positive for the presence of the DAZL. 
A miniprep of clone 1 (Figure 15) was used to process the plasmid DNA for 
sequencing.  Modification of the protocol included splitting the cell pellet into two 
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aliquots and titrating the cell lysis buffer.  Serial precipitation and centrifugation were 
used to assure removal of protein.   All samples were applied to 1 Qiatip 100 column 
 
 
 
 
 
 
MW DAZL in pCR2.1pMAL
6,646 bp
3,900 bp
930 bp
500 bp
1,000 bp
1,500 bp
2,000 bp
3,001 bp
5,001 bp
4,001 bp
8,001 bp
6,001 bp
10,001 bp
Figure 16.  EcoRI Digest of pMAL and pCR2.1.  The 
first lane is the marker, the next two lanes contain the 
digest of pMAL, and the last two lanes contain the 
digest of pCR2.1 containing the DAZL fragment. 
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Figure 17.  Test Expression of pMAL DAZL Clones.  The first lane is the molecular weight 
standard and the second lane is the t0 timepoint of clone number 23 used as comparison against 
clones that induced [this sentence is not complete].  The remaining lanes are proteins 
expressed by clones used in the assay.  The darker bands found below the clones expressing 
DAZL are MBP.  [What about bands above DAZL?]  The clones that produced DAZL are 6, 7, 
8, 11, 12, 15,16, 21, 22, and 23 and are of the right size ( ~ 77 kDa). 
 
(Qiagen) and eluted with 150μl of elution buffer.  The miniprep DNA was submitted to 
Lone Star Labs for sequencing and the DNA sequence verified using Accelrys’ (San 
Diego, CA) DSGene Software.  The sequence showed 100% identity at the nucleotide 
level with DAZL in the NCBI database.  
After verification of the clone sequence in pCR2.1, the fragment was excised 
using EcoRI (Figure 16) and ligated into similarly cleaved pMAL vector.  One feature of 
the pMAL multiple cloning site is the addition of MBP at the amino terminus of the 
protein which facilitates affinity purification on amylose beads.  Initially, the relaxed  
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Figure 18.  PCR Products from PCR Reaction 
after Mutagenesis to Fix the DAZL Clone.  
The PCR product bands are of the correct size 
at 930 bp. 
 
circle of ligated DNA was introduced into chemically-competent TOP10 cells.  To verify 
the presence of the DAZL inserts, 44 test inductions were performed of which 24 are 
shown in Figure 17.  Clones positive for growth (6, 7, 8, 11, 12, 15, 16, 21, 22, and 23 
were grown and saved as freezer stocks.  Clone #6 (Figure 17) was arbitrarily selected, 
grown, and used for a plasmid midiprep, according to manufacturer’s instructions 
(Qiagen), to obtain plasmid DNA.  The plasmid DNA was electroporated into protease 
deficient ER2508 cells to maximize the yield of intact DAZL protein after expression 
and enrichment. 
 Sixteen of the resulting MBP-DAZL clones were selected for test induction.  One 
of the positive clones was chosen for the midiprep procedure.  The purified plasmid 
DNA was subsequently sequenced to verify the presence of DAZL and it was found that 
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the DAZL sequence of this plasmid contained a non wild-type mutation.  The most 
probable cause of the mutation was that the single nucleotide mutation was missed in the 
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Figure 19.  PCR to Determine the Presence of DAZL in ER2508 Cells.  All seven clones 
were positive for the presence of the DAZL insert.  The first lane is the molecular weight 
standard and the rest of the lanes are PCR products of the correct size ( 930 bp). 
 
original sequence data after the original PCR and passed down to the pMAL insert 
before being discovered.  The mutation was repaired using site-directed mutagenesis 
from Stratagene’s QuikChange Site-Directed Mutagenesis Kit.  Clones of the repaired 
DAZL were tested for the presence of the inserts (Figure 18), sequenced, and 
transformed into ER2508 cells and verified by PCR (Figure 19).  Teng et al. 
reported[15] two point mutations in the DAZL locus- one inside the RRM of DAZL and 
one outside of the RRM of DAZL.  These mutations were used to change the amino acid 
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sequence of the DAZL clone and determine the impact of two naturally-occurring 
mutations on DAZL function.  As before, the cells were grown, a midiprep was 
performed and the resulting plasmid DNA was electroporated into ER2508 cells.  During 
this process, clones were directly verified through sequencing for the presence or 
absence of the DAZLmut1 (outside of RRM, nucleotide 260) or DAZLmut2 (inside of 
RRM, nucleotide 286) inserts (Figure 20) and Appendix 1.  The PCR contained the 
original DAZL cloning primers and verified the presence of DAZL. 
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Figure 20.  Gel Showing Presence of DAZLmut1 and DAZLmut2.  The top 
row is DAZLmut1 and the bottom row is DAZLmut2.  The first lane in both 
cases is the molecular weight standard.  The remaining lanes are separate 
clones screened for the presence of absence of PCR product. 
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DAZLmut1 M L K S V
DAZLmut2 M L K S V
 
 
Figure 21.  Amino Acid Alignments of DAZL, DAZL Cloning Mutant, DAZLmut1, and DAZLmut2.  The red boxes highlight the 
mutations of interest.  The green bar represents the RRM of the protein. 
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Figure 22.  Enrichment of MBP, DAZL, DAZLmut1, and 
DAZLmut2.  A series of washes and the eluted proteins from the 
amylose resin indicates proteins of the correct sizes expected. 
 
The amino acid sequences of DAZL, DAZL with the cloning mutation, DAZLmut1 and 
DAZLmut2 are shown in Figure 21.  In addition, Figure 22 shows the enriched proteins 
of MBP, DAZL, DAZLmut1, and DAZLmut2 after binding the proteins to the amylose 
resin, washing away unbound proteins, and elution of the bound proteins.  Of note is the 
low presence of other proteins.  Because there was such a high signal to noise ratio of 
desired DAZL proteins to contaminants it was decided not to further purify the proteins.  
The gel was overloaded to increase the signal of contaminants.  A visual comparison  
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demonstrates that among the DAZL preps, the same non-DAZL proteins were present as 
can be detected by size alone and what remains in one is in the other.  A possibility is 
that there is a small amount of degraded DAZL protein in each of the samples.  The size 
of the DAZL proteins was determined by comparison with the molecular weight marker 
in comparison to the reported value of 77 kDa (Genbank). 
The DAZ2 was also cloned in a manner similar to the cloning of DAZL and was 
also examined for sequence by alignment with DAZ2 database sequence.  This DAZ 
gene contained a single RRM but lacked repeats reported in the published version of 
DAZ2.  For sequence analysis  see Appendix 2. 
The function of DAZL was first addressed using an electrophoretic mobility shift 
assay using an RNA corresponding to a consensus sequence derived from CDC25C.  In 
the first assay, Figure 23, a binding reaction containing  a final concentration of 71nM 
for the CDC25C probe was combined with 8 µM of each protein and applied to a 
polyacrylamide gel.  The results from the initial gel shift indicated that neither BSA nor 
MBP were able to shift any of the RNA, but both DAZL and DAZ were able to shift 
roughly 50% of the RNA at a probe concentration of 71 nM. 
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 - Control BSA MBP DAZL DAZ
Top 952.30 1,202.10 1,515.90 139,023.00 145,343.10
Bottom 291,512.50 296,771.60 316,984.10 146,454.90 161,362.40
Total 292,464.80 297,973.70 318,500.00 285,477.90 306,705.50
Fraction Shifted 0.33 0.40 0.48 48.70 47.39
- MBPBSA
Bound
MBP-
DAZ
MBP-
DAZL
Region for 
Background 
Subtraction
Free
8 uM Final Each Protein
71 nM Final Probe
Figure 23.  Electrophoretic Mobility Shift Assay Control.  The background 
region is labeled with a hatched line and the boxes for reading the 
densities of the bands are shown as solid.  Each protein is indicated above 
each lane.  The data corresponding to the top and bottom boxes are 
indicated along with the fraction shifted.  MBP was purchased from NEB. 
 
Next, a gel shift to estimate the Kd of DAZL for the CDC25C probe was 
performed (Figure 24).  For this assay, a consensus sequence of RNA containing a U-
rich sequence was used as before but in a lower concentration.  A gel shift analysis was 
performed with a limiting amount of RNA and increasing amounts of DAZL protein 
(Figures 24 and 25).  From a 2 hour exposure to the phosphorimaging screen it was 
evident from the calculations that given an input concentration of RNA, DAZL bound 
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with a Kd of 1.03 µM.  When the same procedure was performed after an exposure to 
the screen for 4 hours (Figure 26), the calculated Kd was 0.43 µM. 
Because there were not many data points within the range of the Kd which 
contributes to inaccuracy in calculating Kd, another gel shift was performed which 
contained protein concentrations within the transitional range of the curve, Figure 27.  
From this basic initial analysis it was found that DAZL bound this particular  
Background
Box
0.250 0.500 8.00 0.125 1.0 2.0 4.0
uM DAZL
B
F
710 pM RNA Final
Figure 24.  DAZL and CDC25C Gel Shift to Estimate Kd.  Input RNA was 710 pM 
and protein concentration is indicated above each of the lanes.  The bound species is 
on top and the free species of radiolabeled RNA is on the bottom.  The background 
subtraction box for the calculations is shown. 
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Figure 25.  Graph of 2h Exposure to Phosphorimage Screen.  The x-axis is the protein 
concentration and the y-axis is the fraction of radiolabeled probe shifted.  Final input 
RNA concentration is 71 nM.  A logarithmic curve was fit to the data and the Kd was 
calculated to be 1.03 µM. 
radiolabeled RNA construct where 50% bound was estimated as 1.5 µM of DAZL 
protein (Figure 28).  This value was calculated by fitting a logarithmic curve to the data 
points in Figure 27 and calculating the concentration where 50% of the RNA target was 
shifted.  Additionally, in this case the R2 for the fit line was 0.9774.  Table 10 
summarizes the data from these three experiments. 
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DAZL vs CDC25C, 4h y = 0.1245Ln(x) + 0.6055
R2 = 0.9637
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Figure 26.  Graph of 4h Exposure to Phosphorimage Screen.  The x-axis is protein 
concentration and the y-axis is the fraction of radiolabeled probe shifted.  Final input of 
RNA is 71 nM.  The formula for the logarithmic curve gives a Kd of 0.43 µM. 
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Figure 27.  Polyacrylamide Gel Shift of DAZL and CDC25C RNA.  The RNA lane contains 
RNA without any protein.  The remainder of the lanes contain increasing amounts of DAZL 
indicated above. 
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Figure 28.  Gel Shift of DAZL and CDC25C RNA.  The X axis indicates the concentration of DAZL 
protein in µM while the Y axis demonstrates the % bound/shifted.  As shown in the figure, the static 
RNA concentration was 710 pM in the reaction.  Kd is calculated to be 1.5 µM.  
 
Table 10.  Summary of Kd Data. 
Figure R-square Kd (uM)
24 0.9191 1.03
25 0.9637 0.43
27 0.9774 1.56
Average 1.01   
 
Because the electrophoretic mobility shift assay is time consuming, the 
nitrocellulose binding assay was explored in determining Kd of DAZL for RNA because 
of its relative ease of use and potential for generating large amounts of data quickly.  
Figure 28 shows the data after binding reactions containing 1 pmole of radiolabeled  
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Nitrocellulose Binding Assay
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Figure 29.  Nitrocellulose Binding Assay.  1 pmole of CDC25C radiolabeled RNA was mixed with 
increasing amounts of MPB and MBP-DAZL proteins in a binding reaction and applied to a 
nitrocellulose membrane under vacuum.  The MBP used in this assay was generated from an empty 
vector instead of the commercially-purchased MBP as in Figure 22.  Both DAZL and MBP bind RNA 
although MBP did at a lower extent. 
 
 
probe and increasing amounts of protein.  In this case the MBP used was generated and 
purified in the same way as the recombinant DAZL.  An interesting anomaly occurred in 
the nitrocellulose binding reaction.  Not only did DAZL bind RNA, but so did MBP 
which had been previously shown not to bind RNA (Figure 23).  However, MBP bound 
RNA much less efficiently than DAZL.  Additionally at 15 µM protein, there was a 
decrease in signal retained for both species and further investigation revealed that the 
maximum binding capacity of the nitrocellulose was reached in both cases leading to an 
increased amount of signal passing through the filter. 
 Because of the anomaly indicated in Figure 29, a 5-30% glycerol gradient was 
implemented to help visualize the binding of DAZL, and to a lesser extent similarly 
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Figure 30.  5-30% Glycerol Gradient and CDC25C.  Fractions were taken from the bottom and 
counted in a scintillation counter.  The RNA line shows a fairly wide range over its migration.  Upon 
the addition of MBP, the RNA shifts down with a final pattern which is the same as the RNA by 
itself.  Upon addition of DAZL, a higher less dense band forms which appears over a lower number 
of fractions. 
 
prepared MBP, to the synthetic target RNA.  The binding reaction was applied to the 
gradient and centrifuged.  Fractions of the gradient were read in a scintillation counter 
and plotted as CPM vs fraction number, Figure 30.  The results showed that both DAZL 
and MBP shifted RNA but to different places in each of the gradients.  DAZL shifted the 
RNA higher in the gradient where the solution is less dense in a narrower band while 
MBP shifted the RNA to a more dense, albeit wider and possibly non-specific, place in 
the gradient. 
To address the potential RNA targets for DAZL, a binding method involving the 
use of affinity chromatography with immobilized DAZL was developed.  The idea 
behind this assay was to use amylose affinity resin to separate DAZL-MBP-RNA 
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complexes from unbound RNA where DAZL-MBP, or any given protein construct with 
its radiolabeled target, were retained on the column.  Because there was concern about 
changes in binding that might occur related to processing of recombinant proteins, only 
the target RNA for DAZL binding was radiolabeled and the signal to be counted was 
that which flowed through the column to minimize steps needed to recover material from 
the column.  Any RNA remaining on the column was calculated as the difference 
between that added and the amount that flowed through the column.  Before any binding 
reactions in affinity chromatography were to take place, a survey of possible RNase 
contamination was made.  Double-distilled water, reverse osmosis water, and the buffers 
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Figure 31.  Retention of RNA by Affinity Chromatography 
System.  The first column is input RNA with no treatment.  The 
remaining treatments are indicated under each column and the 
values generated from scintillation counting are shown below 
each column.  The numbersoc  columns in the signal counted in 
the flowthrough for each of the experiments. 
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used in the binding reactions were found to be free of RNase contamination using a 
commercially-available kit from Ambion. 
The system that was used for this assay was also assessed as to retention of RNA 
(Figure 31).  The results showed that nearly 80% of the signal was retained non-
specifically by this system.  Interestingly, when comparing the constructs among 
themselves, the construct containing DAZL retained more RNA than MBP alone which 
validated this approach for finding potential binding targets of DAZL (Figure 32).  To 
use this affinity chromatography in a binding assay comparing different protein 
constructs, MBP, MBP-DAZL, MBP-DAZLmut1, and MBP-DAZLmut2 were incubated 
with in vitro-transcribed RNA for 15 minutes on ice, centrifuged to remove unbound 
RNA, and the radioactively labeled, unbound RNA counted in the flowthrough.  The 
RNA bound to the resin was also counted by subtracting flow-through activity from the 
input RNA activity.  Figure 33 illustrates that DAZL and both mutant forms of DAZL  
bound more RNA than MBP alone on the resin.  However, the difference between the 
DAZL forms was not significant (p > 0.129) using ANOVA with Tukey’s post-hoc test.     
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Figure 32.  Retention of RNA in Column Treated Samples.  When 
the data from the column-treated only samples from Figure 30 are 
compared, it is evident that DAZL-containing resin bound more 
RNA than the resin only containing MBP.  The numbers below 
each of the columns indicate the CPM flowing through the column 
and counted in a scintillation counter. 
 
arcsine modification of the data was not needed.  Variation among experiments was 
observed, but the ability of DAZL to retain more RNA was established and the DAZL 
fusion proteins were functional in RNA binding activity. As a control for nonspecific 
binding, a mouse antisense β-actin RNA binding target was generated and used in 
another affinity chromatography binding assay (Figure 34).  The results from this 
experiment indicated that the DAZL proteins and their mutants possess an enhanced 
affinity for the CDC25C RNA binding target when compared with the mouse non-
specific housekeeping gene (β-actin). 
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Figure 33.  DAZL and Its Mutant Forms Bound More RNA Than MBP Alone.  
However there was no difference in binding among the different clones.  Experiment 1 
contained 22 µM RNA, 25µl protein-bound resin, and the columns were pre-treated 
with 10µl 0.1mg/ml BSA.  Experiment 2 contained 2.2 µM RNA, 100µl protein-bound 
resin, and the columns were pre-treated with 10 µl 0.1mg/ml BSA.  Experiment 3 
contained 13.5 nM RNA, 500µl resin, and the columns were pre-treated with 100µl of 
100 mg/ml BSA. 
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Figure 34.  β-actin Control Showing DAZL Binds CDC25C and Not β-actin.  The 
affinity chromatography data show that DAZL and its mutants bind the CDC25C 
construct in a manner which is more specific than the binding to the mouse antisense 
control. 
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Discussion 
  
The first step in examining the function of DAZL was the production of an active 
recombinant protein.  The straightforward sequence of events outlined in the text 
explaining the cloning procedures belies the difficulty encountered during any cloning 
process.  For example, in the initial attempts the DAZL protein could not be purified as 
an active, intact form using a common vector that included a His tag.  To address this 
problem a different system was used with MBP as a fusion protein.  Other researchers 
expressing DAZ proteins have used other fusion proteins such as glutathione S-
transferase (GST) tags[78].  At Texas A&M University, a popular fusion tag for 
purification is the MBP tag because of the increased solubility MBP provides and the 
elution with a dilute maltose solution.  In addition, resultant multiple cloning steps into 
the pMAL vector took extensive effort.  pMAL was selected to maintain solubility of the 
fusion proteins.  When DAZ proteins were expressed in the E. coli, there was a tendency 
for an increase in the doubling time of induced cells.  To combat possible degradation of 
the recombinant proteins, growth of all cultures destined for expression were grown at 
28°C in a protease deficient cell line (ER2508) designed for protein production.  In 
another series of experiments, Fox et al. used the pET29 vector from Novagen for 
cloning.  In their assay, the purification tag included a 6-His tag[79] which required the 
use of denaturing conditions to purify the protein followed by dialyzing the protein 
against a suitable buffer in which to store and use the protein.  The problem with this 
methodology is that there are risks associated with denaturing and refolding the protein.  
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In this study an MBP tag was used to avoid the harsh conditions.  In addition, while the 
cloned DAZL fragment contained the entire coding region of DAZL (NM_001351.2, 
nucleotides 295-1182) used by Fox et al., these authors did not indicate whether it was 
exactly the same as the accession sequence at NCBI [79].  Additionally it became 
evident that the conditions used to enrich for the desired protein of interest also purified 
proteins that bound RNA (Figures 22 and 28).  This is the most likely hypothesis that 
can explain why there is no RNA binding of MBP when the protein used in the 
experiment is purchased commercially as it is in Figure 23.  However, when MBP is 
enriched using the same methodology and the same cell line as what is used to generate 
the other protein constructs, that “MBP” seems to shift RNA.  However, Figure 30 
shows that DAZL shifts the RNA to a different place than the MBP construct.  
Additionally it takes more of the MBP construct to bind to the same amount of RNA 
than DAZL.  Therefore it is likely that whatever protein is present is binding in a 
relatively non-specific manner. 
 In the present study, human DAZ and DAZL and unique variants of DAZL 
representing mutated forms associated with infertility in Taiwanese populations were 
produced.  Another mutated form not associated with infertility was produced to serve as 
a negative control.  The sizes and sequences of these molecules have been verified.  
Other researchers have produced data describing DAZ interactions[17, 38, 80, 84, 87].  
However, most of the descriptions have been based on yeast two hybrid systems or 
experiments with other species such as in the mouse or C. elegans.  The human DAZ 
and DAZL proteins produced in the present study provide a more direct and simpler 
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approach to determine interactions of the DAZ proteins with other molecules and to 
explore the kinetics associated with DAZ function. 
Up to this point there had been little data determining quantitative binding of the 
DAZ proteins to RNA.  Jiao et al. did examine RNA targets of binding to cloned murine 
DAZL, but the study was limited to only one isoform.[88].  Venables et al. also 
performed an RNA association study where cloned murine DAZL was used to elucidate 
a consensus sequence to which murine DAZL bound.  A mutant form of the RRM of 
murine DAZL exhibiting four point mutations in the RRM was used in their binding 
assay.  None of these investigators reported estimates of Kd for binding activity 
demonstrated in their systems.  The current study assayed not only the DAZL protein but 
also population-derived mutants.  The combination of three different electrophoretic 
mobility shift assays revealed that DAZL binds RNA with a Kd of 1.0 µM.  A decent 
binding value for an RNA binding protein has been reported as in the 5 nM range with 
+/- an order of magnitude[82].  Therefore the binding of DAZL to the CDC25C RNA 
seems less than expected.  However, later experiments show that CDC25C may not be a 
preferred target for the DAZL protein.  However, the electromobility shift assay 
demonstrates definite binding of DAZL for target RNA.   
Additionally, the affinity chromatography binding reaction served as an alternate 
measure for binding after cloning and expression of the DAZL proteins and ultimately 
showed that all forms of DAZL bound to a synthetic RNA target.  Once again it was 
shown that the affinity chromatography system and possibly a factor or factors co-
purified with MBP also bound RNA but not as well as DAZL.  In addition, it was shown 
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through the same binding assay that DAZL preferentially bound the CDC25C RNA 
target when compared with a general housekeeping β-actin RNA.  The column-binding 
assay also served as a starting point for experiments involved in determining the RNA 
targets of DAZL. 
These experiments ultimately showed that cloned and expressed DAZL, DAZ , 
and mutant forms of DAZL can bind RNA in a variety of methods such as gel shift, 
nitrocellulose, or affinity chromatography.  Because the control protein MBP copurifies 
the same proteins as DAZL, MBP can be used as a control for further binding 
experiments. 
By combining the methods of the electrophoretic mobility shift assay and affinity 
chromatography, experiments can be performed to probe the targets for DAZL and DAZ 
binding as well as determining the effects of mutations of DAZL and DAZ on the 
binding efficiencies of each of the proteins for their RNA targets. 
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CHAPTER IV 
FUNCTION OF DAZL 
 
Introduction 
 Many investigations regarding DAZL or DAZ rely on the presence or absence of 
genes or modifications of those genes and correlate the results with infertility.  However, 
an underlying question remains. What is the function of the DAZ and DAZL proteins?  
It is known that DAZL proteins bind RNA and a list of RNAs for both murine DAZL 
and human DAZL have been described [79, 88, 89].  Disappointingly few references 
describe cloning of human DAZL or DAZ for eventual expression as proteins for an 
eventual focus on binding activity.  The binding potential of human DAZL and DAZ is 
based on the presence of an RRM (RNA recognition motif) sequence.  To date, 
procedures such as SELEX (Systematic Evolution of Ligands by Exponential 
Enrichment), tri-hybrid screening, and affinity purification have been utilized in finding 
the targets for DAZL binding in mouse and human [79, 84, 88].  There are points to keep 
in mind when considering such articles.  Methods such as SELEX rely on serial 
amplification of RNA targets and thereby artificially produce enriched numbers of 
targets to which the protein binds.  These methods may prove useful for identifying 
consensus sequences, but may not yield the complete picture concerning the targets of 
DAZL binding.  In addition, controls in these experiments involving affinity purification 
of fusion proteins of DAZL did not include the fusion tag in a separate binding reaction 
as comparison.  In one study by Jiao et al. the control protein was a non-specific RNA-
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binding protein [88].  A comparison was made between targets selected by the control 
protein versus the DAZL protein.  A possible weakness with this study is that a valid 
target of DAZL may be discounted due to selection by the control protein.  In addition, 
the same study used total testis extract in its binding assay in hopes that other binding 
cofactors found within the complement of the extract would yield the true targets of 
DAZL.  In the mouse, DAZL is found expressed in spermatogonial cells from mitosis to 
the beginning of meiosis (Figure 4)[1].  If a total extract is generated from seminiferous 
tubules progressing through many different stages of spermatogenesis it may be possible 
that inhibitors will be included.  In addition, in humans, DAZL is found expressed 
throughout spermatogenesis and DAZ is found expressed from the beginning of mitosis 
through the beginning of differentiation (as in the mouse)[1]  This factor also suggests 
that caution be used when generalizing on the use of targets of DAZL or DAZ binding in 
the mouse to predict targets in the human.  Furthermore, in Jiao et al.’s study, when the 
targets of DAZL were bound to the proteins, the bound RNA was purified through 
multistep procedures where loss of signal becomes a greater issue.  After the RNAs were 
isolated, cDNA was synthesized, cloned into vectors, and analyzed separately in a time-
consuming and expensive process.   
The method outlined in this study utilizing microarray technology allows the 
simultaneous detection of many RNA molecules.  After the binding reaction between 
DAZL and RNA, the RNA was purified from other inhibiting molecules through a 
simple spin column.  Microarray analysis was used to survey the targets that flowed 
through the binding reaction with minimal handling of the substrate.  In this way many 
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targets can be analyzed at the same time and the risk of losing signal through repetitive 
processing is avoided.  An expanded list of targets would further identify pathways in 
which DAZ and DAZL proteins participate. 
Binding affinity of protein for mRNA can be estimated using the electrophoretic 
mobility shift assay or EMSA [82].  The EMSA enables the researcher to determine, 
with some degree of precision, the binding affinity of a protein for an mRNA substrate.  
When differing DAZL protein constructs are used in binding studies, an instructive 
comparison can be made to further define the function of DAZL domains.  
 
Materials & Methods 
 
Growth of Cells and Purification of Proteins 
 NEB’s ER2508 cells with the appropriate pMAL vector were grown in LB under 
conditions cited in Chapter III Materials and Methods.  After purifying the proteins 
through amylose resin affinity chromatography and washing the resin with buffer, the 
resin with the enriched DAZL and DAZ proteins were stored at 4°C until used for 
binding reactions. 
 
Binding Reaction for Microarray 
 Figure 35 shows a flowchart associated with preparing the RNA for use in 
microarrays.  Four Qiagen Small Spin Columns were used for the microarray 
experiment.  Poly A+ RNA from human testis (Clontech, described previously) was  
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divided into two tubes and each tube was subsequently divided into an aliquot for use 
with MBP-bound (maltose binding protein) resin and an aliquot for use with DAZL-
bound resin.  The products of one set were labeled according to manufacturer’s 
instructions with fluorescent dyes (Amersham Biosciences, Piscataway, NJ); the dye 
Cy3 was used with RNAs associated with MBP and the dye Cy5 was used with RNAs 
associated with DAZL.  The products of the second set were labeled with the alternate 
dyes (dye-swap). 
At the Scott and White Microarray Center, Qiagen Small Spin Columns were 
pretreated with 1X Binding Buffer (321mM Tris, pH 7.4, 20mM KCl, 5mM MgCl2, 
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Figure 35.  Flowchart of RNA Preparation for Microarray Analysis of RNAs bound by DAZL 
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1mM DTT, 10% Glycerol, 7.5 µg/mL yeast tRNA, 100µg/mL BSA).  After pre-
treatment, the tubes were centrifuged in a tabletop centrifuge at 13,000 rpm for 1 min.  
In separate PCR tubes, 50μl 1X Binding Buffer, pH 7.4 was added to 2.5 µg in 2.5 µl 
Poly A+ Human Testis RNA from Clontech (Cat# 6535-1).  To this, 300 µg in 100μl of 
the protein-bound resin was added using a 200μl pipette tip with the end cut off to avoid 
resin sticking in the tip.  300µg is based on the maximum binding capacity of the 
amylose resin at 3 mg/ml binding of bed volume.  The mixture was incubated on ice for 
20 min and the complete reaction was applied to the pretreated column.  The column 
was centrifuged at 13,000 rpm for 1 min in a tabletop microcentrifuge and the 
flowthrough was immediately transferred to the technicians at the Scott & White 
Microarray Center for downstream manipulations and analyses. 
 
Microarray Analysis 
In this study, the mRNA after centrifugation required purification due to residual 
proteins and other components of the binding reaction which would inhibit downstream 
microarray manipulations.  Purification of the RNA was achieved using the Ambion 
(Cat# 1908, Austin, TX) Megaclear purification column.  Methods followed were those 
provided in the manufacturer’s instructions.  Briefly, RNA was bound to the column, 
washed with buffer to remove any contaminants, and eluted in a low salt buffer suitable 
for many enzymatic reactions.  The mRNA from each of the enriched samples was 
analyzed using the Agilent 2100 Bioanalyzer (Palo Alto, CA) and an RNA 6000 
NanoLabChip Kit (Agilent, Cat# 5065-4474).  Each of the four chips was loaded with 
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mRNA and analyzed using Agilent Technologies Bio Analyzer Sizing Software (Palo 
Alto, CA). 
 
F
lu
o
r
e
s
c
e
n
c
e
Time (seconds)
0
5
10
15
20
25
 14  19  24  29  34  39  44  49  54  59  64  69  74  79  84
25 bases
200 bases
500 bases
1 kb
2 kb
4 kb
6 kb
 
 
 
Figure 36 shows the results of use of Agilent Technologies’ capillary 
electrophoresis chip for determining quality of RNA.  A simulated gel picture of the run 
is shown on the left.  This picture is simulated because the actual technology relies on 
capillary electrophoresis and fluorescent dye which is associated with the 
electrophoresed sample.  A laser scans the migration of the nucleic acids and the output 
is a chromatogram indicating size and intensity of bands.  In Figure 37, the fluorescence 
data are on the right and are quantitative showing a ladder which is used in sizing 
Figure 36.  Capillary Electrophoresis Microarray Ladder.  This graph displays, on the left, a simulated 
gel run of an RNA from capillary electrophoresis.  On the right is a chromatogram showing the intensity 
of peaks versus migration in time.  The longer pieces of RNA take longer to migrate. 
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unknown samples.  Amplification of the RNA proceeded after the RNA quantity and 
quality was of a sufficient nature. 
The previous RNA assay determined that there was 8.273 ng/ul of RNA which 
flowed through MBP treatment  1, 6.853 ng/ul of RNA from MBP treatment 2, 5.505 
ng/ul of RNA from DAZL treatment 1, and 5.185 ng/ul of RNA from DAZL treatment 
2.  Two hundred nanograms of each sample were used in the generation of labeled 
aRNA (amplified RNA) for the microarray using the Ambion Amino Allyl MessageAmp 
aRNA Kit (Cat# 1752, Austin, TX).  Amplified RNA is RNA which is created from 
transcription from a cDNA template.  The cDNA template is obtained by reverse 
transcription from the original RNA substrate.  Reverse transcription began with an oligo 
(dT) primer containing a T7 promoter sequence binding to the poly A tail of the 
transcript.  A reverse transcription enzyme, Arrayscript, synthesized the cDNA.  Second 
strand synthesis took place next to provide a template for in vitro transcription which 
included the incorporation of the modified nucleotide 5’-(3-aminoallyl)-UTP into the 
aRNA.  Once the aRNA (amplified RNA) was purified and reverse-transcribed, 
fluorescent labeling was achieved during amplification of the cDNA.  For labeling, each 
of the two samples were split into two aliquots in which the RNAs selected using MBP 
resin were labeled red and the RNAs selected using DAZL resin were labeled green.  In 
the other group, the MPB-specific RNAs were labeled green and the DAZL-specific 
RNAs were labeled red.  The dye-swapping method is routinely used to correct for 
anomalies in labeling efficiency.  The modified UTP could then be bound by reactive 
dyes such as Cy3 (green, Cat# PA25001) and Cy5 (red, Cat# 23001) (Amersham 
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Biosciences).  After amplification, nanochip analysis was performed again for both 
samples and repetitions.  In 100 µl, there was 0.59 µg/µl MBP 1, 0.58 µg/µl MBP 2, 
0.11 µg/µl DAZL 1, and 0.16 µg/µl DAZL 2 synthesized. 
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Figure 37.  Lab on a Chip Analysis of Flowthrough RNA After Treatment by MBP and DAZL.  The 
RNAs that flowed through the column after treatment with MBP showed a higher number of larger 
species of RNA than the column treated with DAZL.  DAZL selectively retains most of the 
transcripts larger than 2 kb while the smaller transcript population appears to have been left intact. 
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For the microarray, 3 µg of each amount was applied to each of the microarrays.  The 
mixtures of each group were as follows:  5.1 µl MBP 1 (Cy3, green) X 27.3 µl DAZL 1 
(Cy5, red), 5.1 µl MBP 1 (Cy5, red) X 27.3 µl DAZL 1 (Cy3, green), 5.2 µl MBP 2 
(Cy3, green) X 18.8 µl DAZL 2 (Cy5, red), and 5.2 µl MBP 2 (Cy5, red) X 18.8 µl 
DAZL 2 (Cy3, green).  The paired samples were fragmented using components found in 
the kit from Ambion (Cat# 8740).  The fragmented samples were hybridized overnight 
with hybridization buffer from Ambion (SlideHyb, Cat# 8861) at 48ºC to the 
Human21K Oligo Library V2.1 (Operon, Huntsville, AL).  The microarray plates were 
read in a GenePix 4000A scanner (Axon Instruments, Sunnyvale, CA) and the data were 
normalized and filtered using GeneSpring v7.2 software package (Silicon Genetics, 
Agilent Technologies).  Gene expression was assessed using multiple t-tests (p < 0.05) 
using Benjamini Hochberg false discovery rate multiple testing correction.  From these 
data the GeneSpring software determine pathways and functions which DAZL would 
influence by binding RNAs. 
 
Genes Selected and Not Selected by DAZL for in vitro Transcription 
Genes specifically selected by the DAZL protein from the microarray assay were 
used as targets to create transcripts to verify the binding system.  One of the mRNAs 
preferentially selected by DAZL was PSMD (Proteasome 26S Subunit 6); (Genbank 
Accession #NM_014814) and its cDNA was generated using PCR with the addition of a 
T7 promoter on the 5’ end.  Also, a gene not selectively retained in the DAZL column 
was Testis-Specific Protein Kinase 1; TESK1 (Genbank Accession # NM_006285).  In 
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vitro transcription was used to generate a radiolabeled transcript of the PCR product for 
each of these mRNAs using methods previously described.  Both of the probes 
originated from PCR from the Clontech cDNA Testis Library using the following 
primers:  For TESK1 (low binder) Forward Primer, NM_006285 5F,- 5’- TTG GCT 
TCC TGT CCA TGT GC -3’, TESK1 Reverse Primer, NM_006285 5R, - 5’- GCC AGC 
CAG GCA GTT TTA TTG, PSMD Forward Primer, NM_014814F+T7, -5’- TAA TAC 
GAC TCA CTA TAG GAG AAC CTG GAG GAG GAG -3’, and PSMD Reverse 
Primer, NM_014814R, -5’- GAA ACA ACA ATG CAG TAT TTA TTT TAT ACA 
GCT GAC CTG GGC -3’.  Each of the PCR products was cloned into the pCR2.1 vector 
and verified as to size and identity through sequencing.  Minipreps were made of each of 
the clones. 
For PSMD, the plasmid was linearized with ApaI (NEB, Ipswich, MA) following 
procedures previously described in Chapter III and PCR was performed using the same 
primers as described.  This new PCR product was used as template to support in vitro 
transcription using Ambion’s T7 Polymerase in the presence of 32P-UTP. 
For TESK1, PCR was performed using new primers containing a T7 promoter as 
the original cloning primers did not contain a T7 promoter sequence.  The T7-containing 
forward primer, NM_006285 F+T7.2, possessed the sequence 5’- TAA TAC GAC TCA 
CTA TAG GTT GGC TTC CTG TCC ATG TGC -3’ and the reverse primer, 
NM_006285 RMod.2, contained the sequence 5’- GCC AGC CAG GCA GTT TTA 
TTG AAA TCT TTT TAA ATA ATT GCA CGT G -3’.  The PCR product was used as 
template in an in vitro transcription reaction. 
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Both transcripts were verified for size and purity using a 5% Urea-PAGE gel in a 
BioRad Mini Protean II electrophoresis chamber.  Formulas and conditions used for 
running these gels were from instructions in the MAXIscript Kit (Catalog # 1312, 
Ambion, Austin, TX). 
 
Binding Reactions for Target mRNAs 
A binding reaction was created for each of the protein constructs (MBP, DAZL, 
DAZLmut1, DAZLmut2, and DAZ) using a method similar to that for the binding 
reaction performed for the microarray.  The final concentrations of the buffer for the 
binding reactions were 20 mM Tris, pH 7.4, 50 mM KCl, 5 mM MgCl2, 2 mM DTT, 
10% glycerol, 7.5 µg/ml Yeast tRNA (Ambion, Austin, TX, Cat#7119), and 0.1 mg/ml 
BSA (Ambion, Austin, TX, Cat#2616).  All binding reactions were performed in five 
separate PCR tubes.  As in the previous binding reactions with the spin columns, tubes 
were treated with 100 µl of 1X binding buffer.  A binding reaction consisting of 5 µl of 
water, 40 µl of 2X binding buffer containing tRNA and BSA, 5 µl of RNA (final 
concentration in reaction was 37.5 nM for TESK1 transcript and 26.2 nM for PSMD 
transcript), and 30 µl of resin was added to separate PCR tubes.  The reactions were 
allowed to proceed on ice for 1 h at which time the solutions were applied to pretreated 
small spin columns (100 µl of 0.1 mg/ml BSA) and centrifuged for 2 min at 800 x g at 
room temperature.  The flow-through was pipetted into scintillation vials containing 5 ml 
of Ecoscint XR (National Diagnostics) and assayed for radioactivity based on CPM.  
The binding data were corrected for moles of protein based on calculations that follow. 
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To account for differing amounts of proteins on the resin, 30 µl of the resin was 
mixed with 1ml of column buffer (20 mM Tris-HCl, pH 7.4, 200 mM NaCl, and 1 mM 
EDTA) containing 10mM maltose.  The solutions were read in a spectrophotometer and 
absorbance at 280 nm used to determine concentrations of the proteins using the molar 
extinction coefficient of each protein.  The extinction coefficient of each protein was 
calculated based on data reported by Pace et al. [90].  The final concentrations of 
proteins in the binding reaction, based on elution of proteins from the beads, were: 
MBP- 12.9 µM, DAZL- 15.8 µM, DAZLmut1- 16.2 µM, DAZLmut2- 23.0 µM, and 
DAZ- 13.6 µM. 
 
Creation of Radiolabeled Proteins 
In vivo radiolabeling of proteins began by growing cells to a midlog phase in LB.  
The cells were pelleted and then washed twice in M9 medium (per liter: 6.78g anhydrous 
disodium phosphate, 3.0g monopotassium phosphate, 0.5g sodium chloride, and 1.0g 
ammonium chloride).  The cells were pelleted, resuspended in M9 media containing 0.01 
g/100 ml of each amino acid except methionine, 0.002 g/100 ml thiamine, 0.2 g/100 ml 
glucose, 0.23 g/100 ml IPTG, and 0.01g/100 ml carbenicillin.  The cells were exposed to 
0.3 mM IPTG final to induce expression of proteins for 2 hours and then cells were 
centrifuged and the pellet stored at -20°C overnight.  Cell pellets were diluted into 
column buffer (NEB- 20mM Tris, pH 7.4, 1mM EDTA, and 200mM NaCl) for 
enrichment and sonicated 30 times (15s on 15s off).  The proteins were then purified as 
per NEB instructions and have been described previously.  Specific activity was 
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determined by taking an aliquot of the radiolabeled protein and adding that sample to 5 
ml of Ecoscint XR.  The sample was then associated with protein concentration using the 
extinction coefficient as mentioned previously.  
 
Gel Shifts 
Gel shifts were performed using agarose gels utilizing a 0.5% SeaKem Gold 
(BioWhittaker) gel in 0.5X TBE.  Low percentage agarose gels were needed because of 
the large size of the probes used in the binding assay for PSMD6 and TESK1.  The gels 
were pre-run at 70V for about 30 min prior to loading and loaded when running.  The 
gels were run at 70V for about 3 h and then treated in a solution of 12% methanol and 
10% acetic acid for about 30 min with gentle shaking.  Afterwards the gel was laid on 
Whatman paper, covered on the top side with plastic wrap, and dried on a gel drier for 1 
h without heat and then 1 h with heat.  After drying, the gel was exposed to a 
phosphorimage screen for as long as needed (usually overnight for low signal counting).  
The phosphorimage screen was read in a BioRad Molecular Imager Pro (Hercules, CA). 
 
Results 
To assay the targets of DAZL, human testis poly A mRNA flow through from 
columns containing immobilized DAZL or MBP (control) were applied to a microarray 
for analysis.  Figure 38 shows dot plots of fold signal increase for both DAZL and MBP.  
Each dot above the blue line indicates greater than a 3-fold increase with a p value < 
0.05.  A 3-fold increase was selected as a criterion because the noise of the species 
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retained by MBP was present out to 2-fold.  Therefore, signals greater than 3-fold and 
possessing a p-value < 0.05 were considered as valid targets selected by DAZL.  A total 
of 1,313 targets were specifically selected by the DAZL protein, but not by the MBP 
system (Figure 39). 
 
 
 
 
 
Figure 38.  Species of RNA Retained by DAZL and “Retained” by 
MBP.  The blue line indicates greater than 3-fold ratio of binding and 
the red line indicates greater than 2-fold ratio of binding. 
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Figure 39 shows two genes selected and not selected by the DAZL protein.  The 
top protein is the 26s proteasome subunit (PSMD), involved in degrading ubiquinated 
cell cycle proteins such as CDC25A.  One of the least-selected transcripts by DAZL in 
this experiment was TESK1, a testes-specific kinase.  A complete list of the top three-
fold bound messenger RNAs for testicular proteins is presented in Appendix 4 and the 
Top 20 targets are presented in Table 11. The microarray data were compared with 
published results.  One of the first papers to describe targets of DAZL was by Jiao et al. 
Figure 39.  Possible Targets for DAZ Protein Binding.  The x-axis indicateds fluorescence units 
and the y-axis shows the ratio of signal.  One of the targets specifically selected by DAZL is 
PSMD6 and one of the targets not specifically bound is TESK1. 
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who reported a number of targets of DAZL in mice using a technique called SNAAP 
(Specific Nucleic Acids Associated with Proteins)[88].  Table 12 shows a comparison 
between results of the present study and those reported by Jiao et al.  Pam, Trf2, and 
Grsf1 were targets specifically selected by the human DAZL protein with a p-value < 
0.05 in the present study and by murine DAZL using different methods by Jiao et al.  
This study found CDC25C to be a significant target of DAZL binding, while Jiao et al. 
reported minimal binding to murine DAZL.  Similarly, CDC25A was reported to be 
bound by murine DAZL, but human DAZL showed no significant binding.  Other 
factors not significantly selected by DAZL were; Tpx-1, associated with the process of 
acrosome development and sperm tail movement; Pam, a protein know to interact with 
Myc (a cell proliferation protein); Trf2, a factor supporting telomere maintenance; Grsf1, 
a positive regulator of transcription; Cappβ1, mouse actin capping protein β subunit gene 
which controls actin assembly; and Pα 7/C8, proteasome α 7/C8 subunit.  Functions 
associated with these proteins could influence spermatogenesis and cell cycle control. 
In addition, results were compared to those of Fox et al. in Table 13 where 
targets of DAZL binding in humans were studied[79].  The first group are Fox et al. 
selected genes considered to be significant binding targets with a low p-value in the 
current microarray study.  The second group of genes are also those identified by Fox et 
al., but not statistically significant in the present study.  The third group of genes was not 
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Table 11.  Top 20 Three-Fold Targets of DAZL. 
Systematic ID Reference Sequence Product Biological Process Normalized Ratio P-value† 
NM_014814 NM_014814 proteasome regulatory particle subunit p44S10 ATP-dependent proteolysis 0.0703 14.22 0.0024 
NM_000019 NM_000019 acetyl-Coenzyme A acetyltransferase 1 precursor  0.0731 13.67 0.0012 
AK057433 NM_144674 hypothetical protein FLJ32871 microtubule cytoskeleton organization and biogenesis 0.0784 12.76 0.0090 
NM_005977 NM_005977; NM_183043; NM_183044; NM_183045 
ring finger protein 6 isoform 1; ring finger 
protein 6 isoform 2  0.0811 12.33 0.0011 
NM_006197 NM_006197 pericentriolar material 1  0.0812 12.31 0.0017 
NM_004872 NM_004872 thymic dendritic cell-derived factor 1  0.0835 11.97 0.0012 
NM_014932 NM_014932 neuroligin 1 
synaptogenesis; protein targeting; cell adhesion; synaptic 
vesicle targeting; calcium-dependent cell-cell adhesion; ion 
channel clustering; regulation of neuron differentiation 
0.0853 11.73 0.0013 
NM_007051 NM_007051; NM_131917 FAS-associated factor 1 isoform a; FAS-associated factor 1 isoform b apoptosis 0.0870 11.50 0.0010 
NM_007204 NM_007204 DEAD (Asp-Glu-Ala-Asp) box polypeptide 20 assembly of spliceosomal tri-snRNP; mRNA processing 0.0889 11.25 0.0023 
AK056446 NM_005348 heat shock 90kDa protein 1, alpha  0.0971 10.30 0.0038 
NM_030933 NM_030933 chromosome 1 open reading frame 14  0.0981 10.19 0.0039 
NM_014633 NM_014633 SH2 domain binding protein 1 regulation of transcription, DNA-dependent 0.0982 10.18 0.0041 
NM_003295 NM_003295 tumor protein, translationally-controlled 1  0.1052 9.51 0.0057 
NM_001006 NM_001006; NM_182777 ribosomal protein S3a protein biosynthesis 0.1061 9.43 0.0074 
BC017296 NM_144665 sestrin 3 cell cycle arrest 0.1075 9.30 0.0016 
NM_006554 NM_006554 metaxin 2 mitochondrial transport; intracellular protein transport 0.1089 9.18 0.0046 
NM_003299 NM_003299 tumor rejection antigen (gp96) 1 response to stress; protein folding 0.1096 9.12 0.0031 
NM_006461 NM_006461 mitotic spindle coiled-coil related protein  0.1097 9.12 0.0063 
NM_002592 NM_002592; NM_182649 proliferating cell nuclear antigen DNA repair; DNA replication; cell proliferation; cell cycle control 0.1109 9.01 0.0025 
NM_053023 NM_053023; NM_170768 zinc finger protein 91 isoform 1; zinc finger protein 91 isoform 2  0.1109 9.01 0.0306 
The first two columns indicate the accession numbers found in Genbank.  The product column describes the gene name and the biological process column indicates which pathways are 
involved in the process.  The normalized column contains values generated from the ratios of red to green fluorescence averaged over the duplicate runs found in the experiment.  The 
ratio column is merely the 1/normalized ratio. 
† The p-value is a statistical test as compared to a ratio of 1.0. 
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Table 12.  Comparison of Targets of Human DAZL with Targets of Murine DAZL. 
Mouse ID Binding to mDAZL* Human ID 
Retained by 
hDAZL 
Ratio (SD) 
P-level 
Cdc25A Yes CDC25A 1.4 (0.4) NS 
Cdc25C minimal CDC25C 2.7 (0.9) 0.0005 
Tpx-1 Yes CRISP1 1.1 (0.4) NS 
Pam Yes PAM 2.8 (0.6) 0.0001 
Trf2 Yes TBPL1 4.7 (1.5) 0.004 
Grsf1 Yes GRSF1 4.3 (1.2) 0.001 
Cappbeta1 Yes CAPZB 1.5 (0.3) NS 
Palpha7/C8 Yes PSMA3 0.9 (0.2) NS 
H47 Yes   ND 
Clone D2 Yes   ND 
*Jiao et al. [88] 
 
represented in the arrays used in the current study, but were reported by Fox et al.  Of 
note is that Fox et al. presented some targets for DAZL binding as protein sequences.  A 
Genbank database search was used to assign a cDNA accession number for protein  
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Fox Name Ratio p-value 
NM_183380 Bullous pemphigoid antigen 1 4.18 0.009 
NM_021190 Polypyrimidine tract binding protein 2 6.87 0.010 
NM_022333 TIA1 cytotoxic granule-associated RNA-binding protein-like 1 5.76 0.012 
NM_004362 Calmegin (CLGN) 3.56 0.013 
NP_037534, NM_013402 Fatty acid desaturase 1 (FADS1) 2.60 0.014 
NM_024835 Zinc finger protein 403 (ZNF403) 5.49 0.017 
NM_00210 Integrin a6 precursor (VLA-6) (CD49f) 2.55 0.018 
NM_002762 Protamine P2 5.47 0.019 
NM_004457 Acyl-CoA synthetase long-chain family member 3 (ACSL3) 3.29 0.020 
NM_000365 Triosephosphate isomerase 1 (TPI1) 4.72 0.021 
NP_115789, NM_032413 Normal mucosa of esophagus specific 1 3.11 0.022 
NP_004492, NM_004501 Heterogeneous nuclear ribonucleoprotein U 2.07 0.022 
NM_003103 NREBP, SON binding protein 3.08 0.026 
NM_006263 Proteasome (prosome, macropain) activator subunit 1 (PA28 a) 2.24 0.031 
NP_005768, NM_005777 RNA-binding motif protein 6 2.17 0.033 
NM_007195 Polymerase (DNA directed) L (POLI) 3.01 0.035 
NM_016614 TRAF and TNF receptor-associated protein (AD022) 2.64 0.039 
NM_003054 Solute carrier family 18 (vesicular monoamine), member 1.00 NS 
NP_003065, NM_003074 
Uncharacterized protein with weak homology to SWI/SNF-related, 
matrix-associated, actin-dependent regulator of chromatin, subfamily 
C, member 1 (SMARCC1) 
 
1.73 NS 
NM_001819 Chromogranin B (secretogranin 1) 1.45 NS 
AK057058 Hypothetical protein FLJ32496 1.04 NS 
NM_004147 Developmentally regulated GTP-binding protein 1 (DRG1) 1.75 NS 
NM_020655 Junctophilin 3 1.66 NS 
NM_000157 Glucosidase, h; acid (includes glucosylceramidase) 1.89 NS 
NP_060585, NM_018115 Hypothetical protein FLJ10498 1.52 NS 
NM_002761 Protamine 1 1.69 NS 
Table 13.  Comparison of Targets of Human DAZL with Fox, et al. 
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Fox Name Ratio p-value 
NM_004450 Enhancer of rudimentary (Drosophila) homolog (ERH) 0.85 NS 
NM_006568 Growth regulatory with ring finger domain (CGRR19) 1.47 NS 
NM_005831 Nuclear domain 10 protein NDP52 1.73 NS 
NM_021940 Stromal membrane-associated protein 1 (SMAP1) 1.59 NS 
AK056729 Hypothetical protein FLJ32167 1.65 NS 
NM_032037 Serine/threonine protein kinase (SSTK) 0.34 NS 
NM_000484 Amyloid h (A4) precursor protein 1.57 NS 
AK021619 Hypothetical protein FLJ11557 1.30 NS 
NM_024610 HSPB (heat shock 27 kDa) associated protein 1 2.05 NS 
NM_020411 G antigen, family D, 2 (GAGED2) 1.60 NS 
NM_004184 Tryptophanyl-tRNA synthetase (WARS) 1.49 NS 
NP_002002, 
NM_002011 Fibroblast growth factor receptor 4 (FGFR4) 1.44 NS 
NM_001173 Rho GTPase activating protein 5 (ARHGAP5) 1.39 NS 
NM_024085 Hypothetical protein FLJ22169 2.23 NS 
NM_021179 Hypothetical protein LOC57821 1.95 NS 
P09430 Spermatid nuclear transition protein 1 (STP-1)(TP-1)  ND 
NM_006098 Guanine nucleotide binding protein (G protein), β-polypeptide 2-like 1 (RACK1: receptor of activated protein kinase C)  ND 
BC035631 Solute carrier family 39 (metal ion transporter)  ND 
AK092893 MLLT6: myeloid/lymphoid or mixed-lineage leukemia (trithorax homolog, Drosophila); translocated to 6  ND 
NM_016424 
Cisplatin resistance-associated overexpressed protein (LUC7A); 
homolog of yeast Luc7p, a splicing factor necessary for 
vegetative growth 
 ND 
BC034491 Hypothetical protein MGC26598; no known domains  ND 
AL049461 DKFZp586F0922  ND 
BC046190 Hypothetical protein DKFZp434C0631  ND 
NM_001477 G antigen 7B (GAGE7B)  ND 
NM_001402 Elongation factor 1-a1  ND 
AK022972 Hypothetical protein FLJ12910  ND 
NM_000368 Hamartin (tuberous sclerosis 1 protein)  ND 
NM_015002 F-box only protein 21 (FBXO21)  ND 
NM_017455 Stromal cell-derived receptor-1 a (SDFR1)  ND 
XM_086402 Hypothetical LOC149018  ND 
NM_014786 Rho guanine nucleotide exchange factor (GEF) 17  ND 
BC018132 Hypothetical protein FLJ22955  ND 
NM_003722 Tumor protein p73-like (TP73L)  ND 
XM_376178 Thyroid hormone receptor interactor 12 (TRIP12)  ND 
 
Table 13.  Continued.
The first column in this table indicates the accession number found in Genbank, the second column 
indicates the name of the gene listed, the third column indicates the ratio of signal found in the present 
study, and the fourth column shows the p-value of that signal in the present study in comparison to a 
ratio of 1.0. 
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sequences reported by Fox et al. and permit a side by side comparison with findings 
from the present study. 
 In addition, a complete list of genes with a 3-fold or greater ratio selected by the 
DAZL protein is included in the appendix.  Table 11 lists the top 20 genes.  This list of 
1,313 genes adds to the currently known list of targets of DAZL binding in humans.   
 The results of the microarray were subjected to analysis by Genespring Software 
(Agilent Technologies, Santa Clara, CA) which organized the genes selected by DAZL 
based on known pathways in cellular processes.  Table 14 shows four pathways in which 
DAZL binding likely plays some level of control: ribosome pathway, proteasome 
pathway, cell cycle, and pyruvate metabolism.  Of interest is the p-values associated 
with each pathway indicating the likelihood that overlapping genes selected by DAZL 
are by chance. 
 
Table 14.  Pathways Associated with DAZL-Selected Transcripts. 
P-value Overlapping Genes Pathway # Genes in Pathway
7.79E-08 35 Ribosome - Homo sapiens 81
8.28E-06 18 Proteasome - Homo sapiens 32
0.00022 56 Cell Cycle - Homo sapiens 204
0.0121 18 Pyruvate Metabolism - Homo sapiens 48  
The first column indicates the random chance that all genes selected by DAZL in this experiment was by 
chance.  Overlapping genes are those selected by DAZL.  The pathway indicates the one involving genes 
selected by DAZL.  The number of genes in the pathway are those programmed into Genespring software. 
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The data were then arranged as a series of figures showing where the various 
DAZL-selected genes could play a role in their respective pathways (Figures 40, 41, 42, 
and 43).  For each of figure there is a color bar indicating fold-change (y-axis), as well as 
p-value (x-axis).  In each figure, there is a bar on the right-hand side indicating fold- 
change over MBP.  This means that for each of the genes selected, DAZL bound a 
certain proportion of that gene more times than MBP.  In addition, the location of each 
of the genes is displayed diagrammatically so that for a structural system each of the 
components can be shown with respect to spatial relationships to each other. 
Once targets for DAZL were identified, a test was devised to assess how separate RNA 
targets behaved in the binding assay that generated the initial microarray data.  In 
addition, naturally-occurring mutants of DAZL and DAZ were tested side by side in the 
binding assay.  The PSMD gene was highly selected through the microarray by the 
DAZL protein whereas TESK1 had little preference for DAZL. The mRNAs for both 
genes were constructed and radiolabeled for use in an in vitro column-binding assay 
similar to that used in the microarray.
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Figure 40.  Ribosomal Subunits.  The genes involved in ribosome construction are shown to be selected by DAZL.  The deeper the shade of green, the 
greater the fold-change over MBP as compared with DAZL.  The fold change is labeled in the green area on the right.  The subunits which make up the 
ribosome are indicated in the middle of the figure and located within the ribosome on the left.  The chance that these genes were selected at random by 
the experiment is shown at the top with a p < 7.79 E-08. 
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Figure 41.  Genes Selected by DAZL Which Make Up the Proteasome.  The fold-change over 
MBP is shown on the right side of the figure.  The chance that these genes were randomly 
selected by DAZL is shown on the top with a p < 8.28 E-06.  The components of the 
proteasome are indicated on the bottom with varying colors of green.  The deeper the shade of 
green, the greater the fold-change over MBP.  The locations of the subunits are indicated in the 
model shown above. 
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Figure 42.  Genes Selected by DAZL Involved in the Cell Cycle.  The fold change bar is located on the right side of the figure.  The chance that 
these genes were randomly selected within the binding system is shown above to be p < 0.00022.  The genes selected by the DAZL protein are 
shown ni the box at the bottom and the location of the genes within the displayed cell cycle pathway is indicated.  The varying colors indicate 
the fold change over MBP where the deeper the green, the greater the fold change over MBP.  
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Figure 43.  Genes Involved in Pyruvate Metabolism and Selected by DAZL.  The bar on the right side of the figure indicates fold-
change over MBP for DAZL.  The deeper the shade of green, the greater the fold-change over MBP.  The genes selected by 
DAZL and involved in pyruvate metabolism are shown in the figure.  The chance that these genes were randomly selected by the 
DAZL binding system is shown to be p < 0.0121. 
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Table 15.  Retention (p-levels) of Radiolabeled TESK1 mRNA Retained by Proteins. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The column binding assay outcome represents the number of counts retained by 
the system (spin column + resin + proteins), calculated by subtracting the number of 
counts of flow-through from CPM input.  TESK1, the transcript not preferred by DAZL 
as determined by the microarray, was first used as a probe for binding to various protein 
constructs.  In Table 15, the second row indicates the mean counts retained on the beads 
after subtracting the flowthrough from the input.  In this case the amount of signal 
retained on the resin plus the proteins for MBP is 399 CPM, whereas DAZL retained 
532 CPM, DAZLmut1 retained 310 CPM, DAZLmut2 retained 374 CPM, and DAZ 
retained 468 CPM.  The remaining rows contain a matrix of p-values which indicate 
pairwise comparisons between proteins.  Those less than 0.05 indicate a significant 
Bead type MBP DAZL
MUT1 
Outside 
RRM 
MUT2 
In RRM DAZ 
Mean counts* 399 532 310 374 468 
MBP  0.009 0.086 0.526 0.095 
DAZL   0.0003 0.004 0.126 
MUT1    0.123 0.004 
MUT2     0.065 
*Radioactivity of labeled mRNA construct retained on beads after correction for moles of protein in 5 
replicates for each binding reaction.  The top row indicates type of protein-bound resin involved.  The 
next row indicates counts per minute of radioactivity retained on the column.  The numbers in a matrix 
between the bead types are p-values derived from pairwise comparisons between the different bead types 
using ANOVA and Dunnett’s post-hoc test.  The experiment is corrected for amounts of protein due to 
variances in binding to resin. 
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difference between the proteins.  For example, the number of counts MBP retained is 
different (p<0.009) from that DAZL retains, but not from that retained by DAZLmut1 (p 
= 0.086), DAZLmut2 (p = 0.526), or DAZ (p = 0.095).  When DAZL is compared with 
its mutants and DAZ, it becomes evident that DAZL binds more signal than DAZLmut1 
(p = 0.0003) or DAZLmut2 (p = 0.004), but no more signal than DAZ (p = 0.126).  
DAZLmut1 does not bind more signal than DAZLmut2 (p = 0.123), but does bind less 
RNA than DAZ (p = 0.004).  When DAZLmut2 is compared with DAZ there is only a 
trend toward a difference in binding (p=0.065).  To summarize, MBP binds less RNA 
than DAZL, but MBP binding of RNA is similar to that for DAZLmut1, DAZLmut2, 
and DAZ.  Further, DAZL binds more RNA than DAZLmut1 or DAZLmut2, but not 
more than DAZ.  And, DAZLmut1 does not bind less RNA than DAZLmut2, but does 
bind less RNA than DAZ.  
 When the DAZL-retained radiolabeled transcript of NM_014814 (PSMD) was 
used as a target for DAZL another pattern of results emerged (Table 16).  In this case, 
MBP retained 280 counts of signal, DAZL retained 678 CPM of signal, DAZLmut1 
retained 515 CPM, DAZLmut2 retained 575 CPM, and DAZ retained 532 CPM.  In this 
case MBP retained less signal than DAZL (p = 0.0001), DAZLmut1 (p = 0.0002), 
DAZLmut2 (p = 0.0002), and DAZ (p = 0.0002), whereas DAZL retained more signal 
than DAZLmut1 (p = 0.007), DAZLmut2 (p = 0.031), and DAZ (p = 0.010).  
DAZLmut1 did not bind more signal than DAZLmut2 (p = 0.376) or DAZ (p = 0.696), 
and DAZLmut2 did not bind more material than DAZ (p = 0.342).  Therefore, DAZL 
binding is significantly greater than for any of the other protein constructs and all protein 
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constructs retain more RNA than MBP.  Finally, DAZLmut1, DAZLmut2, and DAZ did 
not differ in binding RNA in this study. 
To examine the Kd of DAZL and its mutant forms for the PSMD RNA probe, an 
electrophoretic mobility shift assay was employed.  Figure 44 shows results of the gel 
shift using the PSMD radiolabeled probe with increasing amounts of DAZL protein, 
indicating a shift in amount of RNA signal with increasing amounts of DAZL protein.  
There is also some shift in the MBP control lane, but not in the same area as the DAZ 
protein shifts. 
 
Table 16.  Retention (p-levels) of PSMD mRNA Retained by Various Protein Constructs. 
Bead type MBP DAZL MUT1 Outside RRM
MUT2
In RRM DAZ 
Mean 
counts* 280 678 515 575 532 
MBP  0.0001 0.0002 0.0002 0.0002 
DAZL   0.007 0.031 0.010 
MUT1    0.376 0.696 
MUT2     0.342 
 
*Radioactivity (CPM) retained on beads after correction for moles of protein in 5 replicates for 
each binding reaction.  The top row indicates type of protein-bound resin involved.  The next row 
indicates counts of radioactivity retained on the column.  The numbers in a matrix between the 
bead types are p-values derived from pairwise comparisons between the different bead types. 
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 Figure 45 documents the quantitative data extracted from the bands from the 
phosphorimage screen.  DAZL under these conditions possessed a Kd of 3.1 µM of 
protein concentration with an R2 of 0.82, DAZLmut1 had a Kd of 3.6 µM with an R2 of 
0.92, and DAZLmut2 had a Kd of 0.9 µM with an R2 of 0.92.  These data indicate 
similar Kds for each of these proteins.  
 
RNA MBP
Free
Bound
DAZL DAZLmut1 DAZLmut20.001 12.00 0.001 5.70 0.001 12.00
Figure 44.  Gel shift Using PSMD as a Radiolabled Probe.  All lanes contain 15nM final 
RNA concentration.  The first lane represents a 20 µl reaction containing RNA only, the 
second lane contains 12µM MBP, the remaining lanes contain increasing amounts of 
protein with the lower amount indicated to the left of the label and the greatest amount 
indicated to the right of the label.  All values are in µM. 
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Discussion 
This study is the first to address many aspects of function of the human DAZ 
family of proteins.  First, microarray analyses identified a large number of genes that 
were specifically retained by the DAZL protein without serial enrichment of RNAs 
reported by Fox et al. to “enhance specificity” [79].”  Their method may increase 
specificity for finding a consensus sequence, but may miss interactions where DAZL 
PSMD vs. DAZL Proteins
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Figure 45.  Gel Shift of DAZL and Mutant Forms of DAZL vs. Radiolabeled PSMD Probe.  Three 
curves were plotted according to type of protein added to the binding reaction.  A logarithmic curve 
was fitted to each of the series of data and the R2 for each of the lines were DAZL = 0.82, DAZLmut1 
= 0.92, and DAZLmut2 = 0.92.  The Kd of each of the proteins was DAZL = 3.1, DAZLmut1 = 3.6, 
and DAZLmut2 = 0.9. 
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proteins serve a bone fide function.  In the present study, the microarray found many 
more targets in less time and likely at less cost.  Differences between results of the 
current study and that of Fox et al. was not unexpected.  First, the 200 colonies that they 
picked at random did not detect any statistically significant targets.   
In 2002, Jaio et al. reported mouse targets of Dazl binding that may not directly 
extend to humans even though there is evolutionary conservation among species.  The 
presence of the DAZ genes on the Y chromosome may affect the specificity of targets of 
Dazl binding in the mouse versus DAZL binding in humans.  The mouse possesses one 
copy of the autosomal Dazl gene while humans have multiple DAZ genes on two 
different chromosomes; the human chromosome Y version is related to infertility and the 
role of autosomal DAZL in supporting spermatogenesis is less clear.  However, a simple 
Genbank search reveals that the mouse Dazl gene is not 100% identical to the human 
DAZL gene which suggests small changes in amino acid sequence that may alter 
functionality.  The current study revealed that MBP “binds” a relatively large number of 
RNAs.  There are a couple of possibilities to explain this phenomenon. First, none of the 
proteins used in this study were highly purified to eliminate small amounts of bacterial 
proteins that could interact with human RNA.  Because the DAZL proteins and MBP 
proteins were expressed in the same cell line, any “contaminating” proteins would be 
equivalent.  Second, MBP binding may result because of the technique used to load 
microarrays with RNA and the fact that, after amplification, the amount of DAZL RNA 
was lower than the amount of MBP RNA.   This had the effect of over representing 
genes for which MBP was selecting.  
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Once targets of DAZL were identified, an experiment was performed to evaluate 
the DAZL-preferred transcript of PSMD and the ignored TESK1 transcript.  Using the 
high and low binders, PSMD and TESK1 RNAs respectively, and the same protocols 
used in the microarray, DAZL binding affinities depended on the sequence involved as a 
target substrate.  For TESK1, the low binder, DAZL bound RNA as well as DAZ, but 
not as well as DAZLmut1 or DAZLmut2.  This is interesting because DAZLmut1 has 
one mutation in the amino acid sequence of the protein, but not in the RRM.  However, 
when the High Binder, PSMD, was used as a target sequence, DAZL bound more RNA 
than any other protein construct.  This suggests that a mutation in the RNA-binding 
protein altered substrate specificity of DAZL compared to wild-type or that  multiple 
levels of translational control were affected by these mutations. 
 There also may be a role for different transcripts in different species operating in 
slightly different ways to affect spermatogenesis.  For example, spermatogenesis does 
not progress in the same way in mice as in humans.  In mice, spermatogenesis is an 
ordered progression along the seminiferous tubules whereas it progresses in a mosaic 
pattern in humans [91].  Because of at least these differences in control of 
spermatogenesis between human and mouse, different pathways may control 
spermatogenesis including those possibly affected by DAZL RNA binding including 
assembly of the ribosome, the proteasome, the cell cycle, and pyruvate metabolism.  If 
DAZL exerts some level of control on any of these pathways, the consequences would 
be very significant. For example, if the ribosome is affected then there would be no 
translation of RNAs to make proteins needed for spermatogenesis.  The proteasome and 
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cell cycle go hand in hand in the sense that at different stages of the cell cycle, proteins 
need to be broken down to inhibit their activities.  The cell cycle is important as 
spermatogenesis is the creation of more cells through a series of defined steps.  Pyruvate 
metabolism is also an interesting area of control because it is used for energy production 
by developing sperm [92].  All of these pathways are vital for proper sperm production.  
 To explore further the interaction of DAZ proteins with RNA, the gel shift was 
utilized to probe the quality of binding of DAZL to RNA.  The binding efficiency under 
the limiting conditions of the RNA suggested that about 50% of the RNA (at 15nM) 
binds DAZL at 3.1 µM while DAZLmut1 bound at 3.6 µM, and DAZLmut2 bound at 
0.9 µM.  As a comparison, at least a 1.5 nM Kd was achieved for Xenopus TFIIIA for 5S 
RNA.  This low binding efficiency of DAZL for RNA may be due to several factors.  
First, the amount of active protein was not determined before performing this 
experiment, so the binding efficiency may be understated.  Second, binding may be 
affected by the fusion tag of MBP.  Third, a simple EMSA was used for generating a 
range for experiments involving further study into binding efficiencies [82].  
Experiments into accurate Kd values involve many dilutions over a specific range and 
utilizing Scatchard analysis.  The EMSA in this study also indicated a shift in RNA 
signal in the MBP lane, but MBP is not known to be an RNA-binding protein [93] and 
was not initially found to bind RNA.  However, co purified factors did bind and shift 
RNA, but to a different area of the gel.  To remedy this situation in future studies, the 
MBP tag must be excised and the binding experiments repeated for comparison, and 
experiments must be with DAZL protein that is not contaminated with other RNA-
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binding factors. Results of binding experiments using highly purified DAZL have not 
been reported.  The gel shift assays in the current study provide a starting point in 
determining the quality and quantity of binding of DAZL to RNA according to Haynes 
et al.[83], but more data points within the transition range are needed to compute a 
reliable Kd for the DAZL-RNA interaction. 
 Discovering targets of binding are crucial to understanding DAZ and DAZL  
function(s).  Because there are so many targets of DAZL representing many different 
functions, both DAZ and DAZL are likely to influence several complex mechanisms.   
 It has been reported that DAZL binds its own RNA[78], which suggests that 
DAZL regulates its own translation via a feedback mechanism.  As shown in Appendix 
4, human DAZL binds its own transcript with a ratio of 7.32 (p = 0.0064).  Interestingly, 
human DAZL does not bind well to the DAZ transcript in the testis library RNAs (data 
not shown). 
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CHAPTER V 
CONCLUSION 
 
This study examined how variation in genomic DNA might contribute to 
infertility in human males.  The DAZ/DAZL family of genes was chosen as a focus 
because of a previously established relationship between deletions on the Y chromosome 
and the number of sperm produced in humans and animal models such as the mouse [63, 
94-96].  While a number of investigators have used evidence for an RNA binding 
domain in the DNA sequence to suggest roles for proteins encoded by these genes, few 
studies have provided information on mRNA species that might be involved in sufficient 
numbers to identify pathways likely to be affected [38, 84, 97].  So binding activity and 
a detailed list of potential targets were not available for this family of genes so that the 
mechanisms for a role in spermatogenesis were unknown.  
 The goal of the first project was to replicate observations of others on the 
frequency of DAZ deletions in a population of infertile patient couples in central Texas.  
Based on reports of deletions of DAZ on the Y chromosome (Table 5) in males with 
reduced or no sperm in their ejaculates, a bank of semen residues and deletion detection 
assays were developed to identify a subpopulation of male candidates for genetic studies.  
The results indicated a lower prevalence of microdeletions than in other published 
reports for the population in Central Texas.  The fact that the present study differed from 
other groups was interesting, but not entirely unexpected.  One group from India 
demonstrated variances in deletions within the AZF region with similar testicular 
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etiologies within India [98] and suggested that Y chromosome fertility based on 
deletions in the AZF region is most likely multifactorial in origin.  That is, there are 
multiple levels of control of genes on the Y chromosome that influence spermatogenesis 
in addition to Y chromosome deletions. This is likely in the case of the DAZ/DAZL 
family of genes as the DAZL locus is on chromosome three in humans and there is 
considerable variability in the range of reduced spermatogenesis with relation to 
complete absence of all DAZ copies on the Y chromosome. 
By examining DNA at the nucleotide level, a second study was to identify SNPs 
(single nucleotide polymorphisms) within the DAZL gene in relation to infertility.  The 
DAZL member of the DAZ/DAZL family of genes was selected because of its 
relationship to DAZ and its necessary function during spermatogenesis in mammals [22, 
24, 80, 97, 99-105].  Up to this point, the pattern of study on this topic had ranged from 
global (whole chromosome staining from Tiepolo and Zuffardi, 1976 to detect large 
deleted segments of chromosomes) to point mutations in DAZL genes resulting in 
theoretical changes in amino acids that might alter function of the DAZL protein as in 
the current study [5].  In the present study, the only mutation discovered in DAZL 
located within an exon was a null mutation.  Other mutations within introns were 
identified.  Another group from Taiwan found mutations both within an exon and within 
introns of DAZL, and one was associated with reduced fertility[69].  In the current 
study, a SNP common within the Taiwanese population but not associated with reduced 
fertility, was also detected in the central Texas population.  However, when the 
published mutations were incorporated into DAZL, the resulting recombinant protein did 
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have altered binding activity to RNA as demonstrated in the third project of this study.  
One of the mutations in question was outside the RRM of DAZL.  This indicated that the 
complete coding sequence, rather than just the RNA-binding domain, should be 
examined for SNPs or other alterations including splice variants where whole exons may 
be deleted.  Taken together, these results indicate some variation among populations 
with respect to genomic DNA.  The larger the population examined, the more likely that 
additional SNPs within the DAZ and DAZL genes will be detected.  This study 
identified reagents which were used that demonstrated the feasibility of creating 
recombinant proteins reflecting known SNPs and characterizing their binding properties.  
As binding properties change, mRNA transcription processes may be affected 
amplifying this single change into the action of multiple genes by altering expression. 
  Scanning of the intronic sequences for SNPs should be considered in a large 
population study, as splicing signals within DAZL or DAZ could also be affected by 
SNPs located within these regions. The result could potentially affect the final protein 
product in a manner similar to the case with a 465 C>T mutation in NADPH [72].  
While the focus of this trial was to identify SNPs from individuals with reduced or 
absent spermatogenesis for use as the basis for a proof of concept trial, a large 
population study should include men with varying spermatogenesis phenotypes and 
scanning of the entire genomic sequence for the presence of SNPs within the four DAZ 
and one DAZL loci.  At present, such a study may be too costly and time consuming as 
the introns within the DAZL and DAZ genes are quite large (~18 kbp) (Genbank 
NC_00003.10).  As an alternative for phenotypes where some sperm cells are present in 
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semen, mRNAs for DAZ and DAZL can be extracted directly from ejaculated sperm 
cells to find splice variants.  During the course of this study, but not reported here, 
cDNAs of DAZ and DAZL were derived from DAZL and DAZ mRNA extracted from 
mature, ejaculated spermatozoa [106].  This technique may allow one to search for splice 
variants or expressed mutations within the DAZL and DAZ genes. 
 To examine the function of DAZ and DAZL proteins, recombinant proteins have 
to be produced and used to assess mRNA-binding.  Because of the inherent nature of the 
DAZL and DAZ proteins to bind RNA, modifications of protocols used to produce 
recombinant proteins were required.  In addition, some cloning systems were not 
amenable to purification of DAZL and DAZ.  Whereas other investigators have prepared 
recombinant proteins under denaturing conditions and renatured the proteins before 
examining activity, proteins used in the present study were purified under native 
conditions using maltose-binding protein (MBP) as a purification and solubilization tag 
[79].  The main problems with methods which rely on denaturation and renaturation is 
that there remains uncertainty as to whether the protein has folded properly at the end of 
the purification process and there may be substantial effort required to perfect the ideal 
conditions under which the protein can be purified [107].  This study utilized the pMAL 
system because of the simplicity in purification of native proteins.  Enrichment of 
proteins involves the binding of the fusion protein to amylose resin and washing away 
the non-specific proteins.  Purification utilizing the MBP fusion protein was not without 
its hindrances though.  In this portion of the study, small quantities of bacterially-
produced proteins were co-purified with the recombinant protein preparations. The 
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control for this process was the production of a MBP fusion protein without the 
DAZ/DAZL component. This important control did, however, have low levels of RNA 
binding which was unexpected based on the use of commercially-prepared MBP.    
While several investigators have reported cloning expressed or enriched DAZL 
proteins from several species, there is no published literature on functional or 
quantitative binding of any DAZ proteins or DAZL or DAZ proteins containing amino 
acid substitutions [38, 78, 84, 88, 97].  Because, in at least one population, a specific 
mutation has been correlated with reduced spermatogenesis, this mutation provided a 
valuable resource for exploring DAZ or DAZL protein and RNA interactions[69].  The 
mutations were incorporated into proteins (labeled as DAZLmut1 and DAZLmut2) that 
were used for binding assays and for detecting differences in RNA binding between the 
various protein constructs of DAZL, DAZLmut1, DAZLmut2, and DAZ.  Based on the 
results of these experiments, SNPs in a general population may or may not alter binding 
to RNA.  For each variant of the DAZ or DAZL protein, the potential to impact 
spermatogenesis by affecting translation of  different subsets of mRNAs could be 
examined to comparing the profile of mRNA species bound relative to the wild type.  
 A portion of this study was devoted to addressing the question of what testicular 
species of mRNA the DAZ/DAZL family of proteins bind with the expectation that the 
answer would suggest mechanisms for control of number of sperm cells produced. As 
DAZL is the only member of this family uniformly found in all mammals (DAZ is 
limited to old world monkeys and apes), it was used for these trials. DAZL was found to 
bind a substantially greater number of targets than previously reported for either murine 
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or human constructs [79, 88].  Others have used RNA-enrichment methods to detect a 
consensus sequence for DAZL binding which also identified targets[84].  It should be 
noted that some DAZ proteins are only found at certain stages of spermatogenesis 
(Figure 4), so the targets should include stages where the particular DAZ protein is 
present.  Research into the targets of DAZ and DAZL have utilized the mouse model 
[84] or screened libraries in yeast to identify targets [17].  The results of those studies are 
not in complete agreement with those from this project as to targets for binding of DAZ 
or DAZL binding.  Therefore, the proposed target sequences within mRNAs can not be 
readily deduced. Even when enrichment methods or three-hybrid screening methods are 
used, there is no real consensus present other than to U-rich sequences.  Based on the 
limited number of previously reported mRNA species binding to DAZL proteins for 
either human or murine constructs, no obvious cellular processes or pathways are 
implicated.  However using the novel method developed in this project, a much longer 
list of targets for DAZL binding were identified (Appendix  4) and four cellular 
processes or pathways became evident including proteins of ribosome, proteasome, cell 
cycle control, and pyruvate metabolism.  These processes, therefore, may be enhanced or 
altered by DAZL binding to transcripts of spermatogonia with shortened poly-A tails. 
Collier et al. speculated that increased production of proteins from the transcription 
process results from circularizing the mRNA to increase the efficiency of ribosomal 
processing [38]. Increasing the number of ribosomes and proteasomes would prepare a 
spermatogonial cell for a series of cell divisions and drastic changes in morphology from 
a round cell to a spermatid.  Increasing certain proteins of the cell-cycle pathway may 
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trigger either additional mitotic divisions prior to entry into meiosis, meiosis or both.  
Finally, increasing proteins for pyruvate metabolism may prepare the spermatogonial 
cells for use of a metabolic fuel commonly available for spermatids.  DAZL also binds 
to DAZL mRNA transcripts so that initiation of DAZL synthesis may trigger the cascade 
of processes or alternatively block DAZL mRNA transcription.  While further 
investigation of the role of DAZL binding on transcription was considered outside of the 
scope of this study, it is clearly an important future step for pursuing the mechanisms of 
DAZ/DAZL family action.   
 The binding of mRNA by DAZ and DAZL is most likely more complicated than 
simply identifying a consensus sequence.  The tools created and used in this study can be 
used to answer further questions.  What do splice variants of DAZ and DAZL bind?  Do 
variations in affinity between DAZ/DAZL proteins for various mRNAs exist?  Also, 
other proteins binding to DAZ/DAZL proteins may alter binding affinities or 
specificities and this has not been described.  What subset of mRNAs do the mutations 
in DAZL or DAZ bind?  Comparisons between these proteins should provide 
information on the potential for genetic variation to impact male fertility.  It may also 
suggest control points that could be targets of spermatogonia-specific treatments to 
impair fertility for use as a contraceptive.  DAZ and DAZL are limited in expression to 
spermatogonia and oogonia in fetuses and to spermatogonia and sperm at various stages 
of spermatogenesis in post-pubertal males [1, 75, 108, 109].  
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 Based on the general concept that DAZ and DAZL have a role in controlling 
gene expression by binding transcripts with short poly-A tails to circularize and increase 
efficiency of ribosomal production of proteins, results of this study suggest that four 
pathways will be enhanced [38].  The proteasome and cell cycle are interdependent and 
DAZL may bind transcripts involved in each of these pathways.  The cell cycle relies on 
the proteasome to remove unwanted factors so that the cycle progresses normally and 
pyruvate metabolism is needed for energy production in developing sperm cells.  If 
DAZL is facilitating the translation of mRNAs involved in protein production, then the 
overall effect of DAZL may be to increase translation of all mRNAs within developing 
sperm cells.  When a mutation forms in DAZL then the global effect would be reduced 
sperm production due to reduced efficiency at translating these transcripts.  The role or 
requirement of a second set of DAZ genes to produce additional proteins only in old 
world monkeys and apes, has not been reconciled with any specific difference in 
spermatogenesis between these species and other mammals that only have DAZL.  
Direct comparisons of human wild type recombinant DAZL and DAZ did demonstrate 
differences in binding activity to certain transcripts in this project.  The DAZ gene is 
also known in humans to exist as four copies, each with some specific differences.  
While variation in the number of copies of DAZ presently has not been related to failed 
or reduced spermatogenesis, it is conceivable that these genes when or if expressed fully 
obtain their mRNA binding function.  While beyond the scope of this project, 
recombinant forms for all of the various DAZ proteins could be produced and compared 
using the bead-binding assay methods to screen mRNA retained relative to DAZL.   
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DAZL would seem to be a prototype molecule as it has been relatively conserved and 
has similar expression profiles across species[1]. 
 While the results of this project are promising, there are limitations to this 
present body of work.  Investigations into the analysis of SNPs began with the intent on 
identifying SNPs within the RRM of DAZL in selected patients with reduced sperm 
numbers.  However, it became evident that one must examine exons of the RRM, as well 
as the whole gene.  Research from Taiwan indicated that there were other regions within 
the DAZL gene which were important [69].  Additionally, to increase knowledge about 
possible mutations within the DAZL gene, the study of SNPs needs to be expanded to 
include a large multi-ethnic population with adequate phenotypic variations in 
spermatogenesis and not just fertility. Also, the entire genomic sequence should be 
searched for the presence of SNPs within DAZL.  With more data, haplotype analyses 
can associate genotype with phenotype and help predict alteration of splicing function.  
Extraction of mRNA from mature ejaculated spermatozoa will help to confirm the 
presence or absence of splice variants of DAZL.   
Another limitation of the results of the present study was exposed when MBP 
purchased from New England Biolabs failed to shift RNA while MBP enriched for the 
current study did shift a small amount of RNA, albeit in a non-specific manner.  Because 
MBP was co-purified in both the MBP control and DAZL protein preps, it was decided 
to analyze the DAZL proteins in the various binding assays as the goal for assessing 
DAZL binding was to identify targets of DAZL and the co-purified contaminants present 
in both samples was not considered a hindrance to interpretation of results.  However, it 
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became evident that proper evaluation of binding affinities for the various recombinant 
DAZL and DAZ mutants would require additional purification and separation from 
MBP.  The constructs developed in this project contain a TEV protease site to enable the 
additional isolation needed for separation of recombinant proteins without using 
denaturing conditions.   
A third concern with the project involved the size of the molecules used for 
electrophoretic mobility gel shift assays after microarray analysis.  Both of the mRNA 
molecules, PSMD and TESK1, used for this experiment were full length and the 
consensus binding sequences within these remain unknown.  This resulted in mRNAs 
that were to large for conventional gel shift assays and retention of material in the wells 
that compromised interpretation of results.   
 To conclude, results of this study demonstrated a reduced frequency of DAZ 
deletions in the general population of male partners of infertile couples in central Texas.  
However, genetic variation was demonstrated as point mutations in DAZL.  While these 
mutations were not specifically associated with failed spermatogenesis, others have 
reported at least one such SNP.  Using modifications to a variety of cloning and 
expression techniques recombinant proteins for DAZL, one variant of DAZ, and two 
DAZL mutant forms were predicted and compared. These different forms of the 
DAZ/DAZL family of proteins differed in binding properties.  Finally, a larger number 
of testicular mRNA species than predicted or previously identified was found to bind to 
both human and wild type versions of DAZL.  These mRNAs were clustered in 
pathways of four discrete cellular processes involved in conversion of mitotically active 
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spermatogonia cells to haploid morphologically specialized spermatids. These cell types 
are consistent with those in which DAZL and DAZ expression has been reported.  These 
results suggest a point in the control of spermatogenesis where expression of a single 
molecule, DAZL, may influence a cascade of functions, and where genetic variation and 
perhaps future therapeutic intervention may be targeted to specifically arrest or limit 
spermatogenesis. 
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APPENDICES 
 
Appendix 1.  Alignments of DAZL, DAZLmut1, and DAZlmut2 
 Listed is the published Genbank version of the human DAZL sequence that is 
aligned with DAZLmut1 and DAZLmut2.  There are three lines of nucleotide sequence 
which are supplemented with additional data above and below their alignments.  The 
amino acid sequence can be found at the beginning of the sequence and shows the TEV 
protease linker and extends into the beginning of the DAZL gene.  The red amino acid 
notation indicates mutations generated from Teng et al.’s research [15].  The two R’s 
where one is red and one is green indicate the SNP which was found during the course of 
the current study and is a conservative change.  
Sequence Analysis 
NM_001351 Top Strand 
DAZLmut1  
DAZLmut2  
 
From-> MBP....  
CNGNAAANGCGCAGANTAAT TCG AGC TCG AAC NAC AAC AAC AAT AAC AAT AAC AAC AAC CTC GGG 
 
                                            |-----------TEV-----------|  M   S 
                        Glu Phe Ala Leu Gly Glu Asn Leu Tyr Phe Gln Gly Met Ser           
ATC GAG GGA AGG ATT TCA GAA TTC GCC CTT GGG GAG AAC CTG TAC TTC CAG GGG ATG TCT 
                                            GAG AAC CTG TAC TTC CAG GGG ATG TCT 
                                            GAG AAC CTG TAC TTC CAG GGG ATG TCT  
 
 
 T   A   N   P   E   T   P   N   S   T   I   S   R   E   A   S   T   Q   S   S 
Thr Ala Asn Pro Glu Thr Pro Asn Ser Thr Ile Ser Arg Glu Ala Ser Thr Gln Ser Ser  
ACT GCA AAT CCT GAA ACT CCA AAC TCA ACC ATC TCC AGA GAG GCC AGC ACC CAG TCC TCA 
ACT GCA AAT CCT GAA ACT CCA AAC TCA GCC ATC TCC AGA GAG GCC AGC ACC CAG TCC TCA 
                                    Ala 
ACT GCA AAT CCT GAA ACT CCA AAC TCA ACC ATC TCC AGA GAG GCC AGC ACC CAG TCC TCA 
 
TCA GCT GCA ACC AGC CAA GGC TAT ATT TTA CCA GAA GGC AAA ATC ATG CCA AAC ACT GTT 
TCA GCT GCA ACC AGC CAA GGC TAT ATT TTA CCA GAA GGC AAA ATC ATG CCA AAC ACT GTT 
TCA GCT GCA ACC AGC CAA GGC TAT ATT TTA CCA GAA GGC AAA ATC ATG CCA AAC ACT GTT 
 
                                            Thr          R 
TTT GTT GGA GGA ATT GAT GTT AGG ATG GAT GAA ACT GAG ATT AGA AGC TTC TTT GCT AGA  
TTT GTT GGA GGA ATT GAT GTT AGG ATG GAT GAA ACT GAG ATT AGG AGC TTC TTT GCT AGA 
                                                         R 
TTT GTT GGA GGA ATT GAT GTT AGG ATG GAT GAA GCT GAG ATT AGG AGC TTC TTT GCT AGA 
                                            Ala 
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TAT GGT TCA GTG AAA GAA GTG AAG ATA ATC ACT GAT CGA ACT GGT GTG TCC AAA GGC TAT 
TAT GGT TCA GTG AAA GAA GTG AAG ATA ATC ACT GAT CGA ACT GGT GTG TCC AAA GGC TAT 
TAT GGT TCA GTG AAA GAA GTG AAG ATA ATC ACT GAT CGA ACT GGT GTG TCC AAA GGC TAT 
 
GGA TTT GTT TCA TTT TTT AAT GAC GTG GAT GTG CAG AAG ATA GTA GAA TCA CAG ATA AAT 
GGA TTT GTT TCA TTT TTT AAT GAC GTG GAT GTG CAG AAG ATA GTA GAA TCA CAG ATA AAT 
GGA TTT GTT TCA TTT TTT AAT GAC GTG GAT GTG CAG AAG ATA GTA GAA TCA CAG ATA AAT 
 
TTC CAT GGT AAA AAG CTG AAG CTG GGC CCT GCA ATC AGG AAA CAA AAT TTA TGT GCT TAT 
TTC CAT GGT AAA AAG CTG AAG CTG GGC CCT GCA ATC AGG AAA CAA AAT TTA TGT GCT TAT 
TTC CAT GGT AAA AAG CTG AAG CTG GGC CCT GCA ATC AGG AAA CAA AAT TTA TGT GCT TAT  
 
CAT GTG CAG CCA CGT CCT TTG GTT TTT AAT CAT CCT CCT CCA CCA CAG TTT CAG AAT GTC 
CAT GTG CAG CCA CGT CCT TTG GTT TTT AAT CAT CCT CCT CCA CCA CAG TTT CAG AAT GTC 
CAT GTG CAG CCA CGT CCT TTG GTT TTT AAT CAT CCT CCT CCA CCA CAG TTT CAG AAT GTC 
 
TGG ACT AAT CCA AAC ACT GAA ACT TAT ATG CAG CCC ACA ACC ACG ATG AAT CCT ATA ACT 
TGG ACT AAT CCA AAC ACT GAA ACT TAT ATG CAG CCC ACA ACC ACG ATG AAT CCT ATA ACT 
TGG ACT AAT CCA AAC ACT GAA ACT TAT ATG CAG CCC ACA ACC ACG ATG AAT CCT ATA ACT 
 
 
 
CAG TAT GTT CAG GCA TAT CCT ACT TAC CCA AAT TCA CCA GTT CAG GTC ATC ACT GGA TAT 
CAG TAT GTT CAG GCA TAT CCT ACT TAC CCA AAT TCA CCA GTT CAG GTC ATC ACT GGA TAT 
CAG TAT GTT CAG GCA TAT CCT ACT TAC CCA AAT TCA CCA GTT CAG GTC ATC ACT GGA TAT 
 
 
CAG TTG CCT GTA TAT AAT TAT CAG ATG CCA CCA CAG TGG CCT GTT GGG GAG CAA AGG AGC 
CAG TTG CCT GTA TAT AAT TAT CAG ATG CCA CCA CAG TGG CCT GTT GGG GAG CAA AGG AGC 
CAG TTG CCT GTA TAT AAT TAT CAG ATG CCA CCA CAG TGG CCT GTT GGG GAG CAA AGG AGC 
 
TAT GTT GTA CCT CCG GCT TAT TCA GCT GTT AAC TAC CAC TGT AAT GAA GTT GAT CCA GGA  
TAT GTT GTA CCT CCG GCT TAT TCA GCT GTT AAC TAC CAC TGT AAT GAA GTT GAT CCA GGA 
TAT GTT GTA CCT CCG GCT TAT TCA GCT GTT AAC TAC CAC TGT AAT GAA GTT GAT CCA GGA 
 
GCT GAA GTT GTG CCA AAT GAA TGT TCA GTT CAT GAA GCT ACT CCA CCC TCT GGA AAT GGC 
GCT GAA GTT GTG CCA AAT GAA TGT TCA GTT CAT GAA GCT ACT CCA CCC TCT GGA AAT GGC 
GCT GAA GTT GTG CCA AAT GAA TGT TCA GTT CAT GAA GCT ACT CCA CCC TCT GGA AAT GGC 
 
CCA CAA AAG AAA TCT GTG GAC CGA AGC ATA CAA ACG GTG GTA TCT TGT CTG TTT AAT CCA 
CCA CAA AAG AAA TCT GTG GAC CGA AGC ATA CAA ACG GTG GTA TCT TGT CTG TTT AAT CCA 
CCA CAA AAG AAA TCT GTG GAC CGA AGC ATA CAA ACG GTG GTA TCT TGT CTG TTT AAT CCA 
 
GAG AAC AGA CTG AGA AAC TCT GTT GTT ACT CAA GAT GAC TAC TTC AAG GAT AAA AGA GTG 
GAG AAC AGA CTG AGA AAC TCT GTT GTT ACT CAA GAT GAC TAC TTC AAG GAT AAA AGA GTG 
GAG AAC AGA CTG AGA AAC TCT GTT GTT ACT CAA GAT GAC TAC TTC AAG GAT AAA AGA GTG 
                                                    
                                                  Stop| 
CAT CAC TTT AGA AGA AGT CGG GCA ATG CTT AAA TCT GTT TGA 
CAT CAC TTT AGA AGA AGT CGG GCA ATG CTT AAA TCT GTT TGA 
CAT CAC TTT AGA AGA AGT CGG GCA ATG CTT AAA TCT GTT TGA 
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Appendix 2.Comparison of NM_020363 (DAZ2) with Cloned Version of DAZ 
 
 Two different DAZ sequences are aligned with the DAZ sequence cloned for use 
in the current study.  The main feature of note is the makeup of the repeat region of the 
DAZ gene cloned for the current study.  Following the sequences are the sequences of 
the repeat regions and their comparisons with each other. 
 
NM_020363, DAZ2, Transcript Variant 1 Top Strand 
Cloned DAZ Sequence, 2nd Strand 
NM_020364, DAZ3, 3rd Strand 
Repeat Region Identifications from Saxena, Nature Genetics, Vol 14, November 1996, pg 292  
 
E1 |Exon 2 ---> 
ATG|TCTGCTGCAAATCCTGAGACTCCAAACTCAACCATCTCCAGAGAGGCCAGCACCCAGTCTTCATCAGCTGCAGCTAGCCAAGGCT 
ATG|TCTGCTGCAAATCCTGAGACTCCAAACTCAACCATCTCCAGAGAGGCCAGCACCCAGTCTTCATCAGCTGCAGCTAGCCAAGGCT 
ATG|TCTGCTGCAAATCCTGAGACTCCAAACTCAACCATCTCCAGAGAGGCCAGCACCCAGTCTTCATCAGCTGCAGCTAGCCAAGGCT 
 
 
                                                              |Exon 3 ---> 
GGGTGTTACCAGAAGGCAAAATCGTGCCAAACACTGTTTTTGTTGGTGGAATTGATGCTAGG|ATGGATGAAACTGAGATTGGAAGCTG 
GGGTGTTACCAGAAGGCAAAATCGTGCCAAACACTGTTTTTGTTGGTGGAATTGATGCTAGG|ATGGATGAAACTGAGATTGGAAGCTG 
GGGTGTTACCAGAAGGCAAAATCGTGCCAAACACTGTTTTTGTTGGTGGAATTGATGCTAGG|ATGGATGAAACTGAGATTGGAAGCTG 
 
 
                                                                  |Exon 4 ---> 
CTTTGGTAGATACGGTTCAGTGAAAGAAGTGAAGATAATCACGAATCGAACTGGTGTGTCCAAAGG|CTATGGATTTGTTTCGTTTGTT 
CTTTGGTAGATACGGTTCAGTGAAAGAAGTGAAGATAATCACGAATCGAACTGGTGTGTCCAAAGG|CTATGGATTTGTTTCGTTTGTT 
CTTTGGTAGATACGGTTCAGTGAAAGAAGTGAAGATAATCACGAATCGAACTGGTGTGTCCAAAGG|CTATGGATTTGTTTCGTTTGTT 
 
 
                              |Exon 5 ---> 
AATGACGTGGATGTCCAGAAGATAGTAGGA|TCACAGATACATTTCCATGGTAAAAAGCTGAAGCTGGGCCCTGCAATCAGGAAACAAA 
AATGACGTGGATGTCCAGAAGATAGTAGGA|TCACAGATACATTTCCATGGTAAAAAGCTGAAGCTGGGCCCTGCAATCAGGAAACAAA 
AATGACGTGGATGTCCAGAAGATAGTAGGA|TCACAGATACATTTCCATGGTAAAAAGCTGAAGCTGGGCCCTGCAATCAGGAAACAAA 
 
 
 
 
 
      |Exon 6 ---> 
AGTTAT|GTGCTCGTCATGTGCAGCCACGTCCTTTGGTAGTTAATCCTCCTCCTCCACCACAGTTTCAGAACGTCTGGCGGAATCCAAA 
AGTTAT|GTGCTCGTCATGTGCAGCCACGTCCTTTGGTAGTTAATCCTCCTCCTCCACCACAGTTTCAGAACGTCTGGCGGAATCCAAA 
AGTTAT|GTGCTCGTCATGTGCAGCCACGTCCTTTGGTAGTTAATCCTCCTCCTCCACCACAGTTTCAGAACGTCTGGCGGAATCCAAA 
 
 
                                                          |Exon 7a ---> 
CACTGAAACCTACCTGCAGCCCCAAATCACGCCGAATCCTGTAACTCAGCACGTTCAG|GCTTATTCTGCTTATCCACATTCACCAGGT 
CACTGAAACCTACCTGCAGCCCCAAATCACGCCGAATCCTGTAACTCAGCACGTTCAG|GCTTACTCTGCTTATCCACATTCACCAGGT 
CACTGAAACCTACCTGCAGCCCCAAATCACGCCGAATCCTGTAACTCAGCACGTTCAG| 
 
 
                                          |Exon 7b ---> 
CAGGTCATCACTGGATGTCAGTTGCTTGTATATAATTATCAG|GAATATCCTACTTATCCCGATTCAGCATTTCAGGTCACCACTGGAT 
CAGGTCATCACTGGATGTCAGTTGCTTGTATATAATTATCAG|GAATATCCTACTTATCCCGATTCAGCATTTCAGGTCACCACTGGAT 
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                          |Exon 7c ---> 
ATCAGTTGCCTGTATATAATTATCAG|CCATTTCCTGCTTATCCAAGATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA 
ATCAGTTGCCTGTATATAATTATCAG|CCATTTCCTGCTTATCCAAAATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA 
 
 
 
          |Exon 7d --->                                                            |Exon   
TAATTATCAG|GCATTTCCTGCTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATACAATTATCAG|CCATT 
TAATTATCAG|CCATTTCCTGCTTATCCAAGATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATATAATTATCAG|GCATT 
 
 
7e ---->                                                           |Exon 7f ---> 
TCCTGCTTATCCAAGTTCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATATAATTATCAG|GCATTTCCTGCTTATCCAAAT 
TCCTGCTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATACAATTATCAG|CCATTTCCTGCTTATCCAAGT 
 
                                                   |Exon 7g ---> 
TCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATACAATTATCAG|GCATTTCCTGCTTATCCAAATTCACCAGTTCAGGTCA 
TCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATATAATTATCAG| 
 
                                   |Exon 7h ---> 
CCACTGGATATCAGTTGCCTGTATACAATTATCAG|GCATTTCCTGCTTATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTT 
 
                   |Exon 7i ---> 
GCCTGTATATAATTATCAG|GCATTTCCTGCTTATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATATAATTAT 
 
   |Exon 7j --->                                                            |Exon 7k ---> 
CAG|GCATTTCCTGCTTATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATATAATTATCAG|GCATTTCCTGCT 
 
                                                            |Exon 7l ---> 
TATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATATAATTATCAG|GCATTTCCTGCTTATCCAAGTTCACCAT 
 
                                            |Exon 7m ---> 
TTCAGGTCACCACTGGATATCAGTTGCCTGTATATAATTATCAG|GCATTTCCTGCTTATCCAAGTTCACCATTTCAGGTCACCACTGG 
 
                            |Exon 7n ---> 
ATATCAGTTGCCTGTATATAATTATCAG|GCATTTCCTGCTTATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTTGCCTGTA 
 
            |Exon 7o --->                                                            |Exo 
TATAATTATCAG|GCATTTCCTGCTTATCCAAATTCAGCAGTTCAGGTCACCACTGGATATCAGTTCCATGTATACAATTACCAG|ATG 
                                                                                     |ATG 
                                                                                     |ATG 
 
 
n 8 --->                        |Exon 10 ----> 
CCACCGCAGTGCCCTGTTGGGGAGCAAAGGAG|AAATCTGTGGACCGAAGCATACAAATGGTGGTATCTTGTCTGTTTAATCCAGAGAA 
CCACCGCAGTGCCCTGTTGGGGAGCAAAGGAG|AAATCTGTGGACCGAAGCATACAAATGGTGGTATCTTGTCTGTTTAATCCAGAGAA 
CCACCGCAGTGCCCTGTTGGGGAGCAAAGGAG|AAATCTGTGGACCGAAGCATACAAATGGTGGTATCTTGTCTGTTTAATCCAGAGAA 
 
 
GAGACTGA 
GAGACTGA 
GAGACTGA 
 
 
 
 
DAZX Repeat Region- Total Number of Repeats=10 
 
Exon 7a 
GCT TAC TCT G CTTATCCACATTCACCAGGTCAGGTCATCACTGGATGTCAGTTGCTTGTATA TAA TTA TCA G 
 
Exon 7b 
GAA TAT CCT A CTTATCCCGATTCAGCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7c 
CCA TTT CCT G CTTATCCAAAATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
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Exon 7c 
CCA TTT CCT G CTTATCCAAGATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
Exon 7c 
CCA TTT CCT G CTTATCCAAGTTCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCAGTTCAGGTCACCACTGGATATCAGTTGCCTGTATA CAA TTA TCA G 
 
Exon 7f 
GCA TTT CCT G CTTATCCAAGTTCACCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7g 
GCA TTT CCT G CTTATCCAAATTCAGCAGTTCAGGTCACCACTGGATATCAGTTCCATGTATA CAA TTA CCA G 
 
 
NM_020364 (DAZ3) Repeat Region- Total Number of Repeats=12 
 
Exon 7a 
GCT TAC TCT G CTTATCCACATTCACCAGGTCAGGTCATCACTGGATGTCAGTTGCTTGTATA TAA TTA TCA G 
 
Exon 7b 
GAA TAT CCT A CTTATCCCGATTCAGCATTTCAGGTCACCACTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7c 
CCA TTT CCT G CTTATCCAAGATCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
Exon 7C 
CCA TTT CCT G CTTATCCAAGTTCACCATTTCAGGTCACTGCTGGATATCAGTTGCCTGTATA TAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCAGTTCAGGTCACCACTGGATATCAGTTGCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCAGTTCAGGTCACCACTGGATATCAGTTGCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCATTTCAAGTCGCCACTGGATATCAGTTCCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCACCAGTTCAGGTCACCACTGGATATCAGTTGCCTGTATA CAA TTA TCA G 
 
Exon 7d 
GCA TTT CCT G CTTATCCAAATTCAGCAGTTCAGGTCACCACTGGATATCAGTTCCATGTATA CAA TTA CCA G 
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Appendix 3.  Concatenation Scheme- Nucleotide Level 
 The nucleotide level of the concatenation scheme showing the final product produced is shown below.  The first round of PCR  
creates a shortened sequence that is extended upon further PCR cycles.  1 indicates the complete product from the PCR reactions.  
 2 shows the result of the first round of PCR and 3 shows the completion of the second round of PCR. 
1- This is the complete product of the PCR.  Bold indicates ordered primers.  Underlined indicates the ordered “template oligo.”  Full product size is 121bp. 
                T7 Promoter-containing primer 
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT GTTTTTTTGTTTTTTTTTTGTTTTTTTTTTGTTTTTTT GTT GAT ATA AAT AGT GCC CAT GGA TCC GCG GGT GTC GGG 3’ 
3’ GCG CCT AGG ATT ATG CTG AGT GAT ATC CCC GGT GGT TGC TGT AA CAAAAAAACAAAAAAAAAACAAAAAAAAAACAAAAAAA CAA CTA TAT TTA TCA CGG GTA CCT AGG CGC CCA CAG CCC 5’ 
                                                          CDC25C Oligo                                                            Rev. Univ. Primer 
   
2- First round of PCR shows the forward primer extending its 3’ end to the end of the template oligo and the extension of the 3’ end of the template oligo.  
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT 3’ 
                                    3’ CCC GGT GGT TGC TGT AA CAAAAAAACAAAAAAAAAACAAAAAAAAAACAAAAAAA CAA CTA TAT TTA TCA CGG GT 5’ 
 Product of first and subsequent rounds 
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT GTTTTTTTGTTTTTTTTTTGTTTTTTTTTTGTTTTTTT GTT GAT ATA AAT AGT GCC CA 3’ 
3’ GCG CCT AGG ATT ATG CTG AGT GAT ATC CCC GGT GGT TGC TGT AA CAAAAAAACAAAAAAAAAACAAAAAAAAAACAAAAAAA CAA CTA TAT TTA TCA CGG GT 5’ 
  
3- Second round of PCR shows the completion of the whole PCR product 
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT GTTTTTTTGTTTTTTTTTTGTTTTTTTTTTGTTTTTTT GTT GAT ATA AAT AGT GCC CA 3’ 
                                                                                                  3’ CAA CTA TAT TTA TCA CGG GTA CCT AGG CGC CCA CAG CCC 5’  
Product of second and subsequent rounds 
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT GTTTTTTTGTTTTTTTTTTGTTTTTTTTTTGTTTTTTT GTT GAT ATA AAT AGT GCC CAT GGA TCC GCG GGT GTC GGG 3’ 
3’ GCG CCT AGG ATT ATG CTG AGT GAT ATC CCC GGT GGT TGC TGT AA CAAAAAAACAAAAAAAAAACAAAAAAAAAACAAAAAAA CAA CTA TAT TTA TCA CGG GTA CCT AGG CGC CCA CAG CCC 5’ 
  
Primers and oligos in reaction  
5’ CGC GGA TCC TAA TAC GAC TCA CTA TAG GGG CCA CCA ACG ACA TT 3’  
3’ CCC GGT GGT TGC TGT AA CAAAAAAACAAAAAAAAAACAAAAAAAAAACAAAAAAA CAA CTA TAT TTA TCA CGG GT 5’ 
3’ CAA CTA TAT TTA TCA CGG GTA CCT AGG CGC CCA CAG CCC 5’ 
4- A gel of PCR products should show a primary band at 121 bp without detectable bands at 103 and 94 bp representing incomplete construction.  
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Appendix 4.  Three-Fold or Greater Targets of DAZL Binding 
 The following table lists in order of fold increase over MBP and with p-values of 
less than p < 0.05 the sequences selected by DAZL in the microarray study.  Only the 
sequences of 3-fold and greater are shown.  The column lists Systematic ID which is 
used by the GeneSpring software, RefSeq used by Genbank, the name of the gene or 
product, the process in which the gene is involved, the normalized number, the ratio, and 
the p-value. 
Systematic ID RefSeq Product GO biological process Normalized Ratio P-value 
NM_014814 NM_014814 proteasome regulatory particle 
subunit p44S10 
ATP-dependent 
proteolysis 
0.0703 14.22 0.0024 
NM_000019 NM_000019 
acetyl-Coenzyme A 
acetyltransferase 1 precursor  0.0731 13.67 0.0012 
AK057433 NM_144674 hypothetical protein FLJ32871 
microtubule cytoskeleton 
organization and 
biogenesis 
0.0784 12.76 0.0090 
NM_005977 
NM_005977; 
NM_183043; 
NM_183044; 
NM_183045 
ring finger protein 6 isoform 1; 
ring finger protein 6 isoform 2 
 0.0811 12.33 0.0011 
NM_006197 NM_006197 pericentriolar material 1  0.0812 12.31 0.0017 
NM_004872 NM_004872 thymic dendritic cell-derived factor 
1 
 0.0835 11.97 0.0012 
NM_014932 NM_014932 neuroligin 1 
synaptogenesis; protein 
targeting; cell adhesion; 
synaptic vesicle 
targeting; calcium-
dependent cell-cell 
adhesion; ion channel 
clustering; regulation of 
neuron differentiation 
0.0853 11.73 0.0013 
NM_007051 
NM_007051; 
NM_131917 
FAS-associated factor 1 isoform a; 
FAS-associated factor 1 isoform b 
apoptosis 0.0870 11.50 0.0010 
NM_007204 NM_007204 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 20 
assembly of spliceosomal 
tri-snRNP; mRNA 
processing 
0.0889 11.25 0.0023 
AK056446 NM_005348 heat shock 90kDa protein 1, alpha  0.0971 10.30 0.0038 
NM_030933 NM_030933 chromosome 1 open reading frame 
14 
 0.0981 10.19 0.0039 
NM_014633 NM_014633 SH2 domain binding protein 1 
regulation of 
transcription, DNA-
dependent 
0.0982 10.18 0.0041 
NM_003295 NM_003295 tumor protein, translationally-
controlled 1 
 0.1052 9.51 0.0057 
NM_001006 
NM_001006; 
NM_182777 ribosomal protein S3a protein biosynthesis 0.1061 9.43 0.0074 
BC017296 NM_144665 sestrin 3 cell cycle arrest 0.1075 9.30 0.0016 
NM_006554 NM_006554 metaxin 2 
mitochondrial transport; 
intracellular protein 
transport 
0.1089 9.18 0.0046 
NM_003299 NM_003299 tumor rejection antigen (gp96) 1 response to stress; 
protein folding 
0.1096 9.12 0.0031 
NM_006461 NM_006461 mitotic spindle coiled-coil related 
protein 
 0.1097 9.12 0.0063 
NM_002592 
NM_002592; 
NM_182649 
proliferating cell nuclear antigen 
DNA repair; DNA 
replication; cell 
proliferation; cell cycle 
0.1109 9.01 0.0025 
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Systematic ID RefSeq Product GO biological process Normalized Ratio P-value 
control 
NM_053023 
NM_053023; 
NM_170768 
zinc finger protein 91 isoform 1; 
zinc finger protein 91 isoform 2  0.1109 9.01 0.0306 
NM_003134 NM_003134 
signal recognition particle 14kDa 
(homologous Alu RNA binding 
protein) 
protein targeting; 
cotranslational 
membrane targeting 
0.1125 8.89 0.0027 
NM_004559 NM_004559 
nuclease sensitive element binding 
protein 1 
response to 
pest/pathogen/parasite; 
transcription from Pol II 
promoter 
0.1126 8.88 0.0054 
NM_030941 NM_030941 exonuclease NEF-sp  0.1135 8.81 0.0062 
AB051469 NM_019061 
phosphatidylinositol-3 phosphate 
3-phosphatase adaptor subunit  0.1151 8.69 0.0020 
NM_006584 NM_006584 chaperonin containing TCP1, 
subunit 6B (zeta 2) 
protein complex 
assembly, 
multichaperone pathway; 
spermatogenesis; protein 
folding 
0.1169 8.55 0.0055 
NM_016027 NM_016027 lactamase, beta 2  0.1173 8.53 0.0012 
NM_003447 NM_003447 zinc finger protein 165 
regulation of 
transcription, DNA-
dependent 
0.1174 8.52 0.0016 
Z68274    0.1186 8.43 0.0036 
NM_003296 NM_003296 testis specific protein 1  0.1195 8.37 0.0062 
NM_006430 NM_006430 chaperonin containing TCP1, 
subunit 4 (delta) 
protein folding; 
regulation of cell cycle 
0.1196 8.36 0.0012 
AL050335    0.1203 8.31 0.0030 
NM_032631 NM_032631 
hepatoma-derived growth factor-
related protein 2 
regulation of 
transcription, DNA-
dependent 
0.1210 8.27 0.0024 
NM_006835 NM_006835 cyclin I spermatogenesis 0.1230 8.13 0.0054 
AJ224082    0.1231 8.13 0.0018 
NM_019644 NM_019644 testis-specific ankyrin motif 
containing protein 
male gonad development 0.1232 8.12 0.0009 
AK057303 NM_139243 testis nuclear RNA-binding protein 
RNA processing; 
proteolysis and 
peptidolysis 
0.1238 8.07 0.0018 
NM_000971 NM_000971 ribosomal protein L7 
regulation of 
transcription, DNA-
dependent; protein 
biosynthesis 
0.1242 8.05 0.0063 
NM_005192 NM_005192 cyclin-dependent kinase inhibitor 3 
G1/S transition of mitotic 
cell cycle; cell cycle 
arrest; negative 
regulation of cell 
proliferation; regulation 
of CDK activity 
0.1244 8.04 0.0057 
NM_002948 NM_002948 ribosomal protein L15 protein biosynthesis 0.1248 8.01 0.0017 
U93181 NM_002972 SET binding factor 1 isoform a protein amino acid 
dephosphorylation 
0.1265 7.90 0.0019 
NM_001015 NM_001015 ribosomal protein S11 protein biosynthesis 0.1266 7.90 0.0069 
NM_003756 NM_003756 
eukaryotic translation initiation 
factor 3, subunit 3 gamma, 40kDa 
regulation of 
translational initiation; 
protein biosynthesis 
0.1279 7.82 0.0020 
NM_020366 NM_020366 
retinitis pigmentosa GTPase 
regulator interacting protein 1  0.1284 7.79 0.0039 
NM_032135 NM_032135 hypothetical protein 
DKFZp434F1017 
 0.1287 7.77 0.0033 
AL049690    0.1289 7.76 0.0026 
NM_017903 NM_017903 hypothetical protein FLJ20618  0.1290 7.75 0.0017 
NM_022443 NM_022443 myeloid leukemia factor 1  0.1291 7.75 0.0035 
NM_018473 NM_018473 thioesterase superfamily member 
2 
 0.1298 7.70 0.0042 
BC014595 NM_145046 calreticulin 3  0.1311 7.63 0.0023 
NM_001005 NM_001005 ribosomal protein S3 protein biosynthesis 0.1314 7.61 0.0039 
NM_017917 NM_017917 chromosome 14 open reading 
frame 10 
 0.1323 7.56 0.0184 
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NM_015571 NM_015571 SUMO-1-specific protease proteolysis and 
peptidolysis 
0.1334 7.49 0.0070 
AK055354 NM_005131 nuclear matrix protein p84 
transport; mRNA-nucleus 
export; signal 
transduction; nuclear 
mRNA splicing, via 
spliceosome 
0.1339 7.47 0.0040 
NM_032580 NM_032580 hairy and enhancer of split 7 
mesoderm development; 
regulation of 
transcription, DNA-
dependent 
0.1340 7.46 0.0032 
NM_018686 NM_018686 
cytidine 5'-monophosphate N-
acetylneuraminic acid synthetase  0.1341 7.46 0.0036 
NM_000183 NM_000183 
hydroxyacyl dehydrogenase, 
subunit B 
fatty acid beta-oxidation; 
fatty acid metabolism 
0.1343 7.44 0.0021 
NM_002631 NM_002631 phosphogluconate dehydrogenase 
pentose-phosphate 
shunt, oxidative branch 0.1344 7.44 0.0099 
NM_006837 NM_006837 COP9 signalosome subunit 5 
protein biosynthesis; 
transcription from Pol II 
promoter 
0.1347 7.42 0.0061 
NM_001418 NM_001418 eukaryotic translation initiation 
factor 4 gamma, 2 
cell cycle arrest; cell 
death; regulation of 
translational initiation; 
regulation of protein 
biosynthesis 
0.1348 7.42 0.0050 
BC010112 NM_002156 heat shock 60kDa protein 1 
(chaperonin) 
 0.1351 7.40 0.0038 
NM_004505 NM_004505 ubiquitin specific protease 6 
deubiquitination; 
oncogenesis; protein 
modification 
0.1355 7.38 0.0081 
NM_002106 NM_002106 H2A histone family, member Z 
nucleosome assembly; 
chromosome 
organization and 
biogenesis (sensu 
Eukarya) 
0.1359 7.36 0.0083 
NM_032315 NM_032315 mitochondrial carrier protein 
MGC4399 
transport 0.1359 7.36 0.0018 
NM_006754 
NM_006754; 
NM_182715 
synaptophysin-like protein isoform 
a; synaptophysin-like protein 
isoform b 
transport; nonselective 
vesicle transport; 
synaptic transmission 
0.1362 7.34 0.0039 
NM_001351 NM_001351 deleted in azoospermia-like spermatogenesis 0.1366 7.32 0.0064 
NM_003992 
NM_001292; 
NM_003992 
CDC-like kinase 3 isoform 
hclk3/152 
protein amino acid 
phosphorylation 
0.1377 7.26 0.0028 
NM_001749 NM_001749 calpain, small subunit 1 positive regulation of cell 
proliferation 
0.1378 7.26 0.0043 
AL096829    0.1378 7.25 0.0037 
NM_016930 NM_016930 syntaxin 18 
ER to Golgi transport; 
nonselective vesicle 
docking; intracellular 
protein transport 
0.1378 7.25 0.0085 
BC007261  Unknown (protein for MGC:15545)  0.1382 7.23 0.0042 
NM_002787 NM_002787 proteasome alpha 2 subunit ubiquitin-dependent 
protein catabolism 
0.1386 7.22 0.0029 
NM_025146 NM_025146 hypothetical protein FLJ13194  0.1386 7.22 0.0051 
NM_017425 NM_017425 sperm autoantigenic protein 17 
spermatogenesis; 
fertilization (sensu 
Animalia); signal 
transduction 
0.1387 7.21 0.0079 
NM_004902 
NM_004902; 
NM_184234; 
NM_184237; 
NM_184241; 
NM_184244 
RNA-binding region containing 
protein 2 isoform b; RNA-binding 
region containing protein 2 isoform 
a; RNA-binding region containing 
protein 2 isoform c; RNA-binding 
region containing protein 2 isoform 
d 
regulation of 
transcription, DNA-
dependent; nuclear 
mRNA splicing, via 
spliceosome 
0.1404 7.12 0.0032 
NM_002687 NM_002687 
pinin, desmosome associated 
protein 
cell adhesion; cell shape 
and cell size control 
0.1408 7.10 0.0352 
NM_014056 NM_014056 DKFZP564K247 protein  0.1411 7.09 0.0010 
NM_006029 NM_006029 paraneoplastic antigen MA1 
spermatogenesis; central 
nervous system 
development 
0.1412 7.08 0.0052 
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NM_003350 NM_003350 ubiquitin-conjugating enzyme E2 
variant 2 
protein 
polyubiquitination; 
regulation of DNA repair; 
ubiquitin cycle; cell 
proliferation; regulation 
of cell cycle 
0.1413 7.08 0.0064 
NM_002790 NM_002790 proteasome alpha 5 subunit ubiquitin-dependent 
protein catabolism 
0.1414 7.07 0.0008 
NM_032858 NM_032858 hypothetical protein FLJ14904  0.1422 7.03 0.0037 
NM_005493 NM_005493 RAN binding protein 9 
microtubule nucleation; 
cell growth and/or 
maintenance; protein 
complex assembly 
0.1426 7.01 0.0046 
BC008767 NM_004035; 
NM_007292 
acyl-Coenzyme A oxidase isoform 
a; acyl-Coenzyme A oxidase 
isoform b 
fatty acid beta-oxidation; 
electron transport; 
prostaglandin 
metabolism; energy 
pathways 
0.1426 7.01 0.0008 
NM_002520 
NM_002520; 
NM_199185 nucleophosmin 1  0.1429 7.00 0.0022 
NM_005154 NM_005154 ubiquitin specific protease 8 
ubiquitin-dependent 
protein catabolism; cell 
proliferation 
0.1435 6.97 0.0013 
NM_014362 NM_014362; 
NM_198047 
3-hydroxyisobutyryl-Coenzyme A 
hydrolase isoform 1; 3-
hydroxyisobutyryl-Coenzyme A 
hydrolase isoform 2 
metabolism 0.1442 6.94 0.0102 
NM_004986 
NM_004986; 
NM_182926 kinectin 1 
non-selective vesicle 
transport 0.1443 6.93 0.0054 
NM_004456 
NM_004456; 
NM_152998 
enhancer of zeste 2 isoform a; 
enhancer of zeste 2 isoform b 
chromatin architecture; 
transcription regulation 
0.1444 6.93 0.0029 
NM_003368 NM_003368 ubiquitin specific protease 1 ubiquitin-dependent 
protein catabolism 
0.1451 6.89 0.0007 
NM_030939 NM_030939 chromosome 6 open reading frame 
62 
 0.1451 6.89 0.0045 
NM_021190 NM_021190 polypyrimidine tract binding 
protein 2 
 0.1455 6.87 0.0009 
AK057501 NM_144673 chemokine-like factor super family 
2 
 0.1469 6.81 0.0166 
BC010281 NM_015161 ADP-ribosylation factor-like 6 
interacting protein 
 0.1472 6.79 0.0001 
NM_006016 NM_006016 CD164 antigen, sialomucin 
negative regulation of 
cell proliferation; cell 
adhesion; development; 
immune response; signal 
transduction 
0.1478 6.76 0.0204 
NM_032905 NM_032905 splicing factor (45kD) 
mRNA processing; mRNA 
splicing; nuclear mRNA 
splicing, via spliceosome 
0.1482 6.75 0.0063 
BC014598 NM_145269 similar to CG6405 gene product  0.1483 6.74 0.0027 
NM_016091 NM_016091 
eukaryotic translation initiation 
factor 3, subunit 6 interacting 
protein 
protein biosynthesis 0.1488 6.72 0.0006 
NM_004786 NM_004786 thioredoxin-like, 32kDa 
protein-disulfide 
reduction; apoptosis; 
signal transduction 
0.1490 6.71 0.0016 
AK023096    0.1491 6.71 0.0473 
NM_005998 NM_005998 chaperonin containing TCP1, 
subunit 3 (gamma) 
protein folding 0.1505 6.65 0.0020 
AK058062 NM_152548 hypothetical protein FLJ25333  0.1508 6.63 0.0023 
NM_031243 NM_002137; 
NM_031243 
heterogeneous nuclear 
ribonucleoprotein A2/B1 isoform 
A2; heterogeneous nuclear 
ribonucleoprotein A2/B1 isoform 
B1 
RNA processing 0.1513 6.61 0.0065 
NM_006406 NM_006406 thioredoxin peroxidase I-kappaB 
phosphorylation 
0.1518 6.59 0.0047 
NM_016220 NM_016220 zinc finger protein (ZFD25) 
regulation of 
transcription, DNA-
dependent; 
biological_process 
unknown 
0.1522 6.57 0.0014 
156 
 
Systematic ID RefSeq Product GO biological process Normalized Ratio P-value 
NM_001831 NM_001831 clusterin 
complement activation, 
classical pathway; cell 
death; lipid metabolism; 
fertilization (sensu 
Animalia); apoptosis 
0.1524 6.56 0.0086 
NM_030752 NM_030752 t-complex 1 protein folding 0.1526 6.55 0.0051 
NM_012189 
NM_012189; 
NM_138643; 
NM_138644; 
NM_153768; 
NM_153769; 
NM_153770 
calcium-binding tyrosine 
phosphorylation-regulated protein 
isoform a; calcium-binding 
tyrosine phosphorylation-regulated 
protein isoform d; calcium-binding 
tyrosine phosphorylation-regulated 
protein isoform c; calcium-binding 
tyrosine phosphorylation-regulated 
protein isoform b; calcium-binding 
tyrosine phosphorylation-regulated 
protein isoform e 
 0.1526 6.55 0.0087 
NM_001726 NM_001726 testis-specific bromodomain 
protein 
 0.1528 6.54 0.0016 
NM_033546 NM_033546 myosin regulatory light chain 
MRCL2 
 0.1533 6.52 0.0048 
NM_002799 NM_002799 proteasome beta 7 subunit 
proprotein 
ubiquitin-dependent 
protein catabolism 
0.1540 6.49 0.0100 
NM_022807 
NM_003097; 
NM_022805; 
NM_022806; 
NM_022807; 
NM_022808 
small nuclear ribonucleoprotein 
polypeptide N 
mRNA splicing 0.1541 6.49 0.0023 
NM_004238 NM_004238 thyroid hormone receptor 
interactor 12 
protein ubiquitination 0.1541 6.49 0.0082 
NM_002497 NM_002497 
NIMA (never in mitosis gene a)-
related kinase 2 
regulation of mitosis; 
meiosis; protein amino 
acid phosphorylation; 
cytokinesis 
0.1552 6.44 0.0065 
AK055714 NM_002789 proteasome alpha 4 subunit ubiquitin-dependent 
protein catabolism 
0.1553 6.44 0.0018 
NM_002539 NM_002539 ornithine decarboxylase 1 polyamine biosynthesis 0.1553 6.44 0.0101 
NM_016640 NM_016640 mitochondrial ribosomal protein 
S30 
apoptosis 0.1556 6.43 0.0010 
NM_001359 NM_001359 2,4-dienoyl CoA reductase 1 
precursor 
metabolism 0.1559 6.42 0.0025 
NM_018093 NM_018093 hypothetical protein FLJ10439  0.1561 6.41 0.0029 
NM_005336 NM_005336 high density lipoprotein binding 
protein 
lipid transport; 
cholesterol metabolism 
0.1565 6.39 0.0109 
NM_006716 NM_006716 activator of S phase kinase 
DNA replication; cell 
cycle control; mitotic 
G1/S transition 
0.1566 6.39 0.0023 
AB033079 NM_020755 tumor differentially expressed 2  0.1569 6.37 0.0058 
NM_001320 NM_001320 casein kinase 2, beta polypeptide signal transduction 0.1571 6.37 0.0037 
NM_003143 NM_003143 single-stranded DNA binding 
protein 1 
DNA replication 0.1572 6.36 0.0092 
NM_017743 
NM_017743; 
NM_130434; 
NM_197960; 
NM_197961 
dipeptidyl peptidase 8 isoform 2; 
dipeptidyl peptidase 8 isoform 1; 
dipeptidyl peptidase 8 isoform 3; 
dipeptidyl peptidase 8 isoform 4 
 0.1572 6.36 0.0029 
NM_032559 NM_032559 kinesin protein  0.1574 6.35 0.0039 
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BC017117 
NM_001881; 
NM_181571; 
NM_182717; 
NM_182718; 
NM_182719; 
NM_182720; 
NM_182721; 
NM_182722; 
NM_182723; 
NM_182724; 
NM_182725; 
NM_182769; 
NM_182770; 
NM_182771; 
NM_182772; 
NM_182850; 
NM_182853; 
NM_183011; 
NM_183012; 
NM_183013; 
NM_183060 
cAMP responsive element 
modulator isoform b; cAMP 
responsive element modulator 
isoform a; cAMP responsive 
element modulator isoform d; 
cAMP responsive element 
modulator isoform e; cAMP 
responsive element modulator 
isoform f; cAMP responsive 
element modulator isoform g; 
cAMP responsive element 
modulator isoform h; cAMP 
responsive element modulator 
isoform i; cAMP responsive 
element modulator isoform j; 
cAMP responsive element 
modulator isoform k; cAMP 
responsive element modulator 
isoform l; cAMP responsive 
element modulator isoform m; 
cAMP responsive element 
modulator isoform n; cAMP 
responsive element modulator 
isoform o; cAMP responsive 
element modulator isoform p; 
cAMP responsive element 
modulator isoform q; cAMP 
responsive element modulator 
isoform r; cAMP responsive 
element modulator isoform u; 
cAMP responsive element 
modulator isoform t; cAMP 
responsive element modulator 
isoform s; cAMP responsive 
element modulator isoform v 
signal transduction 0.1576 6.35 0.0031 
NM_002085 NM_002085 glutathione peroxidase 4 
phospholipid 
metabolism; response to 
oxidative stress; 
development 
0.1579 6.33 0.0104 
D38553 NM_015341 barren 
mitotic chromosome 
condensation; cell cycle; 
mitosis 
0.1580 6.33 0.0108 
NM_006667 NM_006667 progesterone receptor membrane 
component 1 
 0.1581 6.33 0.0001 
NM_004881 
NM_004881; 
NM_147184 
tumor protein p53 inducible 
protein 3  0.1582 6.32 0.0020 
AK055287    0.1583 6.32 0.0042 
NM_003973 NM_003973 ribosomal protein L14 protein biosynthesis 0.1586 6.31 0.0053 
NM_003093 NM_003093 small nuclear ribonucleoprotein 
polypeptide C 
RNA splicing 0.1590 6.29 0.0031 
NM_006007 NM_006007 zinc finger protein 216 biological_process 
unknown 
0.1595 6.27 0.0043 
AL136939 NM_021814 
homolog of yeast long chain 
polyunsaturated fatty acid 
elongatio 
 0.1596 6.27 0.0025 
NM_018180 NM_018180 
DEAD/H (Asp-Glu-Ala-Asp/His) box 
polypeptide 32 
 0.1597 6.26 0.0001 
NM_006265 NM_006265 RAD21 homolog 
meiotic recombination; 
chromosome 
segregation; cell cycle; 
mitosis; double-strand 
break repair; apoptosis 
0.1603 6.24 0.0003 
NM_021794 NM_021794 
a disintegrin and metalloproteinase 
domain 30 preproprotein 
proteolysis and 
peptidolysis 0.1610 6.21 0.0016 
NM_006768 NM_006768 BRCA1 associated protein nucleocytoplasmic 
transport 
0.1611 6.21 0.0010 
NM_002950 NM_002950 ribophorin I protein modification 0.1613 6.20 0.0047 
NM_002893 NM_002893 retinoblastoma binding protein 7 development; cell 
proliferation 
0.1616 6.19 0.0006 
AF132027    0.1618 6.18 0.0035 
NM_030979 NM_030979 poly(A) binding protein, 
cytoplasmic 3 
mRNA metabolism 0.1619 6.18 0.0065 
NM_033122 NM_033122 testis development protein NYD-
SP26 
 0.1623 6.16 0.0038 
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NM_001564 NM_001564 
inhibitor of growth family, member 
1-like 
regulation of 
transcription, DNA-
dependent; signal 
transduction 
0.1624 6.16 0.0040 
NM_003896 NM_003896 sialyltransferase 9 protein amino acid 
glycosylation 
0.1627 6.15 0.0019 
NM_001920 
NM_001920; 
NM_133503; 
NM_133504; 
NM_133505; 
NM_133506; 
NM_133507 
decorin isoform a preproprotein; 
decorin isoform b precursor; 
decorin isoform c precursor; 
decorin isoform d precursor; 
decorin isoform e precursor 
organogenesis 0.1630 6.14 0.0035 
NM_004718 NM_004718 
cytochrome c oxidase subunit VIIa 
polypeptide 2 like 
electron transport 0.1635 6.12 0.0031 
AF130110  PRO1633  0.1636 6.11 0.0053 
NM_001469 NM_001469 
thyroid autoantigen 70kDa (Ku 
antigen) 
DNA ligation; double-
strand break repair via 
nonhomologous end-
joining 
0.1638 6.10 0.0062 
NM_031916 NM_031916 AKAP-associated sperm protein signal transduction 0.1638 6.10 0.0023 
NM_000462 
NM_000462; 
NM_130838; 
NM_130839 
ubiquitin protein ligase E3A 
isoform 2; ubiquitin protein ligase 
E3A isoform 1; ubiquitin protein 
ligase E3A isoform 3 
brain development; 
proteolysis and 
peptidolysis; ubiquitin-
dependent protein 
catabolism 
0.1640 6.10 0.0014 
NM_003380 NM_003380 vimentin  0.1640 6.10 0.0075 
NM_001338 NM_001338 coxsackie virus and adenovirus 
receptor 
 0.1641 6.09 0.0049 
NM_015224 NM_015224 retinoblastoma-associated protein 
140 
 0.1644 6.08 0.0182 
NM_006530 NM_006530 glioma-amplified sequence-41 
regulation of 
transcription, DNA-
dependent 
0.1645 6.08 0.0031 
AK057940 NM_152524 tripin  0.1646 6.07 0.0068 
NM_013264 NM_013264 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 25 
regulation of translation; 
spermatogenesis 
0.1653 6.05 0.0101 
NM_031915 NM_031915 CLLL8 protein chromatin modification 0.1653 6.05 0.0034 
NM_004279 NM_004279 peptidase (mitochondrial 
processing) beta 
proteolysis and 
peptidolysis 
0.1655 6.04 0.0076 
NM_006659 NM_006659 
tubulin, gamma complex 
associated protein 2 
microtubule nucleation; 
protein complex 
assembly 
0.1657 6.03 0.0112 
AB014731 NM_003677 density-regulated protein 
cell growth and/or 
maintenance; 
translational initiation; 
biological_process 
unknown 
0.1657 6.03 0.0001 
NM_052811 
NM_005798; 
NM_052811 
ret finger protein 2 
morphogenesis; negative 
regulation of cell cycle 
0.1657 6.03 0.0007 
NM_012260 NM_012260 2-hydroxyphytanoyl-CoA lyase lipid metabolism 0.1660 6.02 0.0152 
NM_000981 NM_000981 ribosomal protein L19 protein biosynthesis 0.1662 6.02 0.0177 
NM_002887 NM_002887 arginyl-tRNA synthetase arginyl-tRNA 
aminoacylation 
0.1664 6.01 0.0030 
NM_015646 NM_015646 
RAP1B, member of RAS oncogene 
family 
small GTPase mediated 
signal transduction 
0.1665 6.01 0.0034 
NM_001025 NM_001025 ribosomal protein S23 protein biosynthesis 0.1669 5.99 0.0057 
AB058696 NM_022742 hypothetical protein 
DKFZp434G156 
 0.1671 5.98 0.0072 
NM_003069 
NM_003069; 
NM_139035 
SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin a1 isoform 
a; SWI/SNF-related matrix-
associated actin-dependent 
regulator of chromatin a1 isoform 
b 
chromatin remodeling; 
regulation of 
transcription, DNA-
dependent 
0.1674 5.97 0.0021 
NM_001568 NM_001568 
murine mammary tumor 
integration site 6 (oncogene 
homolog) 
cell growth and/or 
maintenance; regulation 
of translational initiation; 
protein biosynthesis 
0.1676 5.97 0.0022 
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AK055378    0.1685 5.93 0.0051 
NM_016042 NM_016042 exosome component Rrp40 rRNA processing 0.1695 5.90 0.0040 
AK027339 NM_022118 cutaneous T-cell lymphoma tumor 
antigen se70-2 
 0.1695 5.90 0.0051 
NM_004365 NM_004365 centrin 3 centrosome cycle; 
mitosis; cytokinesis 
0.1696 5.90 0.0079 
AB023420 
NM_002154; 
NM_198431 
heat shock 70kDa protein 4 
isoform a; heat shock 70kDa 
protein 4 isoform b 
 0.1696 5.89 0.0016 
NM_005917 NM_005917 cytosolic malate dehydrogenase tricarboxylic acid cycle 0.1697 5.89 0.0006 
NM_005030 NM_005030 polo-like kinase 
mitosis; protein amino 
acid phosphorylation; 
regulation of cell cycle 
0.1698 5.89 0.0045 
NM_003022 NM_003022 
SH3 domain binding glutamic acid-
rich protein like 
 0.1703 5.87 0.0002 
NM_024410 NM_024410 outer dense fiber of sperm tails 1 spermatogenesis 0.1706 5.86 0.0080 
NM_006807 NM_006807 
chromobox homolog 1 (HP1 beta 
homolog Drosophila ) 
chromatin 
assembly/disassembly 
0.1709 5.85 0.0002 
NM_006471 NM_006471 
myosin regulatory light chain 
MRCL3 
muscle development; 
regulation of smooth 
muscle contraction 
0.1711 5.85 0.0080 
NM_014841 NM_014841 
synaptosomal-associated protein, 
91kDa homolog  0.1713 5.84 0.0054 
AL136640 NM_016480 poly(A) binding protein interacting 
protein 2 
 0.1719 5.82 0.0061 
M90355  BTF3 homologue 
regulation of 
transcription, DNA-
dependent 
0.1722 5.81 0.0064 
NM_019081 
NM_014647; 
NM_019081 
limkain b1 isoform 1; limkain b1 
isoform 2  0.1724 5.80 0.0004 
NM_002890 
NM_002890; 
NM_022650 
RAS p21 protein activator 1 
isoform 1; RAS p21 protein 
activator 1 isoform 2 
cell growth and/or 
maintenance; 
intracellular signaling 
cascade 
0.1728 5.79 0.0001 
NM_002615 NM_002615 
serine (or cysteine) proteinase 
inhibitor, clade F (alpha-2 
antiplasmin, pigment epithelium 
derived factor), member 1 
development; 
neurogenesis; cell 
proliferation; negative 
regulation of 
angiogenesis 
0.1732 5.77 0.0014 
NM_022333 NM_003252; 
NM_022333 
TIA1 cytotoxic granule-associated 
RNA-binding protein-like 1 isoform 
1; TIA1 cytotoxic granule-
associated RNA-binding protein-
like 1 isoform 2 
induction of apoptosis; 
regulation of 
transcription from Pol II 
promoter 
0.1736 5.76 0.0020 
BC017585 NM_178861 zinc finger protein 183-like 1  0.1738 5.75 0.0086 
NM_018261 
NM_018261; 
NM_178237 
Sec3-like isoform 1; Sec3-like 
isoform 2 
intracellular protein 
transport; exocytosis 0.1741 5.74 0.0003 
AK023009 NM_152437 hypothetical protein 
DKFZp761B128 
 0.1741 5.74 0.0007 
NM_004859 NM_004859 clathrin heavy chain intracellular protein 
transport 
0.1742 5.74 0.0023 
NM_004853 NM_004853 syntaxin 8 transport; nonselective 
vesicle transport 
0.1746 5.73 0.0070 
NM_025180 NM_025180 hypothetical protein FLJ13386  0.1749 5.72 0.0146 
NM_023934 NM_023934 hepatitis C virus core-binding 
protein 6 
 0.1750 5.71 0.0030 
NM_000108 NM_000108 
dihydrolipoamide dehydrogenase 
precursor 
electron transport; 
glycolysis; energy 
pathways 
0.1750 5.71 0.0014 
NM_002803 NM_002803 proteasome 26S ATPase subunit 2 proteolysis and 
peptidolysis 
0.1752 5.71 0.0128 
NM_003653 NM_003653 
COP9 constitutive 
photomorphogenic homolog 
subunit 3 
response to light; signal 
transduction 0.1758 5.69 0.0005 
NM_017948 NM_017948 chromosome 9 open reading frame 
34 
 0.1759 5.68 0.0052 
AK055130 NM_001743 calmodulin 2  0.1759 5.68 0.0101 
NM_002954 NM_002954 
ubiquitin and ribosomal protein 
S27a precursor 
protein biosynthesis; 
biological_process 
unknown 
0.1760 5.68 0.0002 
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NM_005174 NM_005174 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, gamma 
polypeptide 1 
proton transport; energy 
pathways; ATP 
biosynthesis 
0.1763 5.67 0.0031 
AL049987    0.1766 5.66 0.0062 
AF183421 NM_006868 
RAB31, member RAS oncogene 
family 
protein transport; small 
GTPase mediated signal 
transduction 
0.1776 5.63 0.0033 
NM_031301 NM_031301 presenilin stabilization factor-like  0.1779 5.62 0.0052 
BC015858  ZNF37A protein 
regulation of 
transcription, DNA-
dependent 
0.1786 5.60 0.0116 
NM_001151 NM_001151 
solute carrier family 25 
(mitochondrial carrier; adenine 
nucleotide translocator), member 
4 
mitochondrial genome 
maintenance; small 
molecule transport; 
energy pathways 
0.1786 5.60 0.0046 
NM_000534 NM_000534 postmeiotic segregation 1 mismatch repair; 
oncogenesis 
0.1789 5.59 0.0024 
NM_019073 NM_019073 spermatogenesis associated 6  0.1793 5.58 0.0030 
NM_000993 NM_000993 ribosomal protein L31 protein biosynthesis 0.1793 5.58 0.0151 
NM_001029 NM_001029 ribosomal protein S26 
regulation of 
transcription, DNA-
dependent; protein 
biosynthesis 
0.1800 5.56 0.0012 
NM_016167 NM_016167 retinoic acid repressible protein  0.1801 5.55 0.0061 
AB037801 NM_004241 
thyroid hormone receptor 
interactor 8 
regulation of 
transcription, DNA-
dependent 
0.1802 5.55 0.0018 
NM_018448 NM_018448 TIP120 protein  0.1807 5.53 0.0063 
NM_003375 NM_003375 voltage-dependent anion channel 2 anion transport 0.1807 5.53 0.0005 
NM_015415 NM_015415 DKFZP564B167 protein  0.1810 5.53 0.0007 
AL136755 NM_032132 hypothetical protein 
DKFZp434A1315 
 0.1819 5.50 0.0016 
NM_015355 NM_015355 joined to JAZF1 
cell growth and/or 
maintenance; regulation 
of transcription, DNA-
dependent; chromatin 
modification 
0.1820 5.49 0.0025 
NM_024835 NM_024835 C3HC4-type zinc finger protein  0.1820 5.49 0.0071 
NM_016047 NM_016047 pre-mRNA branch site protein p14 nuclear mRNA splicing, 
via spliceosome 
0.1821 5.49 0.0037 
NM_003816 NM_003816 
a disintegrin and metalloproteinase 
domain 9 preproprotein 
protein kinase cascade; 
proteolysis and 
peptidolysis 
0.1826 5.48 0.0117 
NM_002482 
NM_002482; 
NM_152298; 
NM_172164 
nuclear autoantigenic sperm 
protein isoform 2; nuclear 
autoantigenic sperm protein 
isoform 3; nuclear autoantigenic 
sperm protein isoform 1 
DNA packaging; 
spermatogenesis 
0.1826 5.48 0.0132 
NM_002762 NM_002762 protamine 2 
mitotic chromosome 
condensation; 
chromosome 
organization and 
biogenesis (sensu 
Eukarya); DNA 
packaging; 
spermatogenesis 
0.1827 5.47 0.0101 
NM_001154 NM_001154 annexin 5 blood coagulation 0.1832 5.46 0.0020 
AK023362    0.1834 5.45 0.0067 
NM_001277 NM_001277 choline kinase lipid transport; lipid 
metabolism 
0.1834 5.45 0.0058 
NM_005410 NM_005410 selenoprotein P precursor response to oxidative 
stress 
0.1836 5.45 0.0058 
AB037851  KIAA1430 protein  0.1840 5.43 0.0035 
M62896    0.1840 5.43 0.0110 
AK056690 NM_177452 trafficking protein particle complex 
6B 
 0.1842 5.43 0.0063 
NM_016422 NM_016422 ring finger protein 141  0.1843 5.43 0.0091 
NM_005561 NM_005561 lysosomal-associated membrane 
protein 1 
 0.1848 5.41 0.0023 
NM_005717 NM_005717 
actin related protein 2/3 complex 
subunit 5 
cell motility; actin 
cytoskeleton organization 
and biogenesis 
0.1851 5.40 0.0019 
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AF078164 NM_033276 Ku70-binding protein 3  0.1852 5.40 0.0002 
NM_004234 NM_004234 zinc finger protein 93 homolog 
regulation of 
transcription, DNA-
dependent 
0.1854 5.40 0.0051 
NM_005499 NM_005499 SUMO-1 activating enzyme subunit 
2 
ubiquitin cycle 0.1855 5.39 0.0012 
AF070559 NM_138779 hypothetical protein BC015148  0.1855 5.39 0.0172 
NM_014970 NM_014970 kinesin-associated protein 3 
signal transduction; 
protein complex 
assembly 
0.1856 5.39 0.0186 
NM_005869 NM_005869 serologically defined colon cancer 
antigen 10 
protein folding 0.1857 5.38 0.0106 
NM_005731 
NM_005731; 
NM_152862 
actin related protein 2/3 complex 
subunit 2 cell motility 0.1858 5.38 0.0143 
NM_004300 
NM_004300; 
NM_007099; 
NM_177554 
acid phosphatase 1 isoform c; acid 
phosphatase 1 isoform b; acid 
phosphatase 1 isoform a 
 0.1859 5.38 0.0020 
NM_014758 NM_014758 sorting nexin 19 
intracellular protein 
transport; intracellular 
signaling cascade 
0.1863 5.37 0.0058 
NM_002092 NM_002092 G-rich RNA sequence binding 
factor 1 
mRNA polyadenylation 0.1864 5.36 0.0012 
NM_001494 NM_001494 GDP dissociation inhibitor 2 
protein transport; 
nonselective vesicle 
transport 
0.1865 5.36 0.0051 
BC017197 
NM_021960; 
NM_182763 
myeloid cell leukemia sequence 1 
isoform 1; myeloid cell leukemia 
sequence 1 isoform 2 
apoptotic program; heat 
shock response; 
development 
0.1867 5.36 0.0002 
NM_016302 NM_016302 protein x 0001 ATP-dependent 
proteolysis 
0.1869 5.35 0.0028 
NM_020122 NM_020122 potassium channel modulatory 
factor 1 
 0.1869 5.35 0.0048 
D29641 NM_015360 KIAA0052 protein  0.1872 5.34 0.0034 
NM_006428 NM_006428 mitochondrial ribosomal protein 
L28 
 0.1875 5.33 0.0067 
NM_018359 NM_018359 hypothetical protein FLJ11200  0.1876 5.33 0.0002 
NM_017819 NM_017819 hypothetical protein FLJ20432  0.1877 5.33 0.0026 
NM_015344 NM_015344 leptin receptor overlapping 
transcript-like 1 
 0.1881 5.32 0.0081 
NM_001009 NM_001009 ribosomal protein S5 protein biosynthesis 0.1881 5.32 0.0076 
AK055864 NM_018418 spermatogenesis-associated 
protein 7 
 0.1883 5.31 0.0136 
NM_032461 NM_032461 
sperm protein associated with the 
nucleus, X chromosome, family 
member B1 
 0.1887 5.30 0.0022 
AK023044 NM_016290 retinoid x receptor interacting 
protein 
 0.1888 5.30 0.0071 
NM_021076 NM_021076 neurofilament, heavy polypeptide 
200kDa 
 0.1889 5.29 0.0173 
NM_002715 NM_002715 
protein phosphatase 2 (formerly 
2A), catalytic subunit, alpha 
isoform 
regulation of cell cycle; 
protein amino acid 
dephosphorylation 
0.1895 5.28 0.0051 
NM_007027 NM_007027 
topoisomerase (DNA) II binding 
protein 
DNA replication and 
chromosome cycle; DNA 
metabolism 
0.1897 5.27 0.0047 
NM_001697 NM_001697 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, O 
subunit (oligomycin sensitivity 
conferring protein) 
proton transport; ATP 
biosynthesis 
0.1898 5.27 0.0020 
AK056390 NM_018846 SBBI26 protein  0.1899 5.27 0.0000 
NM_014463 NM_014463 Lsm3 protein nuclear mRNA splicing, 
via spliceosome 
0.1900 5.26 0.0040 
AB040938  KIAA1505 protein  0.1901 5.26 0.0086 
NM_016589 NM_016589 M5-14 protein  0.1901 5.26 0.0030 
NM_007214 NM_007214 SEC63-like protein protein-membrane 
targeting 
0.1904 5.25 0.0032 
NM_025165 NM_025165 elongation factor RNA polymerase 
II-like 3 
 0.1904 5.25 0.0060 
AF333334 NM_005893 calicin spermatogenesis 0.1904 5.25 0.0030 
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NM_013291 NM_013291 
cleavage and polyadenylation 
specific factor 1, 160kDa 
mRNA polyadenylation; 
mRNA cleavage 
0.1905 5.25 0.0065 
NM_003914 NM_003914 cyclin A1 
male meiosis I; 
regulation of CDK 
activity; mitosis; 
spermatogenesis; 
cytokinesis 
0.1907 5.24 0.0124 
NM_006988 NM_006988 
a disintegrin and metalloprotease 
with thrombospondin motifs-1 
preproprotein 
integrin-mediated 
signaling pathway; 
negative regulation of 
cell proliferation; 
proteolysis and 
peptidolysis 
0.1909 5.24 0.0075 
NM_016038 NM_016038 Shwachman-Bodian-Diamond 
syndrome protein 
 0.1912 5.23 0.0059 
AK058131 NM_152567 hypothetical protein FLJ25402  0.1918 5.21 0.0032 
NM_016013 NM_016013 CGI-65 protein  0.1920 5.21 0.0055 
AB059277 NM_015446 transcription factor ELYS  0.1921 5.20 0.0015 
AL137385    0.1922 5.20 0.0016 
NM_003187 
NM_003187; 
NM_016283 
TBP-associated factor 9; adrenal 
gland protein AD-004 
transcription from Pol II 
promoter 
0.1922 5.20 0.0105 
NM_014670 NM_014670 basic leucine zipper and W2 
domains 1 
 0.1923 5.20 0.0044 
NM_003753 NM_003753 
eukaryotic translation initiation 
factor 3 subunit 7 
regulation of 
translational initiation; 
protein biosynthesis 
0.1926 5.19 0.0083 
NM_005100 
NM_005100; 
NM_144497 
A-kinase anchor protein 12 isoform 
1; A-kinase anchor protein 12 
isoform 2 
G-protein linked receptor 
protein signalling 
pathway 
0.1927 5.19 0.0053 
NM_001444 NM_001444 
fatty acid binding protein 5 
(psoriasis-associated) 
epidermal differentiation; 
transport; lipid 
metabolism 
0.1932 5.18 0.0004 
NM_014781 NM_014781 Rb1-inducible coiled coil protein 1  0.1932 5.18 0.0088 
NM_013232 NM_013232 programmed cell death 6 
induction of apoptosis by 
extracellular signals 
0.1933 5.17 0.0042 
NM_004728 NM_004728 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 21 
 0.1933 5.17 0.0033 
NM_014222 NM_014222 
NADH dehydrogenase (ubiquinone) 
1 alpha subcomplex, 8, 19kDa 
 0.1934 5.17 0.0017 
AB067512  KIAA1925 protein DNA recombination 0.1935 5.17 0.0030 
NM_017613 
NM_017613; 
NM_145794; 
NM_145795 
downstream neighbor of SON 
isoform a; downstream neighbor of 
SON isoform b; downstream 
neighbor of SON isoform c 
 0.1938 5.16 0.0002 
AK026479 
NM_020468; 
NM_153816 
sorting nexin 14 isoform b; sorting 
nexin 14 isoform a 
intracellular protein 
transport; intracellular 
signaling cascade 
0.1938 5.16 0.0314 
NM_005744 NM_005744 
ariadne homolog, ubiquitin-
conjugating enzyme E2 binding 
protein, 1 
ubiquitin-dependent 
protein catabolism 0.1940 5.15 0.0012 
NM_016227 
NM_014283; 
NM_016227 
chromosome 1 open reading frame 
9; membrane protein CH1  0.1940 5.15 0.0001 
AK057504 NM_144594 hypothetical protein FLJ32942  0.1941 5.15 0.0075 
NM_003798 NM_003798 
catenin (cadherin-associated 
protein), alpha-like 1 apoptosis 0.1943 5.15 0.0041 
NM_002079 NM_002079 aspartate aminotransferase 1 
aspartate catabolism; 
amino acid metabolism; 
biosynthesis 
0.1947 5.14 0.0047 
AK022565 
NM_138423; 
NM_177974 
H63 breast cancer expressed gene 
isoform a; H63 breast cancer 
expressed gene isoform b 
 0.1948 5.13 0.0070 
AB046781 NM_018003 
uveal autoantigen with coiled-coil 
domains and ankyrin repeats 
biological_process 
unknown 
0.1949 5.13 0.0025 
NM_006422 NM_006422 A-kinase anchor protein 3 acrosome reaction; cell 
motility 
0.1954 5.12 0.0178 
NM_000900 NM_000900 matrix Gla protein ossification; cartilage 
condensation 
0.1954 5.12 0.0116 
NM_014160 NM_014160 makorin, ring finger protein, 2 biological_process 
unknown 
0.1955 5.12 0.0058 
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NM_018694 
NM_016638; 
NM_018694 
SRp25 nuclear protein RNA splicing 0.1956 5.11 0.0210 
NM_002810 NM_002810; 
NM_153822 
proteasome 26S non-ATPase 
subunit 4 isoform 1; proteasome 
26S non-ATPase subunit 4 isoform 
2 
 0.1958 5.11 0.0155 
AK027572 NM_153331 
potassium channel tetramerisation 
domain containing 6 
potassium ion transport 0.1960 5.10 0.0045 
NM_000291 NM_000291 phosphoglycerate kinase 1  0.1960 5.10 0.0071 
NM_002805 NM_002805 proteasome 26S ATPase subunit 5 
signal transduction; 
transcription from Pol II 
promoter; protein 
catabolism 
0.1961 5.10 0.0078 
NM_001239 NM_001239 cyclin H 
regulation of CDK 
activity; cell cycle; 
regulation of 
transcription, DNA-
dependent; DNA repair 
0.1961 5.10 0.0011 
NM_016053 NM_016053 CGI-116 protein  0.1961 5.10 0.0017 
NM_002748 NM_002748 mitogen-activated protein kinase 6 
cell cycle; protein amino 
acid phosphorylation; 
signal transduction 
0.1965 5.09 0.0010 
NM_000194 NM_000194 
hypoxanthine 
phosphoribosyltransferase 1 
purine salvage; 
nucleoside metabolism; 
behavior 
0.1967 5.08 0.0018 
NM_000290 NM_000290 
phosphoglycerate mutase 2 
(muscle) 
striated muscle 
contraction; glycolysis; 
metabolism 
0.1970 5.08 0.0004 
Y14039 NM_003879 CASP8 and FADD-like apoptosis 
regulator 
induction of apoptosis by 
extracellular signals; 
anti-apoptosis; 
proteolysis and 
peptidolysis 
0.1971 5.07 0.0024 
BC010282 NM_133259 leucine-rich PPR motif-containing 
protein 
biological_process 
unknown 
0.1972 5.07 0.0002 
AF272348  zinc-finger protein DZIPt1  0.1973 5.07 0.0085 
AB029316 
NM_015435; 
NM_183419 
ring finger protein 19 
microtubule cytoskeleton 
organization and 
biogenesis; protein 
modification 
0.1975 5.06 0.0017 
D80010 NM_145693 lipin 1 adipocyte differentiation 0.1977 5.06 0.0002 
NM_000904 NM_000904 NAD(P)H dehydrogenase, quinone 
2 
electron transport 0.1983 5.04 0.0074 
AK000872    0.1984 5.04 0.0013 
NM_002970 NM_002970 spermidine/spermine N1-
acetyltransferase 
 0.1988 5.03 0.0004 
NM_021103 NM_021103 thymosin, beta 10 
spermatid development; 
cytoskeleton organization 
and biogenesis 
0.1992 5.02 0.0091 
AF226044 NM_017719 HSNFRK  0.1992 5.02 0.0021 
AB023198 NM_015040 
phosphatidylinositol-3-
phosphate/phosphatidylinositol 5-
kinase, type III 
intracellular signaling 
cascade 
0.1994 5.02 0.0009 
NM_033124 NM_033124 NYD-SP28 protein  0.1998 5.00 0.0088 
NM_031943 NM_031943 IFP38 translational initiation 0.1999 5.00 0.0059 
NM_005313 NM_005313 glucose regulated protein, 58kDa 
protein-nucleus import; 
protein-ER retention; 
electron transport; signal 
transduction 
0.2001 5.00 0.0025 
NM_002902 NM_002902 reticulocalbin 2, EF-hand calcium 
binding domain 
 0.2003 4.99 0.0050 
AB046821 NM_007159 sarcolemma associated protein muscle contraction 0.2004 4.99 0.0019 
AK058139 NM_144605 hypothetical protein FLJ25410 cell cycle 0.2004 4.99 0.0121 
NM_003137 NM_003137 SFRS protein kinase 1 protein amino acid 
phosphorylation 
0.2004 4.99 0.0008 
AY027808 NM_130784 hypothetical telomeric protein  0.2005 4.99 0.0074 
NM_016447 NM_016447 membrane protein, palmitoylated 
6 
protein complex 
assembly 
0.2005 4.99 0.0000 
NM_006002 NM_006002 
ubiquitin carboxyl-terminal 
esterase L3 (ubiquitin 
thiolesterase) 
ubiquitin-dependent 
protein catabolism 
0.2006 4.99 0.0000 
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NM_015251 NM_015251 KIAA0431 protein  0.2008 4.98 0.0035 
NM_006870 NM_006870 
destrin (actin depolymerizing 
factor) 
actin polymerization 
and/or depolymerization 0.2008 4.98 0.0084 
NM_002056 NM_002056 glucosamine-fructose-6-phosphate 
aminotransferase 
energy reserve 
metabolism; fructose 6-
phosphate metabolism; 
carbohydrate 
metabolism; glutamine 
metabolism 
0.2010 4.97 0.0019 
NM_003948 NM_003948 cyclin-dependent kinase-like 2 
sex differentiation; 
protein amino acid 
phosphorylation; signal 
transduction 
0.2011 4.97 0.0021 
NM_018844 NM_018844 B-cell receptor-associated protein 
BAP29 
intracellular protein 
transport; apoptosis 
0.2012 4.97 0.0051 
NM_006585 NM_006585 chaperonin containing TCP1, 
subunit 8 (theta) 
 0.2013 4.97 0.0018 
NM_003796 
NM_003796; 
NM_134447 
RPB5-mediating protein isoform a; 
RPB5-mediating protein isoform b 
pathogenesis; protein 
folding; regulation of 
transcription from Pol II 
promoter 
0.2014 4.97 0.0084 
NM_013233 NM_013233 
serine threonine kinase 39 
(STE20/SPS1 homolog, yeast) 
response to stress; 
protein amino acid 
phosphorylation 
0.2015 4.96 0.0028 
NM_006417 NM_006417 
interferon-induced, hepatitis C-
associated microtubular aggregat 
response to virus; 
invasive growth 
0.2015 4.96 0.0053 
NM_006294 NM_006294 
ubiquinol-cytochrome c reductase 
binding protein 
oxidative 
phosphorylation; aerobic 
respiration; electron 
transport; mitochondrial 
electron transport, 
ubiquinol to cytochrome 
c 
0.2017 4.96 0.0136 
AK026843    0.2017 4.96 0.0003 
NM_016607 
NM_016607; 
NM_177947; 
NM_177948 
ALEX3 protein  0.2017 4.96 0.0026 
NM_032368 NM_032368 leucine zipper and CTNNBIP1 
domain containing 
 0.2018 4.95 0.0053 
AF039442  colon cancer antigen NY-CO-45  0.2020 4.95 0.0054 
NM_004708 NM_004708 programmed cell death 5 induction of apoptosis 0.2021 4.95 0.0078 
NM_004446 NM_004446 glutamyl-prolyl tRNA synthetase 
glutamyl-tRNA 
aminoacylation; prolyl-
tRNA aminoacylation; 
protein complex 
assembly 
0.2022 4.95 0.0094 
NM_003118 NM_003118 
secreted protein, acidic, cysteine-
rich (osteonectin) ossification 0.2026 4.94 0.0264 
NM_018322 NM_018322 hypothetical protein FLJ11101  0.2026 4.94 0.0105 
NM_002262 
NM_002262; 
NM_007334 
killer cell lectin-like receptor 
subfamily D, member 1 isoform 1; 
killer cell lectin-like receptor 
subfamily D, member 1 isoform 2 
cell surface receptor 
linked signal 
transduction; heterophilic 
cell adhesion; 
antimicrobial humoral 
response (sensu 
Vertebrata) 
0.2027 4.93 0.0003 
NM_015895 NM_015895 geminin 
negative regulation of 
DNA replication; cell 
cycle arrest 
0.2030 4.93 0.0019 
NM_014372 NM_014372 ring finger protein 11 oncogenesis 0.2032 4.92 0.0006 
NM_007054 NM_007054 kinesin family member 3A organelle organization 
and biogenesis 
0.2033 4.92 0.0000 
NM_002355 NM_002355 
cation-dependent mannose-6-
phosphate receptor precursor 
endosome to lysosome 
transport; receptor 
mediated endocytosis 
0.2034 4.92 0.0015 
NM_004339 NM_004339 
pituitary tumor-transforming gene 
1 protein-interacting protein 
precursor 
protein-nucleus import; 
development 
0.2034 4.92 0.0077 
NM_003462 NM_003462 axonemal dynein light chain cell motility; fertilization 0.2035 4.91 0.0049 
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AK057157 NM_002869; 
NM_198896 
RAB6A, member RAS oncogene 
family isoform a; RAB6A, member 
RAS oncogene family isoform b 
small GTPase mediated 
signal transduction; 
nonselective vesicle 
transport; intracellular 
protein transport 
0.2036 4.91 0.0026 
AF218029 NM_005324 H3 histone, family 3B 
nucleosome assembly; 
chromosome 
organization and 
biogenesis (sensu 
Eukarya) 
0.2037 4.91 0.0097 
NM_001030 NM_001030 ribosomal protein S27 
protein biosynthesis; cell 
proliferation; signal 
transduction 
0.2038 4.91 0.0095 
NM_003908 NM_003908 eukaryotic translation initiation 
factor 2 beta 
translational initiation 0.2044 4.89 0.0029 
NM_000179 NM_000179 mutS homolog 6 oncogenesis; mismatch 
repair 
0.2048 4.88 0.0027 
NM_005752 NM_005752 
C-type lectin, superfamily member 
1 
skeletal development; 
heterophilic cell adhesion 0.2049 4.88 0.0036 
AK027789 NM_178862 
source of immunodominant MHC-
associated peptides 
protein amino acid 
glycosylation 
0.2054 4.87 0.0000 
NM_007045 
NM_007045; 
NM_194429 
FGFR1 oncogene partner isoform 
a; FGFR1 oncogene partner 
isoform b 
positive regulation of cell 
proliferation; 
oncogenesis 
0.2054 4.87 0.0076 
NM_001028 NM_001028 ribosomal protein S25 protein biosynthesis 0.2054 4.87 0.0213 
NM_001068 NM_001068 DNA topoisomerase II, beta 
isozyme 
regulation of 
transcription, DNA-
dependent; DNA 
metabolism; DNA 
topological change 
0.2054 4.87 0.0029 
NM_004280 NM_004280 
eukaryotic translation elongation 
factor 1 epsilon 1 protein biosynthesis 0.2059 4.86 0.0144 
NM_002266 NM_002266 karyopherin alpha 2 
regulation of DNA 
recombination; G2 phase 
of mitotic cell cycle; NLS-
bearing substrate-
nucleus import; 
intracellular protein 
transport; DNA 
metabolism; M-phase 
specific microtubule 
process 
0.2060 4.86 0.0180 
NM_018365 NM_018365 meiosis-specific nuclear structural 
protein 1 
 0.2061 4.85 0.0083 
NM_014269 
NM_014269; 
NM_021779; 
NM_021780 
a disintegrin and metalloproteinase 
domain 29 isoform 1 
preproprotein; a disintegrin and 
metalloproteinase domain 29 
isoform 3 preproprotein; a 
disintegrin and metalloproteinase 
domain 29 isoform 2 preproprotein 
proteolysis and 
peptidolysis; 
spermatogenesis 
0.2062 4.85 0.0071 
NM_022551 NM_022551 ribosomal protein S18 protein biosynthesis 0.2062 4.85 0.0149 
NM_002904 NM_002904 RD RNA-binding protein  0.2067 4.84 0.0056 
AK001693 NM_015420 DKFZP564O0463 protein  0.2071 4.83 0.0054 
NM_032597 NM_032597 testes development-related NYD-
SP21 
 0.2072 4.83 0.0030 
NM_032598 NM_032598 testes development-related NYD-
SP20 
 0.2072 4.83 0.0098 
NM_023008 
NM_023008; 
NM_178159 
hypothetical protein FLJ12949 
isoform 1; hypothetical protein 
FLJ12949 isoform 2 
 0.2075 4.82 0.0040 
NM_004396 NM_004396 DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 5 
cell growth 0.2075 4.82 0.0177 
AB011173 NM_015013 KIAA0601 protein  0.2078 4.81 0.0081 
AL050018 NM_015525 hypothetical protein  0.2079 4.81 0.0074 
NM_001539 NM_001539 DnaJ (Hsp40) homolog, subfamily 
A, member 1 
protein folding; heat 
shock response 
0.2083 4.80 0.0088 
NM_005745 NM_005745 
B-cell receptor-associated protein 
31 
intracellular protein 
transport; apoptosis; 
immune response 
0.2086 4.79 0.0113 
NM_001122 NM_001122 adipose differentiation-related 
protein 
 0.2086 4.79 0.0278 
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NM_015909 NM_015909 neuroblastoma-amplified protein protein biosynthesis 0.2087 4.79 0.0103 
AL136719 NM_006717 spindlin gametogenesis 0.2087 4.79 0.0013 
NM_015653 NM_015653 hypothetical protein MGC4107  0.2088 4.79 0.0031 
NM_078469 
NM_016567; 
NM_078468; 
NM_078469 
BRCA2 and CDKN1A-interacting 
protein isoform BCCIPalpha; 
BRCA2 and CDKN1A-interacting 
protein isoform BCCIPbeta; BRCA2 
and CDKN1A-interacting protein 
isoform C 
regulation of CDK activity 0.2089 4.79 0.0190 
NM_031446 NM_031446 hypothetical protein PNAS-131  0.2089 4.79 0.0130 
BC001082 NM_015448 DKFZP566F084 protein  0.2089 4.79 0.0009 
BC011981 NM_138414 hypothetical protein BC011981  0.2090 4.78 0.0113 
AY009106 NM_015668 DKFZP434I092 protein  0.2092 4.78 0.0133 
AK055491 NM_001378 dynein, cytoplasmic, intermediate 
polypeptide 2 
microtubule-based 
movement 
0.2099 4.77 0.0098 
NM_021634 NM_021634 
leucine-rich repeat-containing G 
protein-coupled receptor 7 
G-protein coupled 
receptor protein signaling 
pathway; signal 
transduction 
0.2099 4.76 0.0020 
NM_016271 
NM_016271; 
NM_198128 
ring finger protein 138 isoform 1; 
ring finger protein 138 isoform 2  0.2100 4.76 0.0142 
NM_031210 NM_031210 hypothetical protein DC50  0.2101 4.76 0.0084 
NM_018186 NM_018186 hypothetical protein FLJ10706 proteolysis and 
peptidolysis 
0.2103 4.76 0.0007 
NM_018693 
NM_012167; 
NM_018693; 
NM_025133 
F-box only protein 11 isoform 3; F-
box only protein 11 isoform 2; F-
box only protein 11 isoform 1 
ubiquitin cycle; ubiquitin-
dependent protein 
catabolism; protein 
modification 
0.2103 4.76 0.0018 
NM_003715 NM_003715 vesicle docking protein p115 
nonselective vesicle 
docking; intracellular 
protein transport 
0.2109 4.74 0.0089 
AL132665 NM_004331 
BCL2/adenovirus E1B 19kD-
interacting protein 3-like 
negative regulation of 
survival gene products; 
induction of apoptosis 
0.2116 4.73 0.0033 
NM_004261 NM_004261 15 kDa selenoprotein  0.2118 4.72 0.0023 
NM_005006 NM_005006 
NADH dehydrogenase (ubiquinone) 
Fe-S protein 1, 75kDa precursor 
complex I (NADH to 
ubiquinone) 
0.2119 4.72 0.0017 
NM_000365 NM_000365 triosephosphate isomerase 1 
pentose-phosphate 
shunt; glycolysis; 
gluconeogenesis; 
metabolism; fatty acid 
biosynthesis 
0.2119 4.72 0.0129 
AK058124 NM_144722 hypothetical protein FLJ25395  0.2119 4.72 0.0047 
AL137345    0.2125 4.71 0.0076 
NM_012341 NM_012341 G protein-binding protein CRFG  0.2127 4.70 0.0078 
NM_003618 NM_003618 mitogen-activated protein kinase 
kinase kinase kinase 3 
protein kinase cascade; 
response to stress; 
protein amino acid 
phosphorylation 
0.2127 4.70 0.0008 
NM_015904 NM_015904 translation initiation factor IF2 
regulation of 
transcription, DNA-
dependent; regulation of 
translational initiation; 
protein biosynthesis 
0.2129 4.70 0.0059 
NM_004766 NM_004766 
coatomer protein complex, subunit 
beta 2 (beta prime) 
intracellular protein 
transport; exocytosis 
0.2129 4.70 0.0004 
NM_020186 NM_020186 ACN9 homolog  0.2132 4.69 0.0152 
NM_021114 NM_021114 
serine protease inhibitor, Kazal 
type, 2 (acrosin-trypsin inhibitor) 
 0.2133 4.69 0.0126 
NM_000018 NM_000018 acyl-Coenzyme A dehydrogenase, 
very long chain precursor 
fatty acid beta-oxidation; 
energy derivation by 
oxidation of organic 
compounds; electron 
transport; fatty acid 
metabolism 
0.2134 4.69 0.0065 
NM_002951 NM_002951 ribophorin II precursor protein modification 0.2135 4.68 0.0021 
AB037810  KIAA1389 protein  0.2137 4.68 0.0001 
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NM_000988 NM_000988 ribosomal protein L27  0.2139 4.68 0.0093 
NM_006696 
NM_006696; 
NM_139199; 
NM_183359 
bromodomain containing 8 isoform 
1; bromodomain containing 8 
isoform 2; bromodomain 
containing 8 isoform 3 
cell surface receptor 
linked signal 
transduction; regulation 
of transcription from Pol 
II promoter 
0.2139 4.67 0.0022 
AL162039    0.2142 4.67 0.0009 
NM_003755 NM_003755 
eukaryotic translation initiation 
factor 3, subunit 4 delta, 44kDa 
regulation of 
translational initiation; 
protein biosynthesis 
0.2146 4.66 0.0079 
NM_032891 NM_032891 WD domain, G-beta repeat-
containing protein 
 0.2148 4.66 0.0061 
NM_006429 NM_006429 chaperonin containing TCP1, 
subunit 7 (eta) 
protein folding; 
regulation of cell cycle 
0.2148 4.65 0.0107 
AK057820    0.2150 4.65 0.0103 
AJ306929 NM_024524 
ATPase family homolog up-
regulated in senescence cells 
cation transport; 
metabolism 
0.2150 4.65 0.0017 
BC010062  Unknown (protein for 
IMAGE:3953648) 
 0.2152 4.65 0.0119 
NM_016127 NM_016127 hypothetical protein MGC8721  0.2152 4.65 0.0131 
AL079314 NM_014455 zinc finger protein 364  0.2153 4.64 0.0079 
NM_024098 NM_024098 hypothetical protein MGC2574 
regulation of 
transcription, DNA-
dependent 
0.2156 4.64 0.0114 
NM_032364 NM_032364 dopamine receptor interacting 
protein 
 0.2157 4.64 0.0007 
NM_004168 NM_004168 
succinate dehydrogenase complex, 
subunit A, flavoprotein precursor 
aerobic respiration; 
tricarboxylic acid cycle 0.2158 4.63 0.0069 
NM_016106 
NM_016106; 
NM_182835 
vesicle transport-related protein 
isoform a; vesicle transport-
related protein isoform b 
 0.2160 4.63 0.0028 
NM_002013 NM_002013 FK506-binding protein 3 protein folding 0.2163 4.62 0.0133 
AF353674 NM_033271 BTB domain protein BDPL  0.2168 4.61 0.0047 
NM_024606 NM_024606 hypothetical protein FLJ11756  0.2169 4.61 0.0000 
NM_032288 NM_032288 hypothetical protein 
DKFZp761B1514 
 0.2172 4.60 0.0029 
NM_016587 NM_007276; 
NM_016587 
chromobox homolog 3 
chromatin 
assembly/disassembly; 
regulation of 
transcription, DNA-
dependent; chromatin 
modification 
0.2172 4.60 0.0014 
NM_002792 
NM_002792; 
NM_152255 
proteasome alpha 7 subunit 
isoform 1; proteasome alpha 7 
subunit isoform 2 
ubiquitin-dependent 
protein catabolism 
0.2175 4.60 0.0064 
NM_031157 NM_002136; 
NM_031157 
heterogeneous nuclear 
ribonucleoprotein A1 isoform a; 
heterogeneous nuclear 
ribonucleoprotein A1 isoform b 
RNA-nucleus export; 
mRNA processing 
0.2175 4.60 0.0155 
NM_016141 NM_016141 dynein light chain-A 
small GTPase mediated 
signal transduction 0.2176 4.60 0.0030 
AK058070    0.2176 4.60 0.0017 
AL354915    0.2176 4.60 0.0093 
NM_007263 NM_007263 coatomer protein complex, subunit 
epsilon 
nonselective vesicle 
transport; intracellular 
protein transport; 
antimicrobial humoral 
response (sensu 
Vertebrata) 
0.2177 4.59 0.0023 
AB037741 NM_020771 
HECT domain and ankyrin repeat 
containing, E3 ubiquitin protein 
ligase 1 
ubiquitin cycle 0.2180 4.59 0.0134 
AL161957 NM_017934 pleckstrin homology domain 
interacting protein 
 0.2182 4.58 0.0064 
NM_004865 NM_004865 TBP-like 1 
transcription initiation 
from Pol II promoter; 
regulation of 
transcription, DNA-
dependent 
0.2182 4.58 0.0041 
AK058144 NM_144708 hypothetical protein FLJ25415  0.2182 4.58 0.0075 
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AL110274 
NM_003888; 
NM_170696; 
NM_170697 
aldehyde dehydrogenase 1A2 
isoform 1; aldehyde 
dehydrogenase 1A2 isoform 2; 
aldehyde dehydrogenase 1A2 
isoform 3 
vitamin A metabolism; 
oncogenesis 
0.2183 4.58 0.0005 
NM_020188 NM_020188 DC13 protein  0.2184 4.58 0.0011 
AF073310 NM_003749 insulin receptor substrate 2  0.2191 4.56 0.0018 
NM_014966 
NM_014966; 
NM_138614; 
NM_138615 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 30 isoform 2; DEAH 
(Asp-Glu-Ala-His) box polypeptide 
30 isoform 3; DEAH (Asp-Glu-Ala-
His) box polypeptide 30 isoform 1 
 0.2191 4.56 0.0106 
BC002971 NM_012073 chaperonin containing TCP1, 
subunit 5 (epsilon) 
protein folding 0.2192 4.56 0.0165 
NM_058216 
NM_002876; 
NM_058216; 
NM_058217 
RAD51 homolog C isoform 2; 
RAD51 homolog C isoform 1; 
RAD51 homolog C isoform 3 
DNA repair; DNA 
recombination 
0.2192 4.56 0.0005 
AB053313    0.2192 4.56 0.0066 
NM_001827 NM_001827 CDC28 protein kinase 2 
regulation of CDK 
activity; cell cycle; 
cytokinesis 
0.2196 4.55 0.0017 
NM_001515 NM_001515 
general transcription factor IIH, 
polypeptide 2, 44kD subunit 
regulation of 
transcription, DNA-
dependent; DNA repair 
0.2196 4.55 0.0034 
BC007344  Similar to RIKEN cDNA 
4833415E20 gene 
 0.2198 4.55 0.0099 
NM_032830 NM_032830 cirhin  0.2204 4.54 0.0032 
NM_006304 NM_006304 candidate for split hand/foot 
malformation type 1 
biological_process 
unknown 
0.2204 4.54 0.0158 
AL049246    0.2205 4.54 0.0008 
AL080111 NM_133494 NIMA (never in mitosis gene a)-
related kinase 7 
protein amino acid 
phosphorylation 
0.2205 4.54 0.0012 
AK024475  FLJ00068 protein  0.2207 4.53 0.0027 
NM_031858 
NM_005899; 
NM_031858; 
NM_031862 
membrane component, 
chromosome 17, surface marker 2 
 0.2210 4.52 0.0137 
NM_003619 NM_003619 neurotrypsin precursor proteolysis and 
peptidolysis 
0.2213 4.52 0.0069 
NM_006324 NM_006324 craniofacial development protein 1  0.2213 4.52 0.0092 
NM_018997 
NM_018997; 
NM_031901 
mitochondrial ribosomal protein 
S21 
 0.2219 4.51 0.0023 
NM_013320 NM_013320 host cell factor 2 
viral life cycle; transport; 
regulation of 
transcription from Pol II 
promoter 
0.2220 4.50 0.0037 
NM_001358 NM_001358 DEAH (Asp-Glu-Ala-His) box 
polypeptide 15 
nuclear mRNA splicing, 
via spliceosome 
0.2221 4.50 0.0002 
AB029551 NM_012234 RING1 and YY1 binding protein 
regulation of 
transcription, DNA-
dependent 
0.2221 4.50 0.0050 
NM_021129 NM_021129 inorganic pyrophosphatase phosphate metabolism 0.2222 4.50 0.0006 
NM_018297 NM_018297 N-glycanase 1  0.2226 4.49 0.0080 
AL133596    0.2228 4.49 0.0023 
AF033199    0.2230 4.49 0.0066 
AB067486 NM_052903 tubulin, gamma complex 
associated protein 5 
microtubule nucleation 0.2230 4.48 0.0043 
NM_001685 NM_001685 
ATP synthase, H+ transporting, 
mitochondrial precursor 
proton transport; energy 
pathways 0.2231 4.48 0.0060 
AK001134    0.2231 4.48 0.0011 
NM_001022 NM_001022 ribosomal protein S19 
hemocyte development; 
protein biosynthesis 0.2235 4.47 0.0123 
NM_016359 
NM_016359; 
NM_018454 
clone HQ0310 PRO0310p1; 
nucleolar and spindle associated 
protein 1 
 0.2237 4.47 0.0022 
NM_018491 NM_018491 COBW-like protein  0.2238 4.47 0.0133 
AK024327    0.2241 4.46 0.0043 
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NM_032930 NM_032930 hypothetical protein MGC13040  0.2242 4.46 0.0012 
NM_006206 NM_006206 
platelet-derived growth factor 
receptor alpha precursor 
transmembrane receptor 
protein tyrosine kinase 
signaling pathway; 
protein amino acid 
phosphorylation; cell 
surface receptor linked 
signal transduction; cell 
proliferation 
0.2243 4.46 0.0045 
NM_001912 
NM_001912; 
NM_145918 cathepsin L preproprotein 
proteolysis and 
peptidolysis 0.2244 4.46 0.0025 
AB037791  KIAA1370 protein  0.2244 4.46 0.0002 
NM_003418 NM_003418 zinc finger protein 9 
cholesterol biosynthesis; 
regulation of 
transcription, DNA-
dependent 
0.2248 4.45 0.0101 
NM_003453 
NM_003453; 
NM_197968 
zinc finger protein 198  0.2248 4.45 0.0040 
AK000315 NM_017758 hypothetical protein FLJ20308  0.2251 4.44 0.0041 
NM_004336 NM_004336 BUB1 budding uninhibited by 
benzimidazoles 1 homolog 
mitotic spindle 
checkpoint; cell cycle; 
mitosis; protein amino 
acid phosphorylation 
0.2255 4.44 0.0023 
NM_014883 NM_014883 family with sequence similarity 13, 
member A1 
 0.2260 4.43 0.0032 
NM_014368 NM_014368 LIM homeobox protein 6 isoform 1 
brain development; 
regulation of 
transcription, DNA-
dependent 
0.2260 4.42 0.0059 
AK057204 NM_152415 hypothetical protein FLJ32642  0.2260 4.42 0.0078 
AF263613  
membrane-associated calcium-
independent phospholipase A2 
gamma 
 0.2264 4.42 0.0013 
AY040873  C21orf57 isoform A protein  0.2264 4.42 0.0039 
NM_001551 NM_001551 immunoglobulin (CD79A) binding 
protein 1 
response to biotic 
stimulus; B-cell 
activation; regulation of 
signal transduction 
0.2265 4.42 0.0038 
NM_006251 NM_006251 
protein kinase, AMP-activated, 
alpha 1 catalytic subunit 
protein amino acid 
phosphorylation; signal 
transduction 
0.2266 4.41 0.0012 
NM_001618 NM_001618 poly(ADP-ribosyl)transferase 
protein amino acid ADP-
ribosylation; cell growth 
and/or maintenance; 
DNA repair; transcription 
from Pol II promoter 
0.2267 4.41 0.0010 
AL121886    0.2275 4.40 0.0135 
AK055070 NM_174909 hypothetical protein MGC23909  0.2280 4.39 0.0023 
NM_006292 NM_006292 tumor susceptibility gene 101 
ubiquitin cycle; 
intracellular protein 
transport; regulation of 
cell growth 
0.2280 4.39 0.0020 
NM_013417 
NM_002161; 
NM_013417 
isoleucine-tRNA synthetase 
isoleucyl-tRNA 
aminoacylation 
0.2284 4.38 0.0029 
NM_002717 NM_002717 
alpha isoform of regulatory subunit 
B55, protein phosphatase 2 
signal transduction; 
protein amino acid 
dephosphorylation 
0.2284 4.38 0.0012 
NM_005445 NM_005445 
chondroitin sulfate proteoglycan 6 
(bamacan) 
mitotic spindle assembly; 
sister chromatid 
cohesion; meiosis; 
chromosome 
segregation; transport; 
cell cycle; DNA repair; 
signal transduction 
0.2285 4.38 0.0008 
NM_002018 NM_002018 flightless I homolog muscle contraction; 
development 
0.2287 4.37 0.0075 
NM_012394 NM_012394 prefoldin 2 protein folding 0.2290 4.37 0.0122 
AL050006 
NM_015522; 
NM_016008 
dynein 2 light intermediate chain 
isoform 2; dynein 2 light 
intermediate chain isoform 1 
 0.2293 4.36 0.0052 
NM_018447 NM_018447 30 kDa protein  0.2295 4.36 0.0051 
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NM_032273 NM_032273 hypothetical protein 
DKFZp586C1924 
 0.2296 4.36 0.0003 
AK057575 
NM_002635; 
NM_005888 
phosphate carrier precursor 
isoform 1b; phosphate carrier 
precursor isoform 1a 
transport; energy 
pathways 0.2297 4.35 0.0030 
NM_005805 NM_005805 26S proteasome-associated pad1 
homolog 
ubiquitin-dependent 
protein catabolism 
0.2297 4.35 0.0143 
AB023163 NM_015336 huntingtin interacting protein 14  0.2298 4.35 0.0036 
NM_023011 NM_023011; 
NM_080687 
UPF3 regulator of nonsense 
transcripts homolog A isoform 
hUpf3p; UPF3 regulator of 
nonsense transcripts homolog A 
isoform hUpf3pdelta 
 0.2303 4.34 0.0013 
NM_024570 NM_024570 hypothetical protein FLJ11712  0.2304 4.34 0.0021 
NM_018171 NM_018171 DIP13 beta  0.2310 4.33 0.0054 
NM_032043 NM_032043 BRCA1 interacting protein C-
terminal helicase 1 
nucleotide-excision repair 0.2311 4.33 0.0063 
BC001511 NM_007277 Sec6 protein intracellular protein 
transport; exocytosis 
0.2312 4.32 0.0027 
AK054750    0.2316 4.32 0.0006 
NM_002574 
NM_002574; 
NM_181696; 
NM_181697 
peroxiredoxin 1 skeletal development; 
cell proliferation 
0.2317 4.32 0.0087 
NM_016004 NM_016004 chromosome 20 open reading 
frame 9 
 0.2317 4.32 0.0087 
NM_013236 NM_013236 like mouse brain protein E46  0.2318 4.31 0.0028 
AK057677    0.2318 4.31 0.0046 
NM_002906 NM_002906 radixin cytoskeletal anchoring 0.2318 4.31 0.0055 
NM_004805 NM_004805 DNA directed RNA polymerase II 
polypeptide D 
transcription from Pol II 
promoter 
0.2318 4.31 0.0080 
NM_005390 NM_005390 pyruvate dehydrogenase 
(lipoamide) alpha 2 
glycolysis; metabolism 0.2321 4.31 0.0021 
AK001750 NM_018309 hypothetical protein FLJ11046  0.2322 4.31 0.0008 
NM_002786 
NM_002786; 
NM_148976 
proteasome alpha 1 subunit 
isoform 2; proteasome alpha 1 
subunit isoform 1 
ubiquitin-dependent 
protein catabolism 
0.2327 4.30 0.0043 
NM_014487 NM_014487 zinc finger protein 330 electron transport; 
mitosis 
0.2328 4.30 0.0068 
NM_016078 NM_016078 CGI-148 protein  0.2333 4.29 0.0006 
NM_003084 NM_003084 small nuclear RNA activating 
complex, polypeptide 3, 50kDa 
snRNA transcription; 
transcription from Pol III 
promoter; regulation of 
transcription, DNA-
dependent; transcription 
from Pol II promoter 
0.2334 4.28 0.0037 
NM_006357 
NM_006357; 
NM_182678 
ubiquitin-conjugating enzyme E2E 
3 ubiquitin cycle 0.2340 4.27 0.0013 
AJ243706 NM_006618 putative DNA/chromatin binding 
motif 
oncogenesis 0.2340 4.27 0.0037 
NM_006827 NM_006827 transmembrane trafficking protein 
ER to Golgi transport; 
intracellular protein 
transport 
0.2342 4.27 0.0004 
BC008739 NM_020141 protein x 013  0.2342 4.27 0.0064 
AK026980    0.2343 4.27 0.0135 
AB051551  KIAA1764 protein  0.2343 4.27 0.0146 
NM_024624 NM_024624 SMC6 protein  0.2344 4.27 0.0109 
NM_003720 NM_003720 Down syndrome critical region 
protein 2 
 0.2347 4.26 0.0053 
NM_012381 
NM_012381; 
NM_181837 
origin recognition complex, subunit 
3 isoform 2; origin recognition 
complex, subunit 3 isoform 1 
DNA replication 0.2351 4.25 0.0094 
NM_013330 
NM_013330; 
NM_197972 
nucleoside-diphosphate kinase 7 
isoform a; nucleoside-diphosphate 
kinase 7 isoform b 
GTP biosynthesis; UTP 
biosynthesis; CTP 
biosynthesis 
0.2353 4.25 0.0016 
NM_031924 NM_031924 radial spokehead-like 2  0.2354 4.25 0.0095 
NM_018838 NM_018838 13kDa differentiation-associated 
protein 
 0.2354 4.25 0.0088 
NM_005552 
NM_005552; 
NM_182923 kinesin 2 60/70kDa  0.2356 4.25 0.0063 
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NM_004891 
NM_004891; 
NM_145330 
mitochondrial ribosomal protein 
L33 isoform a; mitochondrial 
ribosomal protein L33 isoform b 
protein biosynthesis 0.2356 4.24 0.0050 
NM_024047 
NM_024047; 
NM_198038; 
NM_198039 
nudix -type motif 9 isoform a; 
nudix -type motif 9 isoform b 
 0.2359 4.24 0.0091 
NM_006758 NM_006758 U2 small nuclear RNA auxillary 
factor 1 
RNA splicing; regulation 
of transcription, DNA-
dependent; nuclear 
mRNA splicing, via 
spliceosome 
0.2360 4.24 0.0109 
NM_032179 
NM_017871; 
NM_032179 
hypothetical protein FLJ20542  0.2360 4.24 0.0174 
NM_018685 NM_018685 
anillin, actin binding protein 
(scraps homolog, Drosophila) 
regulation of exit from 
mitosis; septin assembly 
and septum formation 
0.2361 4.24 0.0008 
BC008804 NM_015697 hypothetical protein CL640  0.2361 4.24 0.0173 
AK057323 NM_182755 hypothetical protein LOC220929  0.2362 4.23 0.0066 
NM_002069 NM_002069 
guanine nucleotide binding protein 
(G protein), alpha inhibiting 
activity polypeptide 1 
G-protein coupled 
receptor protein signaling 
pathway; signal 
transduction 
0.2363 4.23 0.0037 
AF070578 NM_153811 
N system amino acid transporter 
NAT-1 
amino acid transport; 
regulation of 
transcription, DNA-
dependent 
0.2365 4.23 0.0056 
AK057477 NM_145014 hypothetical protein FLJ32915  0.2365 4.23 0.0051 
NM_022457 NM_022457 constitutive photomorphogenic 
protein 
 0.2370 4.22 0.0069 
NM_005614 NM_005614 Ras homolog enriched in brain 
small GTPase mediated 
signal transduction 0.2371 4.22 0.0086 
NM_004370 
NM_004370; 
NM_080645 
alpha 1 type XII collagen long 
isoform precursor; alpha 1 type 
XII collagen short isoform 
precursor 
skeletal development 0.2375 4.21 0.0073 
NM_003094 NM_003094 small nuclear ribonucleoprotein 
polypeptide E 
spliceosome assembly 0.2375 4.21 0.0156 
AL135926    0.2377 4.21 0.0085 
BC014608 NM_138796 hypothetical protein BC014608  0.2378 4.21 0.0166 
NM_000216 NM_000216 Kallmann syndrome 1 protein 
axon guidance; 
chemotaxis; cell 
adhesion; cell motility 
0.2382 4.20 0.0022 
NM_015684 NM_015684 
mitochondrial ATP synthase 
regulatory component factor B  0.2383 4.20 0.0015 
NM_004792 NM_004792 peptidyl-prolyl isomerase G 
(cyclophilin G) 
RNA splicing; protein 
folding 
0.2385 4.19 0.0106 
NM_003318 NM_003318 TTK protein kinase 
mitotic spindle assembly; 
mitotic spindle 
checkpoint; positive 
regulation of cell 
proliferation; protein 
amino acid 
phosphorylation; 
regulation of cell cycle 
0.2386 4.19 0.0017 
NM_032133 NM_032133 Myc-binding protein-associated 
protein 
 0.2386 4.19 0.0133 
NM_006531 
NM_006531; 
NM_175605 
Tg737 protein isoform 2; Tg737 
protein isoform 1 
excretion 0.2387 4.19 0.0026 
NM_016262 NM_016262 tubulin, epsilon 1 
microtubule-based 
movement; centrosome 
cycle 
0.2389 4.19 0.0012 
NM_005085 NM_005085 nucleoporin 214kDa 
nucleocytoplasmic 
transport; oncogenesis 0.2390 4.18 0.0069 
AF159141 NM_015399 breast cancer metastasis 
suppressor 1 
 0.2391 4.18 0.0049 
NM_014713 NM_014713 
lysosomal-associated protein 
transmembrane 4 alpha transport 0.2391 4.18 0.0240 
NM_015442 NM_015442 CCR4-NOT transcription complex, 
subunit 10 
 0.2392 4.18 0.0015 
AK057730    0.2393 4.18 0.0006 
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AF090094    0.2393 4.18 0.0191 
AB018271 
NM_001723; 
NM_015548; 
NM_020388; 
NM_183380 
bullous pemphigoid antigen 1 
isoform 1e precursor; bullous 
pemphigoid antigen 1 isoform 1eA 
precursor; bullous pemphigoid 
antigen 1 isoform 1eB precursor 
cytoskeleton organization 
and biogenesis 0.2394 4.18 0.0003 
NM_024580 NM_024580 hypothetical protein FLJ13119  0.2394 4.18 0.0071 
NM_005025 NM_005025 
serine (or cysteine) proteinase 
inhibitor, clade I (neuroserpin), 
member 1 
peripheral nervous 
system development; 
central nervous system 
development 
0.2394 4.18 0.0051 
NM_012433 NM_012433 splicing factor 3b, subunit 1, 
155kDa 
nuclear mRNA splicing, 
via spliceosome 
0.2396 4.17 0.0014 
BC009561 NM_138787 hypothetical protein BC009561  0.2398 4.17 0.0072 
NM_005038 NM_005038 peptidylprolyl isomerase D 
(cyclophilin D) 
protein folding 0.2399 4.17 0.0049 
NM_001813 NM_001813 centromere protein E 
mitotic metaphase plate 
congression; mitotic 
chromosome movement; 
DNA replication and 
chromosome cycle; 
cytokinesis 
0.2400 4.17 0.0009 
NM_005534 NM_005534 interferon gamma receptor 2 
(interferon gamma transducer 1) 
response to pathogenic 
bacteria; response to 
virus; cell surface 
receptor linked signal 
transduction 
0.2404 4.16 0.0010 
NM_024619 NM_024619 hypothetical protein FLJ12171  0.2405 4.16 0.0186 
NM_006811 
NM_006811; 
NM_198941 
tumor differentially expressed 
protein 1 
 0.2405 4.16 0.0025 
NM_003620 NM_003620 protein phosphatase 1D 
response to radiation; 
negative regulation of 
cell proliferation; 
regulation of cell cycle; 
protein amino acid 
dephosphorylation 
0.2405 4.16 0.0094 
NM_007192 NM_007192 chromatin-specific transcription 
elongation factor large subunit 
nucleosome disassembly; 
proteolysis and 
peptidolysis; 
transcription from Pol II 
promoter 
0.2409 4.15 0.0005 
NM_014711 NM_014711 CP110 protein biological_process 
unknown 
0.2411 4.15 0.0118 
NM_006246 NM_006246 
epsilon isoform of regulatory 
subunit B56, protein phosphatase 
2A 
signal transduction 0.2411 4.15 0.0010 
NM_002155 NM_002155 heat shock 70kDa protein 6 
(HSP70B') 
heat shock response 0.2411 4.15 0.0203 
NM_019095 NM_019095 chromosome 20 open reading 
frame 155 
phospholipid biosynthesis 0.2413 4.14 0.0043 
BF541376    0.2414 4.14 0.0102 
NM_012087 NM_012087 
general transcription factor IIIC, 
polypeptide 5, 63kDa 
transcription from Pol III 
promoter 
0.2419 4.13 0.0140 
NM_003797 
NM_003797; 
NM_152991 
embryonic ectoderm development 
isoform a; embryonic ectoderm 
development isoform b 
negative regulation of 
transcription 
0.2419 4.13 0.0016 
BC002913 NM_052857 similar to RIKEN cDNA 
2410003C20 gene 
 0.2420 4.13 0.0159 
NM_021029 NM_021029 ribosomal protein L36a  0.2427 4.12 0.0154 
NM_017832 NM_017832 hypothetical protein FLJ20457  0.2428 4.12 0.0007 
BC011593 NM_138408 chromosome 6 open reading frame 
51 
 0.2430 4.12 0.0067 
NM_005527 NM_005527 heat shock 70kDa protein 1-like  0.2432 4.11 0.0062 
NM_001892 NM_001892 casein kinase 1, alpha 1 
protein amino acid 
phosphorylation; cell 
surface receptor linked 
signal transduction 
0.2432 4.11 0.0000 
AK057224 NM_152467 kelch-like 10  0.2435 4.11 0.0056 
NM_001693 NM_001693 
ATPase, H+ transporting, 
lysosomal 56/58kD, V1 subunit B, 
isoform 2 
ATP biosynthesis; energy 
coupled proton transport, 
against the 
electrochemical gradient 
0.2438 4.10 0.0030 
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NM_004553 NM_004553 
NADH dehydrogenase (ubiquinone) 
Fe-S protein 6, 13kDa (NADH-
coenzyme Q reductase) 
mitochondrial electron 
transport, NADH to 
ubiquinone 
0.2440 4.10 0.0093 
NM_002337 NM_002337 
low density lipoprotein receptor-
related protein associated protein 
1 
vesicle-mediated 
transport; protein 
folding; cell proliferation 
0.2440 4.10 0.0120 
AB014560 NM_012297 Ras-GTPase activating protein SH3 
domain-binding protein 2 
cytoplasmic sequestering 
of NF-kappaB; protein-
nucleus import; 
transport; RAS protein 
signal transduction 
0.2443 4.09 0.0006 
NM_003903 NM_003903 CDC16 homolog 
regulation of mitosis; cell 
cycle; cytokinesis 0.2443 4.09 0.0020 
NM_004953 
NM_004953; 
NM_182917; 
NM_198241; 
NM_198242; 
NM_198244 
eukaryotic translation initiation 
factor 4 gamma, 1 isoform 4; 
eukaryotic translation initiation 
factor 4 gamma, 1 isoform 1; 
eukaryotic translation initiation 
factor 4 gamma, 1 isoform 3; 
eukaryotic translation initiation 
factor 4 gamma, 1 isoform 2 
regulation of translation 0.2446 4.09 0.0110 
NM_032679 NM_032679 hypothetical protein MGC4400 
regulation of 
transcription, DNA-
dependent 
0.2447 4.09 0.0018 
AF042162    0.2449 4.08 0.0151 
AB058765  KIAA1862 protein  0.2449 4.08 0.0039 
NM_012385 NM_012385 p8 protein (candidate of 
metastasis 1) 
induction of apoptosis; 
cell growth 
0.2450 4.08 0.0044 
NM_021994 NM_021994 zinc finger protein (C2H2 type) 
277 
 0.2450 4.08 0.0001 
NM_014962 
NM_014962; 
NM_181443 
BTB/POZ domain containing 
protein 3 isoform a; BTB/POZ 
domain containing protein 3 
isoform b 
 0.2452 4.08 0.0004 
BC004923 NM_033107 hypothetical protein BC004923  0.2453 4.08 0.0061 
NM_031956 NM_031956 NYD-SP14 protein  0.2459 4.07 0.0005 
NM_031371 
NM_016374; 
NM_031371 
RBP1-like protein 1 isoform 1; 
RBP1-like protein 1 isoform 2 
 0.2459 4.07 0.0089 
AB020664 NM_015470 gamma-SNAP-associated factor 1  0.2464 4.06 0.0073 
NM_032906 NM_032906 hypothetical protein MGC14156  0.2465 4.06 0.0097 
NM_024688 NM_024688 hypothetical protein FLJ13031  0.2465 4.06 0.0022 
AB007953    0.2467 4.05 0.0077 
AF103803 NM_017548 hypothetical protein H41 cell proliferation 0.2467 4.05 0.0290 
AK055310 NM_181756 zinc finger protein 233  0.2468 4.05 0.0005 
NM_007278 NM_007278 GABA(A) receptor-associated 
protein 
protein targeting; 
synaptic transmission 
0.2469 4.05 0.0125 
NM_001212 NM_001212 
complement component 1, q 
subcomponent binding protein 
precursor 
immune response 0.2472 4.05 0.0046 
NM_002149 
NM_002149; 
NM_134421 hippocalcin-like 1 
vesicle-mediated 
transport 0.2472 4.04 0.0075 
NM_004270 NM_004270 
cofactor required for Sp1 
transcriptional activation, subunit 
9, 33kDa 
transcription initiation 
from Pol II promoter; 
regulation of 
transcription from Pol II 
promoter 
0.2473 4.04 0.0018 
NM_003500 NM_003500 
acyl-Coenzyme A oxidase 2, 
branched chain 
bile acid metabolism; 
fatty acid beta-oxidation; 
fatty acid metabolism 
0.2476 4.04 0.0050 
NM_006021 NM_006021 deleted in lymphocytic leukemia, 2  0.2476 4.04 0.0493 
NM_004652 
NM_004652; 
NM_021906 
ubiquitin specific protease 9, X-
linked isoform 1; ubiquitin specific 
protease 9, X-linked isoform 2 
deubiquitination; female 
gamete generation 0.2477 4.04 0.0123 
NM_057180 
NM_016226; 
NM_057180 
vacuolar protein sorting 29 isoform 
1; vacuolar protein sorting 29 
isoform 2 
 0.2479 4.03 0.0040 
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NM_007318 
NM_000021; 
NM_007318; 
NM_007319 
presenilin 1 isoform I-467; 
presenilin 1 isoform I-463; 
presenilin 1 isoform I-374 
chromosome 
segregation; anti-
apoptosis; chromosome 
organization and 
biogenesis (sensu 
Eukarya); intracellular 
signaling cascade 
0.2479 4.03 0.0026 
NM_014874 NM_014874 mitofusin 2  0.2481 4.03 0.0079 
BC000365 NM_005316 general transcription factor IIH, 
polypeptide 1, 62kDa 
regulation of CDK 
activity; regulation of 
transcription, DNA-
dependent; DNA repair; 
transcription from Pol II 
promoter 
0.2481 4.03 0.0057 
NM_014390 NM_014390 staphylococcal nuclease domain 
containing 1 
 0.2482 4.03 0.0100 
NM_001316 NM_001316; 
NM_177436 
CSE1 chromosome segregation 1-
like protein isoform a; CSE1 
chromosome segregation 1-like 
protein isoform b 
protein-nucleus import, 
docking; intracellular 
protein transport; 
apoptosis; cell 
proliferation 
0.2485 4.02 0.0098 
NM_031898 NM_031898 tektin 3 
microtubule cytoskeleton 
organization and 
biogenesis 
0.2486 4.02 0.0087 
AK025719    0.2487 4.02 0.0051 
NM_013446 NM_013446 makorin, ring finger protein, 1 biological_process 
unknown 
0.2487 4.02 0.0005 
BC017503  CDR2 protein biological_process 
unknown 
0.2487 4.02 0.0012 
BC008952    0.2487 4.02 0.0012 
NM_021188 NM_021188 
clones 23667 and 23775 zinc 
finger protein 
regulation of 
transcription, DNA-
dependent 
0.2488 4.02 0.0055 
NM_021825 NM_021825 hypothetical protein MDS025  0.2491 4.01 0.0244 
NM_000454 NM_000454 superoxide dismutase 1, soluble 
superoxide metabolism; 
response to oxidative 
stress; neurogenesis 
0.2499 4.00 0.0155 
NM_030663 NM_030663 
mitochondrial capsule 
selenoprotein 
fertilization (sensu 
Animalia); sperm motility 
0.2499 4.00 0.0352 
NM_003010 NM_003010 
mitogen-activated protein kinase 
kinase 4 
JNK cascade; protein 
amino acid 
phosphorylation; signal 
transduction 
0.2501 4.00 0.0015 
NM_002157 NM_002157 heat shock 10kDa protein 1 
(chaperonin 10) 
protein folding 0.2501 4.00 0.0163 
NM_014497 NM_014497 NP220 nuclear protein mRNA splicing 0.2501 4.00 0.0170 
NM_001398 NM_001398 
peroxisomal enoyl-coenzyme A 
hydratase-like protein 
fatty acid beta-oxidation; 
fatty acid metabolism; 
energy pathways 
0.2505 3.99 0.0174 
NM_006311 NM_006311 nuclear receptor co-repressor 1 transcription from Pol II 
promoter 
0.2506 3.99 0.0189 
NM_003472 NM_003472 DEK oncogene (DNA binding) 
protein targeting; cell 
growth and/or 
maintenance; signal 
transduction; regulation 
of transcription from Pol 
II promoter; viral 
genome replication 
0.2506 3.99 0.0093 
AL117407 
NM_015093; 
NM_145342 
mitogen-activated protein kinase 
kinase kinase 7 interacting protein 
2 isoform 1; mitogen-activated 
protein kinase kinase kinase 7 
interacting protein 2 isoform 2 
 0.2507 3.99 0.0172 
NM_016147 NM_016147 protein phosphatase 
methylesterase-1 
protein amino acid 
demethylation 
0.2513 3.98 0.0080 
NM_022829 NM_022829 solute carrier family 13 member 3  0.2514 3.98 0.0162 
NM_002372 NM_002372 
mannosidase, alpha, class 2A, 
member 1 
glycoprotein 
biosynthesis; 
carbohydrate metabolism 
0.2516 3.97 0.0119 
AK027647 NM_018981 ER-resident protein ERdj5  0.2517 3.97 0.0008 
AB002308  KIAA0310 protein  0.2521 3.97 0.0005 
NM_013341 NM_013341 hypothetical protein PTD004  0.2521 3.97 0.0065 
NM_018255 NM_018255 elongator protein 2  0.2521 3.97 0.0013 
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NM_006067 NM_006067 neighbor of COX4  0.2522 3.96 0.0085 
NM_001011 NM_001011 ribosomal protein S7 protein biosynthesis 0.2522 3.96 0.0174 
NM_032489 NM_032489 proacrosin binding protein sp32 
precursor 
 0.2525 3.96 0.0102 
NM_001449 NM_001449 four and a half LIM domains 1  0.2529 3.95 0.0022 
NM_018230 NM_018230 nucleoporin 133kDa transport; mRNA-nucleus 
export 
0.2533 3.95 0.0081 
AB025254 NM_014290 tudor repeat associator with 
PCTAIRE 2 
 0.2536 3.94 0.0214 
AK058119 NM_145028 hypothetical protein FLJ25390  0.2537 3.94 0.0001 
NM_014648 NM_014648 zinc finger DAZ interacting protein 
3 
 0.2538 3.94 0.0018 
NM_054016 NM_006625; 
NM_054016 
FUS interacting protein (serine-
arginine rich) 1 isoform 1; FUS 
interacting protein (serine-arginine 
rich) 1 isoform 2 
mRNA processing; 
spliceosome assembly 
0.2539 3.94 0.0012 
NM_058004 NM_002650; 
NM_058004 
phosphatidylinositol 4-kinase, 
catalytic, alpha polypeptide 
isoform 1; phosphatidylinositol 4-
kinase, catalytic, alpha polypeptide 
isoform 2 
phosphatidylinositol 
biosynthesis; synaptic 
transmission; signal 
transduction 
0.2539 3.94 0.0106 
NM_002647 NM_002647 phosphoinositide-3-kinase, class 3 non-selective vesicle 
transport 
0.2540 3.94 0.0048 
NM_006024 NM_006024 
Tax1 (human T-cell leukemia virus 
type I) binding protein 1 anti-apoptosis 0.2544 3.93 0.0069 
NM_018492 NM_018492 T-LAK cell-originated protein 
kinase 
 0.2545 3.93 0.0038 
D87446    0.2545 3.93 0.0027 
NM_003489 NM_003489 receptor interacting protein 140 
transcription; regulation 
of transcription, DNA-
dependent 
0.2545 3.93 0.0016 
NM_024629 NM_024629 KSHV latent nuclear antigen 
interacting protein 1 
 0.2547 3.93 0.0096 
BC015621 NM_144578 MAPK-interacting and spindle-
stabilizing protein 
 0.2547 3.93 0.0040 
AK057021 NM_032661 hypothetical protein MGC5139  0.2548 3.92 0.0106 
NM_012253 NM_012253 transketolase-like 1 thiamin metabolism; 
glucose catabolism 
0.2550 3.92 0.0098 
NM_016516 NM_016516 vacuolar protein sorting 54  0.2553 3.92 0.0029 
NM_001867 NM_001867 cytochrome c oxidase subunit VIIc 
precursor 
electron transport; 
energy pathways 
0.2554 3.92 0.0082 
NM_005762 NM_005762 
tripartite motif-containing 28 
protein 
transcription regulation 
from Pol II promoter 0.2554 3.92 0.0009 
AL050308    0.2555 3.91 0.0072 
BC014605 NM_144627 SSTK-interacting protein  0.2556 3.91 0.0122 
NM_032376 NM_032376 hypothetical protein MGC4251  0.2556 3.91 0.0063 
NM_020404 NM_020404 tumor endothelial marker 1 
precursor 
biological_process 
unknown 
0.2558 3.91 0.0115 
NM_016146 NM_016146 trafficking protein particle complex 
4 
vesicle-mediated 
transport; dendrite 
morphogenesis; 
neurotransmitter 
receptor biosynthesis 
0.2562 3.90 0.0089 
BC015178 NM_015476 DKFZP586M1523 protein  0.2562 3.90 0.0023 
NM_014236 NM_014236 glyceronephosphate O-
acyltransferase 
fatty acid metabolism; 
organogenesis 
0.2563 3.90 0.0125 
BC001854 NM_005911 methionine adenosyltransferase II, 
alpha 
one-carbon compound 
metabolism 
0.2564 3.90 0.0031 
AL137562  hypothetical protein  0.2564 3.90 0.0161 
NM_021911 NM_000813; 
NM_021911 
gamma-aminobutyric acid (GABA) 
A receptor, beta 2 isoform 2; 
gamma-aminobutyric acid (GABA) 
A receptor, beta 2 isoform 1 
gamma-aminobutyric 
acid signaling pathway; 
ion transport; synaptic 
transmission 
0.2565 3.90 0.0093 
NM_004208 
NM_004208; 
NM_145812; 
NM_145813 
programmed cell death 8 isoform 
1; programmed cell death 8 
isoform 2; programmed cell death 
8 isoform 3 
DNA damage response, 
signal transduction 
resulting in induction of 
apoptosis; DNA 
fragmentation; electron 
transport 
0.2565 3.90 0.0134 
AK023175 NM_017975 hypothetical protein FLJ10036  0.2565 3.90 0.0001 
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NM_016576 NM_016576 guanosine monophosphate 
reductase 2 
 0.2565 3.90 0.0048 
BC010744 NM_080677 dynein light chain 2 microtubule-based 
process 
0.2571 3.89 0.0192 
NM_025267 NM_025267 hypothetical protein MGC2744 alanyl-tRNA 
aminoacylation 
0.2572 3.89 0.0092 
NM_006303 NM_006303 JTV1 protein biosynthesis 0.2574 3.88 0.0090 
AL136693 NM_024843 cytochrome b reductase 1 electron transport 0.2574 3.88 0.0022 
NM_024532 NM_024532 PF20  0.2576 3.88 0.0071 
NM_002835 NM_002835 
protein tyrosine phosphatase, non-
receptor type 12 
protein amino acid 
dephosphorylation 0.2577 3.88 0.0003 
NM_005134 NM_005134 protein phosphatase 4, regulatory 
subunit 1 
 0.2577 3.88 0.0056 
X74794 
NM_005914; 
NM_182746 
minichromosome maintenance 
protein 4 DNA replication 0.2577 3.88 0.0070 
AK023358    0.2578 3.88 0.0001 
NM_003352 NM_003352 ubiquitin-like 1 (sentrin) DNA repair 0.2578 3.88 0.0006 
NM_001873 NM_001873 carboxypeptidase E precursor 
neuropeptide signaling 
pathway; proteolysis and 
peptidolysis; 
metabolism; protein 
modification 
0.2579 3.88 0.0117 
NM_004965 NM_004965 
high-mobility group nucleosome 
binding domain 1 
 0.2584 3.87 0.0221 
NM_018114 NM_018114 hypothetical protein FLJ10496  0.2586 3.87 0.0024 
NM_002526 NM_002526 5' nucleotidase, ecto DNA metabolism; 
nucleotide catabolism 
0.2586 3.87 0.0058 
AF112219 NM_001984 esterase D/formylglutathione 
hydrolase 
biological_process 
unknown 
0.2588 3.86 0.0012 
NM_014047 NM_014047 HSPC023 protein  0.2589 3.86 0.0204 
AK057571 NM_014673 KIAA0103 gene product  0.2589 3.86 0.0030 
NM_012158 NM_012158 F-box and leucine-rich repeat 
protein 3A 
protein ubiquitination 0.2590 3.86 0.0022 
NM_007266 NM_007266 XPA binding protein 1 
small GTPase mediated 
signal transduction 0.2591 3.86 0.0022 
NM_014338 NM_014338 phosphatidylserine decarboxylase phospholipid biosynthesis 0.2592 3.86 0.0102 
AL136807 NM_014445 stress-associated endoplasmic 
reticulum protein 1 
plasma membrane 
organization and 
biogenesis; response to 
stress; protein amino 
acid glycosylation 
0.2593 3.86 0.0037 
NM_030790 NM_030790 T-cell immunomodulatory protein  0.2594 3.85 0.0064 
BC016796  Unknown (protein for 
IMAGE:4070070) 
 0.2596 3.85 0.0017 
AK026771 NM_020336 KIAA1219 protein  0.2596 3.85 0.0031 
Z84469    0.2599 3.85 0.0035 
NM_007372 NM_007372 RNA helicase-related protein  0.2600 3.85 0.0018 
NM_003591 NM_003591 cullin 2 
induction of apoptosis by 
intracellular signals; 
G1/S transition of mitotic 
cell cycle; cell cycle 
arrest; negative 
regulation of cell 
proliferation 
0.2603 3.84 0.0114 
NM_000126 NM_000126 electron transfer flavoprotein, 
alpha polypeptide 
electron transport 0.2605 3.84 0.0103 
NM_018281 NM_018281 hypothetical protein FLJ10948  0.2605 3.84 0.0093 
BC008883 NM_025161 hypothetical protein FLJ22175  0.2608 3.83 0.0069 
NM_013237 NM_013237 px19-like protein development; immune 
response 
0.2612 3.83 0.0060 
NM_015907 NM_015907 leucine aminopeptidase proteolysis and 
peptidolysis 
0.2612 3.83 0.0076 
NM_018289 NM_018289 hypothetical protein FLJ10979  0.2612 3.83 0.0033 
NM_022362 NM_022362 MMS19-like (MET18 homolog, S. 
cerevisiae) 
 0.2612 3.83 0.0167 
AL137257    0.2613 3.83 0.0034 
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AB022663 
NM_004290; 
NM_183398; 
NM_183399; 
NM_183400; 
NM_183401 
ring finger protein 14 isoform 1; 
ring finger protein 14 isoform 2 
ubiquitin cycle; signal 
transduction; regulation 
of transcription from Pol 
II promoter; androgen 
receptor signaling 
pathway 
0.2618 3.82 0.0008 
NM_006888 NM_006888 calmodulin 1 
G-protein coupled 
receptor protein signaling 
pathway 
0.2619 3.82 0.0097 
NM_014791 NM_014791 maternal embryonic leucine zipper 
kinase 
protein amino acid 
phosphorylation 
0.2621 3.81 0.0044 
NM_006003 NM_006003 
ubiquinol-cytochrome c reductase, 
Rieske iron-sulfur polypeptide 1 
electron transport 0.2623 3.81 0.0090 
NM_024528 NM_024528 hypothetical protein FLJ22626 
regulation of 
transcription, DNA-
dependent 
0.2625 3.81 0.0106 
NM_004889 NM_004889 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
f, isoform 2 
proton transport; ATP 
biosynthesis 
0.2627 3.81 0.0107 
NM_005617 NM_005617 ribosomal protein S14 protein biosynthesis 0.2629 3.80 0.0321 
NM_016623 NM_016623 hypothetical protein BM-009  0.2631 3.80 0.0084 
NM_032547 NM_032547 short coiled-coil protein  0.2634 3.80 0.0009 
NM_007285 NM_007285 GABA(A) receptor-associated 
protein-like 2 
intracellular protein 
transport 
0.2636 3.79 0.0027 
NM_031421 NM_031421 hypothetical protein 
DKFZp434H0115 
 0.2637 3.79 0.0140 
NM_016008 
NM_015522; 
NM_016008 
dynein 2 light intermediate chain 
isoform 2; dynein 2 light 
intermediate chain isoform 1 
 0.2640 3.79 0.0002 
NM_006055 NM_006055 
lanthionine synthetase C-like 
protein 1 
G-protein coupled 
receptor protein signaling 
pathway 
0.2640 3.79 0.0021 
AL161952 NM_002065 
glutamate-ammonia ligase 
(glutamine synthase) 
regulation of 
neurotransmitter levels; 
glutamine biosynthesis; 
nitrogen fixation 
0.2641 3.79 0.0140 
NM_014321 NM_014321 origin recognition complex subunit 
6 
DNA replication 0.2644 3.78 0.0000 
NM_025211 NM_025211 protein kinase anchoring protein 
GKAP42 
 0.2646 3.78 0.0195 
NM_020685 NM_020685 HT021  0.2648 3.78 0.0010 
AF395440  HEJ1  0.2648 3.78 0.0130 
AF204231 
NM_015003; 
NM_181076; 
NM_181077 
golgin-67 isoform a; golgin-67 
isoform b; golgin-67 isoform c 
 0.2649 3.77 0.0025 
NM_021096 NM_021096 
calcium channel, voltage-
dependent, alpha 1I subunit 
cation transport; calcium 
ion transport 
0.2649 3.77 0.0150 
NM_003587 NM_003587 
DEAH (Asp-Glu-Ala-His) box 
polypeptide 16 
RNA splicing; regulation 
of cell cycle; nuclear 
mRNA splicing, via 
spliceosome 
0.2654 3.77 0.0074 
NM_016001 NM_016001 CGI-48 protein 
regulation of 
transcription, DNA-
dependent 
0.2657 3.76 0.0046 
NM_020194 NM_020194 GL004 protein  0.2660 3.76 0.0005 
NM_017899 NM_017899 hypothetical protein FLJ20607  0.2661 3.76 0.0070 
NM_005415 NM_005415 
solute carrier family 20 (phosphate 
transporter), member 1 
phosphate metabolism; 
small molecule transport 
0.2662 3.76 0.0024 
AL139112    0.2662 3.76 0.0138 
AK054863    0.2663 3.75 0.0033 
NM_016081 NM_016081 palladin  0.2664 3.75 0.0057 
NM_012470 NM_012470 transportin 3 nucleocytoplasmic 
transport 
0.2664 3.75 0.0149 
AJ303380 NM_030906 serine/threonine kinase 33  0.2666 3.75 0.0086 
Y08772  poly(A) binding protein  0.2666 3.75 0.0099 
AL163279    0.2666 3.75 0.0018 
NM_022473 NM_022473 zinc finger protein 106 homolog  0.2669 3.75 0.0002 
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AK025620    0.2672 3.74 0.0045 
AK027135    0.2672 3.74 0.0125 
NM_003516 NM_003516 H2A histone family, member O 
nucleosome assembly; 
chromosome 
organization and 
biogenesis (sensu 
Eukarya) 
0.2673 3.74 0.0039 
AF042163    0.2675 3.74 0.0015 
NM_000123 NM_000123 XPG-complementing protein 
hearing; transcription-
coupled nucleotide-
excision repair 
0.2678 3.73 0.0063 
NM_018077 NM_018077 hypothetical protein FLJ10377  0.2680 3.73 0.0072 
NM_015941 NM_015941 
ATPase, H+ transporting, 
lysosomal 50/57kDa, V1 subunit H 
proton transport; ATP 
biosynthesis 0.2681 3.73 0.0007 
AF346509 
NM_006599; 
NM_138713; 
NM_138714; 
NM_173214; 
NM_173215 
nuclear factor of activated T-cells 5 
isoform c; nuclear factor of 
activated T-cells 5 isoform b; 
nuclear factor of activated T-cells 5 
isoform a 
regulation of 
transcription, DNA-
dependent; excretion; 
signal transduction; 
transcription from Pol II 
promoter 
0.2683 3.73 0.0037 
NM_024426 
NM_000378; 
NM_024424; 
NM_024425; 
NM_024426 
Wilms tumor 1 isoform A; Wilms 
tumor 1 isoform B; Wilms tumor 1 
isoform C; Wilms tumor 1 isoform 
D 
regulation of 
transcription, DNA-
dependent; negative 
regulation of cell cycle 
0.2685 3.72 0.0069 
NM_018430 NM_018430 translin-associated factor X 
interacting protein 1 
 0.2687 3.72 0.0009 
NM_015416 NM_015416 cervical cancer 1 protooncogene 
protein p40 
 0.2689 3.72 0.0043 
NM_000693 NM_000693 aldehyde dehydrogenase 1A3 alcohol metabolism; lipid 
metabolism 
0.2690 3.72 0.0082 
AL133096 NM_018602 DnaJ (Hsp40) homolog, subfamily 
A, member 4 
 0.2690 3.72 0.0129 
BC007436 NM_138369 hypothetical protein BC007436  0.2691 3.72 0.0092 
BC015138 NM_152729 5'-nucleotidase, cytosolic II-like 1 
protein 
 0.2692 3.72 0.0019 
AB053314 NM_139163 ALS2CR12 gene product  0.2692 3.72 0.0005 
AK024268   
regulation of 
transcription, DNA-
dependent 
0.2692 3.71 0.0194 
NM_016019 NM_016019 LUC7-like 2  0.2693 3.71 0.0016 
NM_000310 NM_000310 
palmitoyl-protein thioesterase 1 
(ceroid-lipofuscinosis, neuronal 1, 
infantile) 
vision; neurogenesis; 
protein modification 
0.2696 3.71 0.0238 
NM_002940 NM_002940 
ATP-binding cassette, sub-family 
E, member 1 
transport; electron 
transport; viral capsid 
assembly 
0.2697 3.71 0.0007 
NM_052969 NM_052969 ribosomal protein L39-like protein protein biosynthesis 0.2697 3.71 0.0167 
BC007973 NM_016534 apoptosis-related protein PNAS-1  0.2700 3.70 0.0050 
NM_001985 NM_001985 electron-transfer-flavoprotein, 
beta polypeptide 
electron transport 0.2701 3.70 0.0094 
AK027191    0.2701 3.70 0.0145 
NM_005605 NM_005605 
protein phosphatase 3 (formerly 
2B), catalytic subunit, gamma 
isoform (calcineurin A gamma) 
 0.2703 3.70 0.0098 
BC015121    0.2704 3.70 0.0016 
NM_017632 NM_017632 
collaborates/cooperates with ARF 
(alternate reading frame) protein 
 0.2707 3.69 0.0029 
NM_000039 NM_000039 apolipoprotein A-I precursor 
lipid transport; 
cholesterol metabolism; 
circulation 
0.2707 3.69 0.0043 
NM_000089 NM_000089 alpha 2 type I collagen skeletal development 0.2707 3.69 0.0102 
AK026809 NM_145284 similar to hypothetical protein 
MGC17347 
 0.2711 3.69 0.0101 
AB033076  KIAA1250 protein  0.2713 3.69 0.0016 
NM_006370 NM_006370 vesicle-associated soluble NSF 
attachment protein receptor (v-SN 
membrane fusion; 
vesicle transport; cell 
proliferation; non-
selective vesicle docking 
0.2714 3.68 0.0084 
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NM_004800 NM_004800 transmembrane 9 superfamily 
member 2 
transport 0.2715 3.68 0.0014 
BC004895 NM_138368 hypothetical protein BC004895  0.2715 3.68 0.0143 
NM_016122 NM_016122 NY-REN-58 antigen  0.2718 3.68 0.0004 
NM_015965 NM_015965 
cell death-regulatory protein 
GRIM19 
protein-nucleus import; 
induction of apoptosis by 
extracellular signals; 
negative regulation of 
protein biosynthesis; 
negative regulation of 
cell growth; negative 
regulation of 
transcription, DNA-
dependent; apoptotic 
nuclear changes 
0.2718 3.68 0.0064 
NM_005776 NM_005776 cornichon-like 
intracellular signaling 
cascade; immune 
response 
0.2718 3.68 0.0043 
NM_024724 NM_024724 hypothetical protein FLJ22332  0.2719 3.68 0.0080 
NM_002853 
NM_002853; 
NM_133282; 
NM_133377 
RAD1 homolog isoform 1; RAD1 
homolog isoform 2 
DNA damage response, 
signal transduction 
resulting in cell cycle 
arrest; meiotic prophase 
I; response to DNA 
damage stimulus; DNA 
repair 
0.2719 3.68 0.0006 
AL109684    0.2721 3.68 0.0004 
AB037844  KIAA1423 protein  0.2723 3.67 0.0132 
NM_032251 NM_032251 hypothetical protein 
DKFZp434G0920 
 0.2725 3.67 0.0082 
NM_002162 NM_002162 intercellular adhesion molecule 3 
precursor 
cell-cell adhesion 0.2725 3.67 0.0047 
NM_002097 NM_002097 general transcription factor IIIA 
rRNA transcription; 
transcription from Pol III 
promoter; regulation of 
transcription, DNA-
dependent 
0.2726 3.67 0.0067 
NM_001414 NM_001414 
eukaryotic translation initiation 
factor 2B, subunit 1 alpha, 26kDa 
translational initiation 0.2727 3.67 0.0113 
NM_033022 
NM_001026; 
NM_033022 
ribosomal protein S24 isoform c; 
ribosomal protein S24 isoform a protein biosynthesis 0.2732 3.66 0.0031 
AB051504 NM_030648 SET domain-containing protein 7 chromatin modification 0.2733 3.66 0.0002 
NM_003340 
NM_003340; 
NM_181886; 
NM_181887; 
NM_181888; 
NM_181889; 
NM_181890; 
NM_181891; 
NM_181892; 
NM_181893 
ubiquitin-conjugating enzyme E2D 
3 isoform 1; ubiquitin-conjugating 
enzyme E2D 3 isoform 2; 
ubiquitin-conjugating enzyme E2D 
3 isoform 3 
protein modification; 
ubiquitin-dependent 
protein degradation 
0.2733 3.66 0.0241 
BC017696  Similar to RIKEN cDNA 
2410075D05 gene 
 0.2733 3.66 0.0069 
NM_014342 NM_014342 mitochondrial carrier homolog 2 transport 0.2733 3.66 0.0008 
NM_020474 NM_020474 
polypeptide N-
acetylgalactosaminyltransferase 1 
O-linked glycosylation; 
heterophilic cell adhesion 
0.2733 3.66 0.0003 
NM_006211 NM_006211 proenkephalin 
neuropeptide signaling 
pathway; signal 
transduction; cell-cell 
signaling 
0.2735 3.66 0.0220 
AF148537 
NM_007008; 
NM_020532; 
NM_153828 
reticulon 4 
apoptosis; negative 
regulation of axon 
extension; negative 
regulation of anti-
apoptosis 
0.2736 3.66 0.0106 
NM_002492 NM_002492 
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 5, 16kDa 
precursor 
mitochondrial electron 
transport, NADH to 
ubiquinone 
0.2736 3.66 0.0095 
AF255666 NM_015436 zinc finger protein 363  0.2736 3.65 0.0024 
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NM_023012 
NM_023012; 
NM_198261; 
NM_198262; 
NM_198263 
similar to splicing factor, 
arginine/serine-rich 4 isoform a; 
similar to splicing factor, 
arginine/serine-rich 4 isoform b; 
similar to splicing factor, 
arginine/serine-rich 4 isoform c; 
similar to splicing factor, 
arginine/serine-rich 4 isoform d 
 0.2737 3.65 0.0048 
NM_018210 NM_018210 hypothetical protein FLJ10769  0.2737 3.65 0.0039 
NM_013360 NM_013360 zinc finger protein 222 
regulation of 
transcription, DNA-
dependent 
0.2738 3.65 0.0023 
AK027091    0.2739 3.65 0.0016 
BC014000 NM_138447 hypothetical protein BC014000 
regulation of 
transcription, DNA-
dependent 
0.2741 3.65 0.0017 
NM_021631 NM_021631 apoptosis inhibitor apoptosis 0.2742 3.65 0.0065 
U61166  SH3 domain-containing protein 
SH3P17 
 0.2742 3.65 0.0005 
NM_016056 NM_016056 CGI-119 protein  0.2743 3.65 0.0158 
NM_018842 NM_018842 insulin receptor tyrosine kinase 
substrate 
 0.2745 3.64 0.0086 
NM_001695 NM_001695 
ATPase, H+ transporting, 
lysosomal 42kD, V1 subunit C, 
isoform 1 
proton transport 0.2745 3.64 0.0133 
NM_015361 NM_015361 
R3H domain (binds single-stranded 
nucleic acids) containing 
 0.2746 3.64 0.0093 
NM_004667 NM_004667 hect domain and RLD 2 
ubiquitin cycle; 
intracellular protein 
transport 
0.2747 3.64 0.0055 
BC014603 NM_152779 hypothetical protein MGC26856 
G-protein coupled 
receptor protein signaling 
pathway; vision 
0.2748 3.64 0.0117 
NM_014258 NM_014258 synaptonemal complex protein 2 
synaptonemal complex 
formation; meiosis; 
cytokinesis 
0.2748 3.64 0.0016 
NM_016258 NM_016258 high glucose-regulated protein 8 humoral defense 
mechanism 
0.2748 3.64 0.0175 
NM_019005 NM_019005 hypothetical protein FLJ20323  0.2749 3.64 0.0045 
NM_015339 
NM_015339; 
NM_181442 
activity-dependent neuroprotector 
regulation of 
transcription, DNA-
dependent 
0.2750 3.64 0.0035 
AC006017    0.2750 3.64 0.0005 
NM_000919 
NM_000919; 
NM_138766; 
NM_138821; 
NM_138822 
peptidylglycine alpha-amidating 
monooxygenase isoform a, 
preproprotein; peptidylglycine 
alpha-amidating monooxygenase 
isoform b, preproprotein; 
peptidylglycine alpha-amidating 
monooxygenase isoform c, 
preproprotein; peptidylglycine 
alpha-amidating monooxygenase 
isoform d, preproprotein 
protein modification 0.2750 3.64 0.0001 
NM_005886 NM_005886 katanin p80 subunit B 1 
cell cycle; cell motility; 
microtubule 
depolymerization 
0.2752 3.63 0.0053 
NM_004272 NM_004272 Homer, neuronal immediate early 
gene, 1B 
metabotropic glutamate 
receptor, phospholipase 
C activating pathway; 
regulation of synapse 
0.2752 3.63 0.0048 
NM_001553 NM_001553 
insulin-like growth factor binding 
protein 7 
negative regulation of 
cell proliferation; 
regulation of cell growth 
0.2753 3.63 0.0164 
D87684 NM_014607 UBX domain containing 2 
regulation of 
transcription, DNA-
dependent 
0.2753 3.63 0.0159 
NM_022550 
NM_003401; 
NM_022406; 
NM_022550 
X-ray repair cross complementing 
protein 4 isoform 1; X-ray repair 
cross complementing protein 4 
isoform 2 
double-strand break 
repair; DNA 
recombination 
0.2753 3.63 0.0027 
NM_007208 NM_007208 mitochondrial ribosomal protein L3 protein biosynthesis 0.2756 3.63 0.0047 
NM_020216 NM_020216 arginyl aminopeptidase 
(aminopeptidase B) 
proteolysis and 
peptidolysis 
0.2756 3.63 0.0182 
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NM_058246 NM_005494; 
NM_058246 
DnaJ (Hsp40) homolog, subfamily 
B, member 6 isoform b; DnaJ 
(Hsp40) homolog, subfamily B, 
member 6 isoform a 
biological_process 
unknown 
0.2757 3.63 0.0134 
NM_018300 NM_018300 zinc finger protein 83 (HPF1)  0.2759 3.62 0.0055 
NM_016462 NM_016462 chromosome 6 open reading frame 
53 
 0.2760 3.62 0.0003 
NM_014255 NM_014255 transmembrane protein 4  0.2760 3.62 0.0152 
NM_016222 NM_016222 DEAD-box protein abstrakt RNA processing; 
development; apoptosis 
0.2761 3.62 0.0057 
NM_005783 NM_005783 
ATP binding protein associated 
with cell differentiation electron transport 0.2763 3.62 0.0008 
AB037735 NM_030672 KIAA1314 protein  0.2764 3.62 0.0232 
BC015397 NM_138811 chromosome 7 open reading frame 
31 
 0.2764 3.62 0.0015 
NM_006567 NM_006567 phenylalanine-tRNA synthetase 
tRNA processing; 
transport; phenylalanyl-
tRNA aminoacylation 
0.2765 3.62 0.0065 
NM_017864 NM_017864 hypothetical protein FLJ20530  0.2766 3.62 0.0005 
AF061735 NM_006356 
ATP synthase, H+ transporting, 
mitochondrial F0 complex, subunit 
d 
proton transport 0.2766 3.62 0.0155 
NM_003651 NM_003651 cold shock domain protein A 
response to cold; 
negative regulation of 
transcription from Pol II 
promoter 
0.2767 3.61 0.0181 
AL133023 NM_021185 hypothetical protein 
DKFZp434A1022 
 0.2767 3.61 0.0023 
NM_006063 NM_006063 sarcomeric muscle protein striated muscle 
contraction 
0.2768 3.61 0.0003 
NM_005051 NM_005051 glutaminyl-tRNA synthetase 
glutaminyl-tRNA 
aminoacylation; 
glutamyl-tRNA 
aminoacylation 
0.2769 3.61 0.0048 
NM_033657 
NM_004632; 
NM_033657 death-associated protein 3 
induction of apoptosis by 
extracellular signals 0.2769 3.61 0.0031 
NM_002858 NM_002858 
ATP-binding cassette, sub-family 
D, member 3 
peroxisome organization 
and biogenesis; 
peroxisomal long-chain 
fatty acid import 
0.2770 3.61 0.0013 
NM_018474 NM_018474 uncharacterized hypothalamus 
protein HT013 
 0.2771 3.61 0.0088 
AL353681    0.2773 3.61 0.0017 
NM_006421 NM_006421 
brefeldin A-inhibited guanine 
nucleotide-exchange protein 1 exocytosis 0.2773 3.61 0.0127 
NM_021974 NM_021974 DNA directed RNA polymerase II 
polypeptide F 
transcription from Pol II 
promoter 
0.2776 3.60 0.0109 
NM_006268 NM_006268 D4, zinc and double PHD fingers 
family 2 
induction of apoptosis by 
extracellular signals; 
regulation of 
transcription, DNA-
dependent 
0.2777 3.60 0.0027 
AL137660 NM_018051 hypothetical protein FLJ10300  0.2777 3.60 0.0077 
NM_020154 NM_020154 
chromosome 15 hypothetical 
ATG/GTP binding protein 
biological_process 
unknown 
0.2777 3.60 0.0148 
NM_006645 NM_006645 START domain containing 10  0.2778 3.60 0.0094 
AB020684  KIAA0877 protein immune response 0.2780 3.60 0.0105 
NM_000397 NM_000397 
cytochrome b-245, beta 
polypeptide (chronic 
granulomatous disease) 
electron transport; 
energy pathways; 
inflammatory response; 
antimicrobial humoral 
response (sensu 
Vertebrata) 
0.2784 3.59 0.0077 
NM_018364 NM_018364 hypothetical protein FLJ11220  0.2785 3.59 0.0004 
NM_016207 NM_016207 
cleavage and polyadenylation 
specific factor 3, 73kDa 
mRNA processing 0.2786 3.59 0.0007 
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NM_000587 NM_000587 
complement component 7 
precursor 
response to pathogenic 
bacteria; complement 
activation, classical 
pathway; immune 
response; complement 
activation, alternative 
pathway; cytolysis 
0.2791 3.58 0.0015 
AB033114 NM_020749 KIAA1288 protein  0.2791 3.58 0.0014 
NM_033328 NM_033328 capping protein alpha 3 
actin cytoskeleton 
organization and 
biogenesis 
0.2792 3.58 0.0059 
NM_015510 NM_015510 DKFZP566O084 protein  0.2792 3.58 0.0040 
X59405 
NM_002389; 
NM_153826; 
NM_172350; 
NM_172351; 
NM_172352; 
NM_172353; 
NM_172354; 
NM_172355; 
NM_172356; 
NM_172357; 
NM_172358; 
NM_172359; 
NM_172360; 
NM_172361 
membrane cofactor protein 
isoform 1 precursor; membrane 
cofactor protein isoform 4 
precursor; membrane cofactor 
protein isoform 14 precursor; 
membrane cofactor protein 
isoform 3 precursor; membrane 
cofactor protein isoform 5 
precursor; membrane cofactor 
protein isoform 6 precursor; 
membrane cofactor protein 
isoform 7 precursor; membrane 
cofactor protein isoform 9 
precursor; membrane cofactor 
protein isoform 10 precursor; 
membrane cofactor protein 
isoform 11 precursor; membrane 
cofactor protein isoform 13 
precursor; membrane cofactor 
protein isoform 2 precursor; 
membrane cofactor protein 
isoform 8 precursor; membrane 
cofactor protein isoform 12 
precursor 
virulence; complement 
activation; invasive 
growth 
0.2793 3.58 0.0048 
AK001731 NM_152261 hypothetical protein MGC17943  0.2797 3.58 0.0030 
NM_005548 NM_005548 lysyl-tRNA synthetase protein biosynthesis 0.2800 3.57 0.0063 
NM_014737 
NM_014737; 
NM_170773; 
NM_170774 
Ras association domain family 2 
isoform 1; Ras association domain 
family 2 isoform 2 
 0.2802 3.57 0.0025 
BC000143 
NM_022086; 
NM_133171; 
NM_182764 
engulfment and cell motility 2 phagocytosis; apoptosis 0.2802 3.57 0.0005 
NM_004939 NM_004939 
DEAD (Asp-Glu-Ala-Asp) box 
polypeptide 1 
ribosome biogenesis; cell 
growth and/or 
maintenance; 
spliceosome assembly; 
regulation of 
translational initiation; 
spermatogenesis; 
development 
0.2804 3.57 0.0139 
AL080113 
NM_006386; 
NM_030881 
DEAD box polypeptide 17 isoform 
p82; DEAD box polypeptide 17 
isoform 2 
RNA processing 0.2805 3.57 0.0041 
NM_019038 NM_019038 tudor domain containing 4  0.2806 3.56 0.0117 
NM_004362 NM_004362 calmegin fertilization (sensu 
Animalia) 
0.2807 3.56 0.0033 
NM_017761 NM_017761 proline-rich nuclear receptor 
coactivator 2 
 0.2809 3.56 0.0004 
NM_024692 NM_024692 hypothetical protein FLJ21069  0.2810 3.56 0.0022 
AK023762 
NM_003128; 
NM_178313 
spectrin, beta, non-erythrocytic 1 
isoform 1; spectrin, beta, non-
erythrocytic 1 isoform 2 
 0.2810 3.56 0.0013 
NM_005701 NM_005701 RNA, U transporter 1 nucleocytoplasmic 
transport 
0.2810 3.56 0.0039 
BC004538 NM_152271 hypothetical protein FLJ23749 ATP-dependent 
proteolysis 
0.2811 3.56 0.0104 
NM_031953 NM_031953 sorting nexin 25  0.2811 3.56 0.0042 
AL050022 NM_015631 DKFZP564D116 protein  0.2811 3.56 0.0044 
AL442092 NM_018334 leucine rich repeat neuronal 3  0.2812 3.56 0.0099 
AL117595    0.2812 3.56 0.0049 
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NM_002946 NM_002946 replication protein A2, 32kDa DNA dependent DNA 
replication 
0.2813 3.56 0.0054 
NM_001010 NM_001010 ribosomal protein S6 protein biosynthesis 0.2813 3.55 0.0151 
NM_006708 NM_006708 glyoxalase I carbohydrate metabolism 0.2814 3.55 0.0062 
NM_022157 NM_022157 Ras-related GTP binding C  0.2816 3.55 0.0196 
AF049615  huntingtin interacting protein 
HYPM 
 0.2819 3.55 0.0128 
NM_021980 NM_021980 optineurin 
pathogenesis; cell death; 
signal transduction 0.2820 3.55 0.0024 
NM_002078 NM_002078 golgi autoantigen, golgin subfamily 
a, 4 
vesicle-mediated 
transport 
0.2820 3.55 0.0064 
AK056615 NM_152484 FLJ32053 protein  0.2820 3.55 0.0010 
AF288392 NM_017673 chromosome 1 open reading frame 
26 
 0.2821 3.55 0.0142 
NM_032361 NM_032361 THO complex 3 
transport; mRNA-nucleus 
export; nuclear mRNA 
splicing, via spliceosome 
0.2821 3.54 0.0089 
AB007935 NM_001542 immunoglobulin superfamily, 
member 3 
 0.2829 3.54 0.0252 
NM_033028 NM_033028 Bardet-Biedl syndrome 4 vision 0.2831 3.53 0.0125 
NM_014000 
NM_003373; 
NM_014000 
vinculin isoform VCL; VCL isoform 
meta-VCL 
cell shape and cell size 
control 
0.2831 3.53 0.0070 
BC011751 NM_133491 polyamine N-acetyltransferase  0.2833 3.53 0.0077 
NM_005494 NM_005494; 
NM_058246 
DnaJ (Hsp40) homolog, subfamily 
B, member 6 isoform b; DnaJ 
(Hsp40) homolog, subfamily B, 
member 6 isoform a 
biological_process 
unknown 
0.2834 3.53 0.0136 
NM_006839 NM_006839 inner membrane protein, 
mitochondrial (mitofilin) 
biological_process 
unknown 
0.2834 3.53 0.0153 
NM_014477 NM_014477 
chromosome 20 open reading 
frame 10 
intracellular signaling 
cascade; negative 
regulation of cell growth 
0.2834 3.53 0.0124 
AJ420469    0.2840 3.52 0.0131 
BC009905  Unknown (protein for MGC:2525)  0.2840 3.52 0.0049 
NM_016171 NM_016171 prothymosin a14  0.2842 3.52 0.0109 
NM_002074 NM_002074 guanine nucleotide-binding 
protein, beta-1 subunit 
acetyl choline receptor 
signaling, muscarinic 
pathway; RAS protein 
signal transduction 
0.2844 3.52 0.0127 
NM_001107 NM_001107 erythrocyte acylphosphatase 1 phosphate metabolism 0.2846 3.51 0.0273 
NM_003558 NM_003558 
phosphatidylinositol-4-phosphate 
5-kinase, type I, beta  0.2846 3.51 0.0001 
Z29067 
NM_002498; 
NM_152720 
NIMA-related kinase 3 
cell cycle; mitosis; 
protein amino acid 
phosphorylation; 
cytokinesis 
0.2847 3.51 0.0111 
NM_020401 NM_020401 nuclear pore complex protein transport; mRNA-nucleus 
export 
0.2848 3.51 0.0216 
NM_003886 
NM_003886; 
NM_139289 
A-kinase anchor protein 4 isoform 
1; A-kinase anchor protein 4 
isoform 2 
fertilization (sensu 
Animalia); cell motility; 
signal transduction 
0.2848 3.51 0.0376 
NM_015966 NM_015966; 
NM_198398 
serologically defined breast cancer 
antigen 84 isoform b; serologically 
defined breast cancer antigen 84 
isoform a 
 0.2849 3.51 0.0172 
NM_023937 NM_023937 mitochondrial ribosomal protein 
L34 
protein biosynthesis 0.2849 3.51 0.0119 
NM_031423 
NM_031423; 
NM_145697 cell division cycle associated 1  0.2850 3.51 0.0001 
NM_003011 NM_003011 
SET translocation (myeloid 
leukemia-associated) 
nucleosome assembly; 
DNA replication; 
oncogenesis 
0.2851 3.51 0.0148 
AK025794 
NM_014006; 
NM_015092 
PI-3-kinase-related kinase SMG-1 
isoform 2; PI-3-kinase-related 
kinase SMG-1 isoform 1 
 0.2851 3.51 0.0412 
NM_019048 NM_019048 HCV NS3-transactivated protein 1 protein amino acid 
prenylation 
0.2851 3.51 0.0098 
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NM_020632 
NM_020632; 
NM_130840; 
NM_130841 
ATPase, H+ transporting, 
lysosomal V0 subunit a isoform 4 
 0.2852 3.51 0.0065 
NM_000016 NM_000016 acyl-Coenzyme A dehydrogenase, 
C-4 to C-12 straight chain 
fatty acid beta-oxidation; 
electron transport; fatty 
acid metabolism; energy 
pathways 
0.2853 3.51 0.0023 
BC017179 NM_152455 hypothetical protein FLJ35867 
regulation of 
transcription, DNA-
dependent 
0.2856 3.50 0.0142 
NM_015896 NM_015896 zinc finger, MYND domain-
containing 10 
 0.2860 3.50 0.0204 
AL133102    0.2861 3.50 0.0021 
NM_020359 NM_020359 phospholipid scramblase 2 phospholipid scrambling 0.2865 3.49 0.0088 
NM_021145 NM_021145 cyclin D binding myb-like 
transcription factor 1 
 0.2866 3.49 0.0024 
NM_004869 NM_004869 vacuolar protein sorting factor 4B 
membrane fusion; 
regulation of 
transcription, DNA-
dependent 
0.2867 3.49 0.0036 
NM_004247 NM_004247 U5 snRNP-specific protein, 116 kD 
RNA splicing; 
translational elongation; 
nuclear mRNA splicing, 
via spliceosome 
0.2868 3.49 0.0137 
NM_024687 NM_024687 hypothetical protein FLJ23049  0.2868 3.49 0.0020 
NM_032027 NM_032027 beta-amyloid binding protein 
precursor 
 0.2868 3.49 0.0006 
NM_016329 NM_016329 Scm-like with four mbt domains 1  0.2874 3.48 0.0073 
NM_031291 NM_031291 hypothetical protein 
DKFZp434N1235 
transport 0.2874 3.48 0.0137 
NM_033280 NM_033280 
similar to signal peptidase complex 
(18kD) 
proteolysis and 
peptidolysis; signal 
peptide processing 
0.2874 3.48 0.0122 
NM_017569 NM_017569 transcription factor (p38 
interacting protein) 
 0.2876 3.48 0.0197 
NM_006602 NM_006602 transcription factor-like 5 protein 
spermatogenesis; cell 
proliferation; 
developmental 
processes; transcription 
from Pol II promoter 
0.2877 3.48 0.0013 
NM_007194 
NM_007194; 
NM_145862 
protein kinase CHK2 isoform a; 
protein kinase CHK2 isoform b  0.2878 3.47 0.0064 
NM_032944 
NM_031414; 
NM_032944 
serine/threonine kinase 31 isoform 
a; serine/threonine kinase 31 
isoform b 
protein amino acid 
phosphorylation 
0.2879 3.47 0.0175 
NM_016020 NM_016020 transcription factor B1, 
mitochondrial 
rRNA modification 0.2881 3.47 0.0197 
AK056682    0.2881 3.47 0.0124 
NM_032573 NM_032573 testis-specific protein TSP-NY  0.2882 3.47 0.0180 
NM_005826 NM_005826 
heterogeneous nuclear 
ribonucleoprotein R 
mRNA processing; 
regulation of 
transcription, DNA-
dependent 
0.2886 3.47 0.0025 
NM_018453 NM_018453 chromosome 14 open reading 
frame 11 
 0.2886 3.47 0.0021 
NM_002087 NM_002087 granulin 
positive regulation of cell 
proliferation; signal 
transduction; cell-cell 
signaling 
0.2888 3.46 0.0170 
AB058697  KIAA1794 protein  0.2890 3.46 0.0182 
AK000745 NM_178812 LYRIC/3D3  0.2890 3.46 0.0025 
NM_025075 NM_025075 hypothetical protein FLJ23445  0.2891 3.46 0.0033 
AF301222    0.2893 3.46 0.0091 
NM_016176 
NM_016176; 
NM_016547 
calcium binding protein Cab45 
precursor  0.2894 3.46 0.0409 
NM_030934 NM_030934 
N2,N2-dimethylguanosine tRNA 
methyltransferase-like 
 0.2896 3.45 0.0236 
NM_017746 NM_017746 hypothetical protein FLJ20287  0.2897 3.45 0.0002 
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NM_007080 NM_007080 Sm protein F 
RNA splicing; nuclear 
mRNA splicing, via 
spliceosome 
0.2899 3.45 0.0122 
NM_003582 NM_003582 
dual-specificity tyrosine-(Y)-
phosphorylation regulated kinase 3 
protein amino acid 
phosphorylation 
0.2900 3.45 0.0198 
BC012356 NM_001126 adenylosuccinate synthase 
AMP biosynthesis; purine 
nucleotide biosynthesis 0.2901 3.45 0.0033 
AK054969 NM_174916 
ubiquitin protein ligase E3 
component n-recognin 1 
ubiquitin cycle; protein 
biosynthesis 
0.2903 3.44 0.0007 
NM_001777 
NM_001777; 
NM_198793 
CD47 antigen isoform 1 precursor; 
CD47 antigen isoform 2 precursor 
integrin-mediated 
signaling pathway; cell-
matrix adhesion 
0.2903 3.44 0.0001 
NM_000314 NM_000314 phosphatase and tensin homolog 
regulation of CDK 
activity; development; 
cell proliferation; protein 
amino acid 
dephosphorylation; 
negative regulation of 
cell cycle 
0.2904 3.44 0.0029 
NM_004426 NM_004426 polyhomeotic 1-like 
'de novo' pyrimidine base 
biosynthesis; 
development 
0.2906 3.44 0.0046 
NM_024520 NM_024520 hypothetical protein FLJ22555  0.2907 3.44 0.0093 
NM_018975 NM_018975 
TRF2-interacting telomeric RAP1 
protein 
telomerase-dependent 
telomere maintenance 0.2908 3.44 0.0022 
NM_000979 NM_000979 ribosomal protein L18 protein biosynthesis 0.2910 3.44 0.0069 
NM_030924 NM_030924 bubblegum related protein metabolism 0.2910 3.44 0.0169 
NM_016505 NM_016505 putative S1 RNA binding domain 
protein 
 0.2912 3.43 0.0154 
NM_000373 NM_000373 uridine monophosphate synthase 
'de novo' pyrimidine base 
biosynthesis; UMP 
biosynthesis; nucleoside 
metabolism; pyrimidine 
nucleotide biosynthesis 
0.2912 3.43 0.0100 
NM_030877 NM_030877 beta catenin-like 1 
regulation of 
transcription, DNA-
dependent 
0.2912 3.43 0.0006 
NM_004681 NM_004681 
eukaryotic translation initiation 
factor 1A, Y chromosome 
translational initiation 0.2913 3.43 0.0033 
NM_014394 NM_014394 
growth hormone inducible 
transmembrane protein  0.2916 3.43 0.0193 
AL354613 NM_018087 hypothetical protein FLJ10407  0.2916 3.43 0.0016 
NM_002095 NM_002095 general transcription factor IIE, 
polypeptide 2, beta 34kDa 
transcription initiation 
from Pol II promoter; 
regulation of 
transcription, DNA-
dependent 
0.2919 3.43 0.0114 
NM_005901 NM_005901 
MAD, mothers against 
decapentaplegic homolog 2 
regulation of 
transcription, DNA-
dependent; signal 
transduction 
0.2920 3.42 0.0029 
AB037795  KIAA1374 protein  0.2922 3.42 0.0019 
AK055509    0.2924 3.42 0.0020 
AL050005 NM_005801 putative translation initiation factor 
cell growth and/or 
maintenance; regulation 
of translational initiation 
0.2926 3.42 0.0188 
NM_000999 NM_000999 ribosomal protein L38 protein biosynthesis 0.2929 3.41 0.0273 
NM_004990 NM_004990 methionine-tRNA synthetase protein biosynthesis 0.2930 3.41 0.0022 
NM_017589 NM_017589 B-cell translocation gene 4  0.2931 3.41 0.0120 
NM_001790 
NM_001790; 
NM_022809 
cell division cycle 25C protein 
isoform a; cell division cycle 25C 
protein isoform b 
regulation of mitosis; 
regulation of CDK 
activity; start control 
point of mitotic cell 
cycle; protein amino acid 
dephosphorylation; 
cytokinesis 
0.2931 3.41 0.0005 
NM_020987 
NM_001149; 
NM_020987 
ankyrin 3 isoform 2; ankyrin 3 
isoform 1 
cytoskeletal anchoring; 
nonselective vesicle 
transport 
0.2931 3.41 0.0043 
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NM_017577 NM_017577 hypothetical protein 
DKFZp434C0328 
 0.2933 3.41 0.0005 
NM_001464 NM_001464 a disintegrin and metalloproteinase 
domain 2 proprotein 
fusion of sperm to egg 
plasma membrane; 
proteolysis and 
peptidolysis; cell 
adhesion 
0.2934 3.41 0.0096 
NM_003234 NM_003234 transferrin receptor (p90, CD71) iron transport; iron 
homeostasis 
0.2936 3.41 0.0061 
AL137077    0.2937 3.41 0.0100 
NM_018436 NM_018436 allantoicase isoform a  0.2937 3.40 0.0037 
NM_002894 NM_002894 retinoblastoma binding protein 8 
DNA repair; cell cycle 
checkpoint; transcription 
regulation from Pol II 
promoter 
0.2939 3.40 0.0005 
AB032981  KIAA1155 protein  0.2940 3.40 0.0143 
NM_002584 NM_002584; 
NM_013945 
paired box gene 7 isoform 1; 
paired box gene 7 isoform 2 
morphogenesis; anti-
apoptosis; cell growth 
and/or maintenance; 
regulation of 
transcription, DNA-
dependent 
0.2943 3.40 0.0002 
BC000233 NM_005272 
guanine nucleotide binding protein, 
alpha transducing activity 
polypeptide 2 
phototransduction; G-
protein coupled receptor 
protein signaling 
pathway; vision; signal 
transduction 
0.2943 3.40 0.0113 
NM_019896 NM_019896 
polymerase (DNA-directed), 
epsilon 4 (p12 subunit) 
 0.2943 3.40 0.0036 
BC009702 NM_145261 similar to RIKEN cDNA 
1810055D05 
 0.2944 3.40 0.0009 
NM_003157 NM_003157 
NIMA (never in mitosis gene a)-
related kinase 4 
mitosis; protein amino 
acid phosphorylation 
0.2944 3.40 0.0181 
AB033113 NM_020748 KIAA1287 protein  0.2948 3.39 0.0012 
NM_014549 NM_014549 POM121-like protein 
regulation of 
transcription, DNA-
dependent 
0.2952 3.39 0.0089 
AK054769 NM_006402 hepatitis B virus x-interacting 
protein 
viral genome replication 0.2952 3.39 0.0138 
NM_003115 NM_003115 
UDP-N-acteylglucosamine 
pyrophosphorylase 1 
UDP-N-
acetylglucosamine 
biosynthesis; metabolism 
0.2953 3.39 0.0098 
NM_024040 NM_024040 hypothetical protein MGC2491  0.2955 3.38 0.0248 
NM_018675 
NM_018443; 
NM_018675 
zinc finger protein 302; ZNF135-
like protein 
regulation of 
transcription, DNA-
dependent 
0.2957 3.38 0.0103 
NM_032520 NM_032520 hypothetical protein CAB56184  0.2958 3.38 0.0079 
AK057305 NM_145020 hypothetical protein FLJ32743  0.2959 3.38 0.0202 
NM_003016 NM_003016 splicing factor, arginine/serine-rich 
2 
mRNA splicing; mRNA 
processing 
0.2959 3.38 0.0156 
NM_005433 NM_005433 viral oncogene yes-1 homolog 1 
cell growth and/or 
maintenance; protein 
amino acid 
phosphorylation; 
intracellular signaling 
cascade 
0.2960 3.38 0.0120 
AB040882 NM_020839 WD repeat endosomal protein  0.2961 3.38 0.0131 
NM_004788 NM_004788 ubiquitination factor E4A ubiquitin-dependent 
protein catabolism 
0.2962 3.38 0.0212 
NM_020362 NM_020362 HT014  0.2964 3.37 0.0007 
NM_014052 NM_014052 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
beta polypeptide 
 0.2965 3.37 0.0180 
NM_004619 
NM_004619; 
NM_145759 
TNF receptor-associated factor 5 
apoptosis; signal 
transduction 
0.2965 3.37 0.0014 
NM_005003 NM_005003 
NADH dehydrogenase (ubiquinone) 
1, alpha/beta subcomplex, 1, 8kDa fatty acid biosynthesis 0.2965 3.37 0.0040 
NM_002093 NM_002093 glycogen synthase kinase 3 beta 
glycogen metabolism; 
protein amino acid 
phosphorylation 
0.2965 3.37 0.0090 
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NM_000841 NM_000841 glutamate receptor, metabotropic 
4 
negative regulation of 
adenylate cyclase 
activity; G-protein 
coupled receptor protein 
signaling pathway; 
synaptic transmission 
0.2966 3.37 0.0069 
NM_022818 NM_022818 
microtubule-associated proteins 
1A/1B light chain 3 
 0.2967 3.37 0.0144 
AF155654 NM_152301 hypothetical protein MGC9651  0.2967 3.37 0.0054 
NM_006787  melanoma antigen, family D, 2  0.2968 3.37 0.0038 
NM_022826 NM_022826 axotrophin  0.2969 3.37 0.0051 
NM_016470 NM_016470 chromosome 20 open reading 
frame 111 
 0.2970 3.37 0.0279 
AB002323 NM_001376 
dynein, cytoplasmic, heavy 
polypeptide 1 
mitotic spindle assembly; 
microtubule-based 
movement 
0.2971 3.37 0.0196 
X60155 NM_007130; 
NM_153380 
zinc finger protein 41 
regulation of 
transcription, DNA-
dependent; 
biological_process 
unknown 
0.2972 3.36 0.0041 
NM_005066 NM_005066 
splicing factor proline/glutamine 
rich (polypyrimidine tract binding 
protein associated) 
RNA splicing; nuclear 
mRNA splicing, via 
spliceosome 
0.2975 3.36 0.0417 
AK057543 NM_130899 hypothetical protein MGC26988  0.2975 3.36 0.0272 
NM_016488 NM_016488 periphilin 1  0.2976 3.36 0.0020 
NM_006577 
NM_006577; 
NM_033252 
beta-1,3-N-
acetylglucosaminyltransferase 
bGnT-1 
protein amino acid 
glycosylation; 
biological_process 
unknown 
0.2976 3.36 0.0355 
NM_018256 NM_018256 WD repeat domain 12 protein  0.2976 3.36 0.0020 
NM_007015 NM_007015 chondromodulin I precursor 
proteoglycan 
metabolism; cell growth 
and/or maintenance; 
skeletal development 
0.2980 3.36 0.0016 
NM_003630 NM_003630 peroxisomal biogenesis factor 3 peroxisome organization 
and biogenesis 
0.2981 3.35 0.0069 
BC013151 NM_138451 hypothetical protein BC013151 
regulation of 
transcription, DNA-
dependent 
0.2985 3.35 0.0034 
NM_014177 NM_014177 HSPC154 protein  0.2986 3.35 0.0057 
AK055091    0.2986 3.35 0.0055 
NM_014931 NM_014931 KIAA1115 protein  0.2988 3.35 0.0021 
NM_032320 NM_032320 K+ channel tetramerization protein  0.2989 3.35 0.0075 
NM_019058 NM_019058 RTP801  0.2989 3.35 0.0260 
D86981 NM_006380 amyloid beta precursor protein-
binding protein 2 
intracellular protein 
transport 
0.2990 3.34 0.0073 
AF085233 NM_013257; 
NM_170709 
serum/glucocorticoid regulated 
kinase-like isoform 1; 
serum/glucocorticoid regulated 
kinase-like isoform 2 
protein amino acid 
phosphorylation; 
intracellular signaling 
cascade 
0.2990 3.34 0.0049 
AB029041  KIAA1118 protein  0.2991 3.34 0.0189 
AK023151 NM_024953 hypothetical protein FLJ13089  0.2991 3.34 0.0029 
NM_006500 NM_006500 melanoma cell adhesion molecule morphogenesis; cell 
adhesion 
0.2993 3.34 0.0010 
NM_014050 
NM_014050; 
NM_172177; 
NM_172178 
mitochondrial ribosomal protein 
L42 isoform a; mitochondrial 
ribosomal protein L42 isoform b 
protein biosynthesis 0.2995 3.34 0.0159 
AB058747 
NM_016628; 
NM_100264; 
NM_100486 
WW domain-containing adapter 
with a coiled-coil region isoform 1; 
WW domain-containing adapter 
with a coiled-coil region isoform 2; 
WW domain-containing adapter 
with a coiled-coil region isoform 3 
 0.2995 3.34 0.0004 
NM_016291 NM_016291 inositol hexaphosphate kinase 2  0.2995 3.34 0.0054 
X89657    0.2996 3.34 0.0023 
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NM_018446 
NM_018446; 
NM_152932 
glycosyltransferase AD-017  0.2996 3.34 0.0061 
NM_006940 
NM_006940; 
NM_152989; 
NM_178010 
SRY (sex determining region Y)-
box 5 isoform a; SRY (sex 
determining region Y)-box 5 
isoform b; SRY (sex determining 
region Y)-box 5 isoform c 
transcription from Pol II 
promoter 
0.2998 3.34 0.0058 
NM_017760 NM_017760 hypothetical protein FLJ20311  0.2998 3.34 0.0006 
NM_032988 
NM_012453; 
NM_032988 
transducin (beta)-like 2 isoform 1; 
transducin (beta)-like 2 isoform 2 
biological_process 
unknown 
0.2998 3.34 0.0271 
NM_004666 NM_004666 vanin 1 precursor cell motility; nitrogen 
metabolism 
0.2998 3.34 0.0061 
AK021841    0.2998 3.34 0.0027 
AK058080 NM_152525 hypothetical protein FLJ25351  0.2999 3.33 0.0097 
NM_031217 NM_031217 kinesin family member 18A  0.2999 3.33 0.0075 
NM_004127 NM_004127 G protein pathway suppressor 1 
JNK cascade; inactivation 
of MAPK; cell cycle 
0.2999 3.33 0.0119 
NM_002815 NM_002815 proteasome 26S non-ATPase 
subunit 11 
 0.3001 3.33 0.0066 
AK002085    0.3003 3.33 0.0004 
NM_006903 
NM_006903; 
NM_176866; 
NM_176867; 
NM_176869 
inorganic pyrophosphatase 2 
isoform 2; inorganic 
pyrophosphatase 2 isoform 3; 
inorganic pyrophosphatase 2 
isoform 4; inorganic 
pyrophosphatase 2 isoform 1 
 0.3003 3.33 0.0017 
NM_005750 NM_005750 chromosome 4 open reading frame 
6 
neurogenesis 0.3004 3.33 0.0210 
NM_016410 NM_016410 hypothetical protein HSPC177  0.3004 3.33 0.0118 
NM_016936 NM_016936 ubinuclein 1 
regulation of 
transcription from Pol II 
promoter 
0.3006 3.33 0.0050 
AL096749 NM_198547 FLJ46354 protein  0.3006 3.33 0.0160 
NM_002129 NM_002129 high-mobility group box 2 
regulation of 
transcription, DNA-
dependent 
0.3007 3.33 0.0428 
BC011587  Similar to RIKEN cDNA 
1700018O18 gene 
 0.3010 3.32 0.0120 
NM_005811 NM_005811 growth differentiation factor 11 
mesoderm development; 
skeletal development; 
neurogenesis; growth 
0.3010 3.32 0.0081 
AK024951 NM_001733 complement component 1, r 
subcomponent 
complement activation, 
classical pathway; 
proteolysis and 
peptidolysis; immune 
response 
0.3011 3.32 0.0209 
NM_014166 NM_014166 
vitamin D receptor interacting 
protein 
transcription initiation 
from Pol II promoter; 
regulation of 
transcription, DNA-
dependent; androgen 
receptor signaling 
pathway 
0.3012 3.32 0.0020 
NM_007207 
NM_007207; 
NM_144728; 
NM_144729 
dual specificity phosphatase 10 
isoform a; dual specificity 
phosphatase 10 isoform b 
JNK cascade; response to 
stress; protein amino 
acid dephosphorylation 
0.3012 3.32 0.0380 
AK021551    0.3012 3.32 0.0015 
AK025557    0.3012 3.32 0.0065 
NM_000386 NM_000386 bleomycin hydrolase proteolysis and 
peptidolysis 
0.3012 3.32 0.0020 
AF190642 NM_016341 pancreas-enriched phospholipase 
C 
 0.3013 3.32 0.0002 
NM_013285 NM_013285 nucleolar GTPase biological_process 
unknown 
0.3013 3.32 0.0018 
AL133101    0.3015 3.32 0.0241 
NM_006918 NM_006918 
sterol-C5-desaturase (ERG3 delta-
5-desaturase homolog, fungal)-like 
lipid metabolism; sterol 
biosynthesis 0.3019 3.31 0.0176 
AK057296 NM_144681 hypothetical protein FLJ32734  0.3021 3.31 0.0111 
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NM_003404 NM_003404; 
NM_139323 
tyrosine 3-
monooxygenase/tryptophan 5-
monooxygenase activation protein, 
beta polypeptide 
 0.3022 3.31 0.0157 
NM_005713 NM_005713; 
NM_031361 
alpha 3 type IV collagen binding 
protein isoform 1; alpha 3 type IV 
collagen binding protein isoform 2 
protein amino acid 
phosphorylation; immune 
response 
0.3023 3.31 0.0125 
NM_021999 NM_021999 integral membrane protein 2B hearing; neurogenesis 0.3024 3.31 0.0233 
AK055891 NM_024549 hypothetical protein FLJ21127  0.3027 3.30 0.0000 
NM_020244 NM_020244 choline phosphotransferase 1 
phospholipid 
biosynthesis; electron 
transport 
0.3029 3.30 0.0019 
NM_014937 
NM_014937; 
NM_198330; 
NM_198331 
inositol polyphosphate-5-
phosphatase F isoform 1; inositol 
polyphosphate-5-phosphatase F 
isoform 2; inositol polyphosphate-
5-phosphatase F isoform 3 
 0.3030 3.30 0.0016 
NM_030594 NM_030594 
cytoplasmic polyadenylation 
element binding protein 1  0.3030 3.30 0.0018 
NM_020187 NM_020187 DC12 protein  0.3031 3.30 0.0027 
NM_006325 NM_006325 ras-related nuclear protein 
mitotic spindle assembly; 
protein-nucleus export; 
small GTPase mediated 
signal transduction; RNA-
nucleus export; 
intracellular protein 
transport; regulation of 
cell cycle; DNA 
metabolism 
0.3032 3.30 0.0352 
BC014941 NM_001546 
inhibitor of DNA binding 4, 
dominant negative helix-loop-helix 
protein 
regulation of 
transcription from Pol II 
promoter 
0.3033 3.30 0.0034 
NM_015959 NM_015959 thioredoxin-related 
transmembrane protein 2 
electron transport 0.3034 3.30 0.0042 
NM_017867 NM_017867 hypothetical protein FLJ20534  0.3034 3.30 0.0076 
AK025774 NM_018206 vacuolar protein sorting 35 
intracellular protein 
transport; retrograde 
(endosome to Golgi) 
transport 
0.3037 3.29 0.0319 
NM_014364 NM_014364 
glyceraldehyde-3-phosphate 
dehydrogenase, testis-specific glycolysis 0.3038 3.29 0.0074 
NM_004457 NM_004457 long-chain fatty-acid-Coenzyme A 
ligase 3 
 0.3042 3.29 0.0117 
NM_004330 NM_004330 BCL2/adenovirus E1B 19kD 
interacting protein 2 
anti-apoptosis 0.3045 3.28 0.0112 
NM_015370 NM_015370 hypothetical protein HS747E2A  0.3046 3.28 0.0347 
AK025583    0.3046 3.28 0.0066 
AB033029 NM_020718 ubiquitin-specific protease 
KIAA1203 
ubiquitin-dependent 
protein catabolism 
0.3047 3.28 0.0022 
BC013920    0.3052 3.28 0.0138 
NM_014500 NM_014500 HIV TAT specific factor 1 
regulation of 
transcription from Pol II 
promoter; viral genome 
replication 
0.3052 3.28 0.0151 
AK026646 NM_033161 surfeit 4 biological_process 
unknown 
0.3053 3.28 0.0003 
NM_014239 NM_014239 
eukaryotic translation initiation 
factor 2B, subunit 2 beta, 39kDa translational initiation 0.3054 3.27 0.0049 
NM_014924 NM_014924 KIAA0831  0.3055 3.27 0.0154 
BC018085 NM_145267 chromosome 6 open reading frame 
57 
 0.3055 3.27 0.0024 
AK022842    0.3058 3.27 0.0008 
NM_016200 NM_016200 U6 snRNA-associated Sm-like 
protein LSm8 
nuclear mRNA splicing, 
via spliceosome 
0.3059 3.27 0.0138 
BC001563 
NM_144596; 
NM_198309; 
NM_198310 
tetratricopeptide repeat domain 8 
isoform 3; tetratricopeptide repeat 
domain 8 isoform 1; 
tetratricopeptide repeat domain 8 
isoform 2 
 0.3059 3.27 0.0041 
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NM_006867 NM_006867 RNA-binding protein with multiple 
splicing 
RNA processing 0.3059 3.27 0.0177 
NM_006330 NM_006330 lysophospholipase I  0.3060 3.27 0.0030 
NM_015285 
NM_015285; 
NM_052834 
WD repeat domain 7 protein 
isoform 1; WD repeat domain 7 
protein isoform 2 
 0.3060 3.27 0.0015 
NM_024899 NM_024899 hypothetical protein FLJ12542  0.3061 3.27 0.0081 
NM_006437 NM_006437 poly(ADP-ribosyl)transferase-like 1 
protein amino acid ADP-
ribosylation; transport; 
necrosis; DNA repair; 
inflammatory response; 
response to drug 
0.3061 3.27 0.0099 
NM_032126 NM_032126 hypothetical protein 
DKFZp564J047 
 0.3063 3.26 0.0153 
NM_001821 NM_001821 choroideremia-like Rab escort 
protein 2 
vision; intracellular 
protein transport 
0.3072 3.26 0.0021 
NM_002402 
NM_002402; 
NM_177524; 
NM_177525 
mesoderm specific transcript 
isoform a; mesoderm specific 
transcript isoform b 
mesoderm development 0.3073 3.25 0.0031 
AB051537 NM_033512 KIAA1750 protein 
nucleosome assembly; 
regulation of 
transcription, DNA-
dependent 
0.3074 3.25 0.0042 
M12679 NM_002117 
major histocompatibility complex, 
class I, C precursor 
immune response 0.3075 3.25 0.0102 
NM_016052 NM_016052 CGI-115 protein  0.3076 3.25 0.0330 
AY007149    0.3076 3.25 0.0079 
NM_002692 NM_002692 
polymerase (DNA directed), 
epsilon 2 (p59 subunit) 
DNA replication; DNA 
repair 0.3079 3.25 0.0159 
NM_016648 NM_016648 HDCMA18P protein  0.3081 3.25 0.0061 
NM_003457 NM_003457 zinc finger protein 207 
regulation of 
transcription, DNA-
dependent 
0.3083 3.24 0.0125 
AK025656    0.3084 3.24 0.0087 
BC009230 NM_130467 PAGE-5 protein  0.3086 3.24 0.0238 
NM_030974 NM_030974 hypothetical protein 
DKFZp434N1923 
 0.3087 3.24 0.0133 
NM_032837 NM_032837 hypothetical protein FLJ14775 
regulation of 
transcription, DNA-
dependent 
0.3087 3.24 0.0146 
AF041429 NM_145169 chromosome 6 open reading frame 
83 
 0.3087 3.24 0.0014 
AL136945 NM_005455 zinc finger protein 265 RNA splicing 0.3088 3.24 0.0259 
NM_005484 NM_005484 poly (ADP-ribosyl) transferase-like 
2 
protein amino acid ADP-
ribosylation 
0.3089 3.24 0.0019 
NM_018442 NM_018442 PC326 protein  0.3090 3.24 0.0238 
NM_004083 NM_004083 DNA-damage-inducible transcript 3 
cell cycle arrest; 
response to DNA damage 
stimulus; cell growth 
and/or maintenance; 
regulation of 
transcription, DNA-
dependent 
0.3091 3.24 0.0158 
D29954   
regulation of 
transcription, DNA-
dependent 
0.3092 3.23 0.0258 
NM_018840 NM_018840 putative Rab5-interacting protein  0.3093 3.23 0.0038 
AK057629    0.3093 3.23 0.0072 
NM_001064 NM_001064 transketolase  0.3094 3.23 0.0072 
NM_003611 NM_003611 oral-facial-digital syndrome 1 
defense response; 
biological_process 
unknown 
0.3095 3.23 0.0170 
NM_003757 NM_003757 
eukaryotic translation initiation 
factor 3, subunit 2 beta, 36kDa 
regulation of 
translational initiation; 
protein biosynthesis 
0.3095 3.23 0.0093 
NM_019006 NM_019006 protein associated with PRK1  0.3095 3.23 0.0150 
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NM_031370 
NM_002138; 
NM_031369; 
NM_031370 
heterogeneous nuclear 
ribonucleoprotein D isoform c; 
heterogeneous nuclear 
ribonucleoprotein D isoform b; 
heterogeneous nuclear 
ribonucleoprotein D isoform a 
RNA processing; RNA 
catabolism 
0.3096 3.23 0.0095 
AL137295 NM_004641 
myeloid/lymphoid or mixed-
lineage leukemia (trithorax 
(Drosophil 
cell growth and/or 
maintenance; regulation 
of transcription, DNA-
dependent 
0.3097 3.23 0.0252 
NM_002134 NM_002134 heme oxygenase (decyclizing) 2 heme oxidation 0.3097 3.23 0.0169 
NM_003878 NM_003878 gamma-glutamyl hydrolase 
precursor 
 0.3100 3.23 0.0013 
Z82202    0.3101 3.23 0.0190 
AC004955    0.3103 3.22 0.0072 
NM_032231 NM_032231 hypothetical protein FLJ22875  0.3103 3.22 0.0003 
NM_004504 NM_004504 HIV-1 Rev binding protein transport; mRNA-nucleus 
export 
0.3105 3.22 0.0145 
BC006436 NM_032497 hypothetical protein MGC13105 
regulation of 
transcription, DNA-
dependent 
0.3106 3.22 0.0038 
NM_016039 NM_016039 chromosome 14 open reading 
frame 166 
 0.3106 3.22 0.0174 
NM_005087 NM_005087 
fragile X mental retardation-
related protein 1 
regulation of 
transcription, DNA-
dependent; apoptosis 
0.3107 3.22 0.0036 
NM_003145 NM_003145 signal sequence receptor, beta 
precursor 
cotranslational 
membrane targeting 
0.3107 3.22 0.0038 
BC017590  Unknown (protein for MGC:26890)  0.3109 3.22 0.0308 
NM_016626 NM_016626 hypothetical protein LOC51320  0.3110 3.22 0.0014 
NM_007044 NM_007044 katanin p60 subunit A 1 mitosis; cell shape and 
cell size control 
0.3112 3.21 0.0148 
AF070641    0.3112 3.21 0.0030 
NM_018159 NM_018159 
nudix (nucleoside diphosphate 
linked moiety X)-type motif 11 
 0.3115 3.21 0.0232 
NM_006571 NM_006571 dynactin 6 
mitochondrion 
organization and 
biogenesis; lipid 
biosynthesis 
0.3115 3.21 0.0095 
NM_001998 NM_001998 fibulin 2 precursor  0.3116 3.21 0.0190 
NM_002306 NM_002306 galectin-3 heterophilic cell adhesion 0.3119 3.21 0.0058 
NM_030809 NM_030809 TGF-beta induced apotosis protein 
12 
 0.3121 3.20 0.0002 
AL080132    0.3121 3.20 0.0046 
NM_005918 NM_005918 
mitochondrial malate 
dehydrogenase precursor 
tricarboxylic acid cycle; 
biological_process 
unknown 
0.3122 3.20 0.0044 
BC017472 NM_152682 hypothetical protein MGC10198  0.3123 3.20 0.0036 
AK057395 NM_152488 hypothetical protein FLJ32833  0.3123 3.20 0.0136 
AF155103 NM_033121 ankyrin repeat domain 13  0.3123 3.20 0.0247 
BC015365 NM_145274 hypothetical protein MGC21518  0.3126 3.20 0.0006 
AK021668    0.3126 3.20 0.0091 
NM_004356 NM_004356 CD81 antigen 
defense response; cell 
proliferation; protein 
complex assembly 
0.3129 3.20 0.0091 
NM_018571 NM_018571 
amyotrophic lateral sclerosis 2 
(juvenile) chromosome region, 
candidate 2 
protein amino acid 
phosphorylation 0.3130 3.20 0.0003 
NM_014803  KIAA0335 gene product  0.3132 3.19 0.0027 
NM_014642 NM_014642 KIAA0036 gene product  0.3132 3.19 0.0250 
AL359591 NM_018710 hypothetical protein 
DKFZp762O076 
 0.3133 3.19 0.0009 
NM_003800 NM_003800 
RNA guanylyltransferase and 5'-
phosphatase 
mRNA capping; protein 
amino acid 
dephosphorylation 
0.3133 3.19 0.0010 
NM_000287 NM_000287 peroxisomal biogenesis factor 6 
protein-peroxisome 
targeting; peroxisome 
organization and 
biogenesis 
0.3135 3.19 0.0092 
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NM_031420 NM_031420 mitochondrial ribosomal protein L9 protein biosynthesis 0.3135 3.19 0.0057 
NM_024586 
NM_024586; 
NM_148904; 
NM_148905; 
NM_148906; 
NM_148907; 
NM_148908; 
NM_148909 
oxysterol-binding protein-like 
protein 9 isoform e; oxysterol-
binding protein-like protein 9 
isoform a; oxysterol-binding 
protein-like protein 9 isoform b; 
oxysterol-binding protein-like 
protein 9 isoform c; oxysterol-
binding protein-like protein 9 
isoform d; oxysterol-binding 
protein-like protein 9 isoform f 
 0.3138 3.19 0.0087 
AK057666    0.3140 3.18 0.0026 
BC015370  Unknown (protein for 
IMAGE:3916023) 
 0.3141 3.18 0.0073 
AF278605    0.3143 3.18 0.0098 
NM_017906 NM_017906 PAK1 interacting protein 1  0.3144 3.18 0.0077 
NM_002495 NM_002495 
NADH dehydrogenase (ubiquinone) 
Fe-S protein 4, 18kDa (NADH-
coenzyme Q reductase) 
mitochondrial electron 
transport, NADH to 
ubiquinone 
0.3146 3.18 0.0111 
NM_001923 NM_001923 damage-specific DNA binding 
protein 1 
nucleotide-excision repair 0.3150 3.17 0.0031 
NM_015640 NM_015640 PAI-1 mRNA-binding protein 
regulation of 
transcription, DNA-
dependent 
0.3150 3.17 0.0279 
NM_004092 NM_004092 
mitochondrial short-chain enoyl-
coenzyme A hydratase 1 precursor 
fatty acid beta-oxidation; 
fatty acid metabolism; 
energy pathways 
0.3150 3.17 0.0075 
BC014310 NM_080746 ribosomal protein L10-like protein protein biosynthesis 0.3151 3.17 0.0019 
NM_031966 NM_031966 cyclin B1 
G2/M transition of mitotic 
cell cycle; mitosis; 
regulation of cell cycle; 
cytokinesis 
0.3151 3.17 0.0457 
BC011706 NM_144988 hypothetical protein MGC19780  0.3152 3.17 0.0103 
NM_002621 NM_002621 properdin P factor, complement 
immune response; 
complement activation, 
alternative pathway 
0.3153 3.17 0.0128 
NM_015387 NM_015387 preimplantation protein 3  0.3153 3.17 0.0083 
AF072928 NM_004685 myotubularin related protein 6 protein 
dephosphorylation 
0.3153 3.17 0.0007 
NM_001750 
NM_001750; 
NM_173060; 
NM_173061; 
NM_173062 
calpastatin isoform a; calpastatin 
isoform b; calpastatin isoform c; 
calpastatin isoform d 
 0.3154 3.17 0.0170 
NM_000521 NM_000521 hexosaminidase B preproprotein 
glycosphingolipid 
metabolism; 
carbohydrate metabolism 
0.3154 3.17 0.0003 
NM_032146 
NM_032146; 
NM_177976 
ADP-ribosylation factor-like 6 
small GTPase mediated 
signal transduction 
0.3155 3.17 0.0117 
AK054588    0.3156 3.17 0.0159 
NM_005509 NM_005509 Dmx-like 1 proteolysis and 
peptidolysis 
0.3158 3.17 0.0001 
AK026295    0.3159 3.17 0.0119 
NM_002959 NM_002959 sortilin 1 preproprotein non-selective vesicle 
targeting 
0.3163 3.16 0.0103 
AB037797 NM_020801 KIAA1376 protein sensory perception; 
signal transduction 
0.3163 3.16 0.0029 
AB033767 NM_020531 chromosome 20 open reading 
frame 3 
biological_process 
unknown; biosynthesis 
0.3164 3.16 0.0083 
NM_006622 NM_006622 serum-inducible kinase 
cell cycle; protein amino 
acid phosphorylation 
0.3166 3.16 0.0221 
NM_001875 NM_001875 
carbamoyl-phosphate synthetase 
1, mitochondrial 
urea cycle; arginine 
biosynthesis; pyrimidine 
base biosynthesis 
0.3166 3.16 0.0135 
AL157421    0.3167 3.16 0.0091 
NM_014109 NM_014109 PRO2000 protein  0.3169 3.16 0.0112 
NM_014367 NM_014367 growth and transformation-
dependent protein 
 0.3169 3.16 0.0000 
NM_014398 NM_014398 lysosomal-associated membrane 
protein 3 
cell proliferation 0.3169 3.16 0.0022 
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NM_005367 NM_005367 melanoma antigen, family A, 12 biological_process 
unknown 
0.3170 3.15 0.0037 
NM_013241 NM_013241 formin homology 2 domain 
containing 1 
 0.3170 3.15 0.0022 
NM_014714 NM_014714 KIAA0590 gene product  0.3172 3.15 0.0092 
NM_022371 NM_022371 torsin family 3, member A  0.3174 3.15 0.0116 
BC002924  MGC1842 protein  0.3174 3.15 0.0189 
NM_002765 NM_002765 phosphoribosyl pyrophosphate 
synthetase 2 
ribonucleoside 
monophosphate 
biosynthesis; nucleoside 
metabolism; nucleotide 
biosynthesis 
0.3174 3.15 0.0192 
NM_022756 NM_022756 hypothetical protein FLJ11730  0.3174 3.15 0.0096 
NM_002305 NM_002305 beta-galactosidase binding lectin 
precursor 
apoptosis; heterophilic 
cell adhesion 
0.3176 3.15 0.0091 
NM_014763 NM_014763 mitochondrial ribosomal protein 
L19 
protein biosynthesis 0.3177 3.15 0.0071 
AF070647    0.3177 3.15 0.0106 
NM_016316 NM_016316 REV1-like DNA repair 0.3178 3.15 0.0064 
BC004215  eukaryotic translation elongation 
factor 1 gamma 
 0.3179 3.15 0.0239 
AF146760 
NM_144710; 
NM_178584 
septin 10 isoform 1; septin 10 
isoform 2 
 0.3181 3.14 0.0402 
NM_022753 NM_022753 hypothetical protein FLJ12903  0.3182 3.14 0.0153 
NM_001530 NM_001530; 
NM_181054 
hypoxia-inducible factor 1, alpha 
subunit isoform 1; hypoxia-
inducible factor 1, alpha subunit 
isoform 2 
response to stress; 
regulation of 
transcription, DNA-
dependent; signal 
transduction 
0.3182 3.14 0.0121 
NM_014504 NM_014504 RAB guanine nucleotide exchange 
factor (GEF) 1 
 0.3182 3.14 0.0224 
NM_014765 NM_014765 
translocase of outer mitochondrial 
membrane 20 homolog 
mitochondrial 
translocation; protein 
targeting 
0.3185 3.14 0.0127 
NM_021953 NM_021953 forkhead box M1 
regulation of 
transcription, DNA-
dependent; response to 
oxidative stress; 
transcription from Pol II 
promoter 
0.3188 3.14 0.0005 
NM_003851 NM_003851 cellular repressor of E1A-
stimulated genes 
development; cell 
proliferation; regulation 
of transcription from Pol 
II promoter 
0.3188 3.14 0.0000 
NM_014302 NM_014302 Sec61 gamma protein targeting 0.3188 3.14 0.0090 
NM_032874 NM_032874 hypothetical protein MGC15438  0.3188 3.14 0.0392 
NM_005035 NM_005035 
mitochondrial DNA-directed RNA 
polymerase precursor 
DNA replication, priming; 
transcription 
0.3189 3.14 0.0068 
AL049714    0.3191 3.13 0.0179 
NM_016098 NM_016098 brain protein 44-like  0.3192 3.13 0.0063 
NM_016044 NM_016044 CGI-105 protein metabolism 0.3192 3.13 0.0263 
NM_002296 
NM_002296; 
NM_194442 
lamin B receptor  0.3192 3.13 0.0086 
NM_005389 NM_005389 
protein-L-isoaspartate (D-
aspartate) O-methyltransferase 
protein amino acid 
methylation; protein 
modification 
0.3195 3.13 0.0208 
NM_012207 NM_012207; 
NM_021644 
heterogeneous nuclear 
ribonucleoprotein H3 isoform a; 
heterogeneous nuclear 
ribonucleoprotein H3 isoform b 
mRNA processing 0.3197 3.13 0.0008 
NM_030766 
NM_030766; 
NM_138722; 
NM_138723; 
NM_138724 
apoptosis regulator BCL-G isoform 
2; apoptosis regulator BCL-G 
isoform 1; apoptosis regulator 
BCL-G isoform 3 
 0.3197 3.13 0.0128 
NM_021141 NM_021141 ATP-dependant DNA helicase II 
double-strand break 
repair via 
nonhomologous end-
joining; DNA 
0.3198 3.13 0.0032 
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recombination 
NM_003176 NM_003176 synaptonemal complex protein 1 
synapsis; meiosis; 
meiotic recombination; 
spermatogenesis; 
cytokinesis 
0.3199 3.13 0.0051 
NM_014810 NM_014810 centrosome-associated protein 350  0.3199 3.13 0.0153 
NM_003363 NM_003363 ubiquitin specific protease, proto-
oncogene 
ubiquitin cycle; cell 
growth and/or 
maintenance; ubiquitin-
dependent protein 
catabolism 
0.3199 3.13 0.0159 
NM_003416 NM_003416 
zinc finger protein 7 (KOX 4, clone 
HF.16) 
regulation of 
transcription, DNA-
dependent; development 
0.3201 3.12 0.0050 
NM_006070 NM_006070 TRK-fused gene  0.3202 3.12 0.0017 
NM_001417 NM_001417 
eukaryotic translation initiation 
factor 4B 
regulation of 
translational initiation; 
protein biosynthesis 
0.3202 3.12 0.0100 
AF332223 NM_139214 
TGFB-induced factor 2-like, Y-
linked 
regulation of 
transcription, DNA-
dependent 
0.3208 3.12 0.0060 
AJ006835    0.3210 3.11 0.0040 
NM_024997 NM_024997 
activating transcription factor 7 
interacting protein 2 
 0.3211 3.11 0.0007 
NM_016029 NM_016029 
dehydrogenase/reductase (SDR 
family) member 7 metabolism 0.3212 3.11 0.0003 
NM_003875 NM_003875 guanine monophosphate 
synthetase 
purine nucleotide 
biosynthesis; purine base 
biosynthesis; GMP 
biosynthesis; glutamine 
metabolism 
0.3212 3.11 0.0137 
NM_021824 NM_021824 NIF3 NGG1 interacting factor 3-
like 1 
 0.3215 3.11 0.0044 
NM_012447 
NM_012447; 
NM_024070 stromal antigen 3 
synaptonemal complex 
formation 0.3215 3.11 0.0241 
NM_032413 
NM_032413; 
NM_197955 
normal mucosa of esophagus 
specific 1 
 0.3216 3.11 0.0134 
NM_016467 NM_016467 hypothetical protein LOC51240  0.3218 3.11 0.0009 
L38951 NM_002265 karyopherin beta 1 
protein-nucleus import, 
docking; NLS-bearing 
substrate-nucleus 
import; protein-nucleus 
import, translocation; 
intracellular protein 
transport 
0.3218 3.11 0.0402 
NM_001871 NM_001871 pancreatic carboxypeptidase B1 
precursor 
proteolysis and 
peptidolysis 
0.3219 3.11 0.0096 
NM_012215 NM_012215 meningioma expressed antigen 5 
(hyaluronidase) 
glycoprotein catabolism 0.3221 3.10 0.0098 
NM_024824 NM_024824 nuclear protein UKp68  0.3223 3.10 0.0281 
AL049998    0.3226 3.10 0.0066 
NM_020347 NM_020347 leucine zipper transcription factor-
like 1 
 0.3227 3.10 0.0040 
NM_004046 NM_004046 
ATP synthase, H+ transporting, 
mitochondrial F1 complex, alpha 
subunit, isoform 1, cardiac muscle 
proton transport; ATP 
biosynthesis 
0.3227 3.10 0.0194 
NM_005530 NM_005530 
isocitrate dehydrogenase 3 
(NAD+) alpha precursor 
tricarboxylic acid cycle; 
carbohydrate metabolism 0.3228 3.10 0.0051 
NM_003799 NM_003799 RNA (guanine-7-) 
methyltransferase 
mRNA capping 0.3229 3.10 0.0102 
NM_003625 NM_003625 PTPRF interacting protein alpha 2 cell-matrix adhesion 0.3229 3.10 0.0214 
NM_032487 NM_032487 actin related protein M1  0.3230 3.10 0.0144 
NM_001186 NM_001186 
BTB and CNC homology 1, basic 
leucine zipper transcription factor 
1 
regulation of 
transcription, DNA-
dependent 
0.3232 3.09 0.0047 
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BC013128 NM_001806 
CCAAT/enhancer binding protein 
gamma 
regulation of 
transcription, DNA-
dependent 
0.3232 3.09 0.0007 
NM_024678 NM_024678 hypothetical protein FLJ23441 aspartyl-tRNA 
aminoacylation 
0.3233 3.09 0.0002 
AK000003 NM_015889 
positive cofactor 2, glutamine/Q-
rich-associated protein 
neurogenesis; 
transcription from Pol II 
promoter 
0.3233 3.09 0.0006 
NM_024740 NM_024740 disrupted in bipolar disorder 1  0.3235 3.09 0.0010 
AK055653    0.3236 3.09 0.0016 
BC017998 NM_145658 sperm equatorial segment protein 
1 
 0.3239 3.09 0.0271 
NM_000983 NM_000983 ribosomal protein L22 proprotein protein biosynthesis 0.3241 3.09 0.0169 
NM_006931 NM_006931 
solute carrier family 2 (facilitated 
glucose transporter), member 3 
glucose transport; 
carbohydrate 
metabolism; 
carbohydrate transport 
0.3241 3.09 0.0052 
NM_005566 NM_005566 lactate dehydrogenase A glycolysis 0.3241 3.09 0.0084 
AK001452    0.3243 3.08 0.0019 
NM_015681 NM_015681 B9 protein  0.3243 3.08 0.0089 
NM_004988 NM_004988 melanoma antigen, family A, 1  0.3243 3.08 0.0019 
NM_003103 
NM_003103; 
NM_032195; 
NM_058183; 
NM_138925; 
NM_138926; 
NM_138927 
SON DNA-binding protein isoform 
G; SON DNA-binding protein 
isoform B; SON DNA-binding 
protein isoform E; SON DNA-
binding protein isoform A; SON 
DNA-binding protein isoform C; 
SON DNA-binding protein isoform 
F 
anti-apoptosis; 
biological_process 
unknown 
0.3244 3.08 0.0196 
NM_003905 NM_003905 amyloid beta precursor protein-
binding protein 1 
signal transduction 0.3244 3.08 0.0095 
NM_007216 
NM_007216; 
NM_181507; 
NM_181508 
Hermansky-Pudlak syndrome 5 
isoform b; Hermansky-Pudlak 
syndrome 5 isoform a 
 0.3244 3.08 0.0078 
NM_006398 NM_006398 diubiquitin 
proteolysis and 
peptidolysis; protein 
modification; 
antimicrobial humoral 
response (sensu 
Vertebrata) 
0.3245 3.08 0.0063 
NM_016400 NM_016400 Huntingtin interacting protein K  0.3246 3.08 0.0127 
AB007952 NM_015176 KIAA0483 protein  0.3246 3.08 0.0121 
AL080234    0.3247 3.08 0.0185 
AB014566 NM_014992 
dishevelled-associated activator of 
morphogenesis 1 
 0.3248 3.08 0.0240 
AK026873    0.3249 3.08 0.0131 
NM_004417 NM_004417 dual specificity phosphatase 1 
cell cycle; response to 
oxidative stress; protein 
amino acid 
dephosphorylation 
0.3249 3.08 0.0007 
M82882 NM_172373 E74-like factor 1 (ets domain 
transcription factor) 
 0.3250 3.08 0.0052 
NM_001903 NM_001903 
catenin (cadherin-associated 
protein), alpha 1, 102kDa cell adhesion 0.3250 3.08 0.0143 
AK056001 NM_005506 scavenger receptor class B, 
member 2 
cell adhesion 0.3252 3.08 0.0198 
NM_052961 
NM_052961; 
NM_138718 
solute carrier family 26, member 8 
isoform a; solute carrier family 26, 
member 8 isoform b 
 0.3253 3.07 0.0004 
NM_025078 NM_025078 hypothetical protein FLJ22378  0.3254 3.07 0.0039 
NM_014764 NM_014764 DAZ associated protein 2 transport 0.3254 3.07 0.0004 
NM_021822 NM_021822 
apolipoprotein B mRNA editing 
enzyme, catalytic polypeptide-like 
3G 
 0.3258 3.07 0.0110 
NM_024045 NM_024045 nucleolar protein GU2  0.3260 3.07 0.0109 
NM_032412 NM_032412 putative nuclear protein ORF1-
FL49 
 0.3260 3.07 0.0095 
NM_001512 NM_001512 glutathione S-transferase A4 response to stress; 
metabolism 
0.3264 3.06 0.0040 
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NM_016289 NM_016289 MO25 protein  0.3264 3.06 0.0010 
AL035563    0.3266 3.06 0.0008 
NM_016397 
NM_016397; 
NM_198976 
TH1-like protein  0.3267 3.06 0.0156 
AK026669 NM_006519 t-complex-associated-testis-
expressed 1-like 1 
biological_process 
unknown 
0.3268 3.06 0.0059 
NM_004548 NM_004548 
NADH dehydrogenase (ubiquinone) 
1 beta subcomplex, 10, 22kDa 
 0.3268 3.06 0.0147 
AL050199 NM_181706 hypothetical protein LOC120526  0.3268 3.06 0.0026 
NM_025155 NM_025155 hypothetical protein FLJ11848  0.3270 3.06 0.0091 
NM_016015 
NM_016015; 
NM_016309 leucine carboxyl methyltransferase protein modification 0.3271 3.06 0.0060 
NM_005655 NM_005655 
TGFB inducible early growth 
response 
negative regulation of 
cell proliferation; 
TGFbeta receptor 
signaling pathway; 
regulation of 
transcription, DNA-
dependent; skeletal 
development; cell-cell 
signaling; negative 
regulation of 
transcription from Pol II 
promoter 
0.3273 3.06 0.0103 
NM_001288 NM_001288 chloride intracellular channel 1 chloride transport; ion 
transport 
0.3273 3.05 0.0049 
NM_020198 NM_020198 GK001 protein  0.3275 3.05 0.0075 
NM_012459 NM_012459 
translocase of inner mitochondrial 
membrane 8 homolog B 
mitochondrial 
translocation; protein 
targeting; hearing 
0.3278 3.05 0.0107 
NM_006901 NM_006901 myosin IXA vision 0.3280 3.05 0.0116 
NM_002494 NM_002494 
NADH dehydrogenase (ubiquinone) 
1, subcomplex unknown, 1, 6kDa 
mitochondrial electron 
transport, NADH to 
ubiquinone 
0.3280 3.05 0.0255 
AB058743 NM_025137 hypothetical protein FLJ21439 carbohydrate metabolism 0.3281 3.05 0.0021 
NM_012198 NM_012198 grancalcin, EF-hand calcium 
binding protein 
membrane fusion 0.3281 3.05 0.0209 
NM_001179 NM_001179 ADP-ribosyltransferase 3 protein amino acid ADP-
ribosylation 
0.3282 3.05 0.0278 
AL117621    0.3282 3.05 0.0085 
NM_014320 NM_014320 heme binding protein 2  0.3283 3.05 0.0066 
NM_004301 
NM_004301; 
NM_177989; 
NM_178042 
BAF53a isoform 1; BAF53a isoform 
2 
response to 
pest/pathogen/parasite; 
chromatin remodeling; 
signal transduction 
0.3284 3.05 0.0139 
NM_031289 
NM_031289; 
NM_153823 
germ cell associated 1  0.3285 3.04 0.0158 
NM_003379 NM_003379 villin 2 cytoskeletal anchoring 0.3286 3.04 0.0088 
AL049331    0.3286 3.04 0.0023 
AL049974    0.3286 3.04 0.0007 
NM_000463 NM_000463 
UDP glycosyltransferase 1 family, 
polypeptide A1 
digestion; estrogen 
metabolism; bilirubin 
conjugation 
0.3286 3.04 0.0045 
NM_017737 NM_017737 hypothetical protein FLJ20275 signal transduction 0.3288 3.04 0.0137 
AB051544 NM_018187 KIAA1757 protein  0.3289 3.04 0.0182 
AL050372 NM_001441 fatty acid amide hydrolase fatty acid metabolism 0.3290 3.04 0.0072 
NM_005249 NM_005249 forkhead box G1B 
brain development; 
transcription regulation; 
embryogenesis and 
morphogenesis 
0.3290 3.04 0.0134 
AF022789 NM_182488 
ubiquitin-specific protease 12-like 
1 
ubiquitin-dependent 
protein catabolism; 
protein modification 
0.3290 3.04 0.0176 
NM_052888 NM_052888 KIAA0563-related gene  0.3293 3.04 0.0071 
AK025435    0.3293 3.04 0.0026 
AK021437    0.3294 3.04 0.0193 
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NM_018848 
NM_018848; 
NM_170784 
McKusick-Kaufman syndrome 
protein 
gonad development; 
heart development; 
protein folding 
0.3294 3.04 0.0195 
NM_007106 NM_007106 ubiquitin-like 3  0.3296 3.03 0.0054 
NM_003151 NM_003151 signal transducer and activator of 
transcription 4 
JAK-STAT cascade; 
intracellular signaling 
cascade; regulation of 
transcription from Pol II 
promoter 
0.3296 3.03 0.0012 
AK027306 NM_030782 cisplatin resistance related protein 
CRR9p 
 0.3298 3.03 0.0019 
NM_005135 NM_005135 potassium chloride cotransporter 
KCC3 
chloride transport; amino 
acid transport; sodium 
ion transport; potassium 
ion transport 
0.3298 3.03 0.0046 
NM_032918 NM_032918 
RAS-like, estrogen-regulated, 
growth-inhibitor 
small GTPase mediated 
signal transduction 
0.3298 3.03 0.0033 
AF065241  thioredoxin delta 3  0.3299 3.03 0.0177 
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